

HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Reg. Office: 8-A, Gulnar, Chinar - Gulnar Appt., V V Nagar Road, Anand, 388001

E-mail.: drdineshpatel@rediffmail.com; Website: www.hemoorganicltd.com Mo.No.9426075525

Date: September 7, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Respected Sir / Ma'am,


Sub: Submission of Annual Report for F.Y. 2020-21

Ref: Hemo Organic Limited (Security Id/Code: HEMORGANIC/524590)

With reference to captioned subject and pursuant to Regulation 34 of SEBI (LODR) Regulation, 2015, we hereby submit the Stock Exchange Annual Report of the Company for the financial year 2020-21.

Kindly disseminate the same on your website and oblige us.

For, Hemo Organic Limited





Dr. Dinesh Patel
Chairman and Managing Director
DIN 00481641

Place: Anand

HEMO ORGANIC LIMITED
(CIN: L24231GJ1992PLC018224)

29th ANNUAL REPORT
F.Y. 2020 - 2021

INSIDE THIS REPORT

Sr. No.	Particulars	Page No.
1.	Corporate Information	1
2.	Notice to Shareholders	2
3.	Board of Directors' Report	13
	Annexure to the Board of Director's Report	
	Annexure I - Annual Return	20
	Annexure II - Disclosure of Remuneration	52
	Annexure III - Secretarial Audit Report	53
4.	Management Discussion and Analysis Report	56
5.	Financial Section	
	Independent Auditors' Report	57
	Balance sheet	63
	Profit and Loss Account	64
	Statement of Changes in Equity and Other Equity	65
	Cash Flow Statement	66
	Notes to Financial Statement	67

CORPORATE INFORMATION

Board of Directors

Dr. Dineshbhai Patel	Chairman and Managing Director
Mrs. Sonalben Patel	Executive Director
Mrs. Siyona Jhanwar	Non-Executive Director
Mr. Krushnakant Patel	Independent Director
Mr. Sanjeev Lodha	Independent Director

Registered Office

8-A, Gulnar, Chinar-Gulnar Appt., V V Nagar Road, Anand - 388 001

Phone: +91 2692 248535

E-mail: drdineshpatel@rediffmail.com

Website: www.hemoorganicltd.com

Registrar and Share Transfer Agents

MCS Share Transfer Agent Limited

10, Aaram Apartment, 12, Sampatrao Coony, B/h. Laxmi Hall, Alkapuri, Vadodra - 390 007.

Phone: +91 265 2314757 / 2350490

E-mail: mcsltdbaroda@gmail.com

Statutory Auditors

M/s. M A A K & Associates,

Chartered Accountants

5, 1st Floor, Devashish Complex, Nr. Bavarchi Rest, Off. C.G. Road, Ahmedabad - 380 006

Secretarial Auditors

M/s. Payal Dhamecha & Associates

Practicing Company Secretary

S/1, 2nd Floor, Olway House, Nr. Navneet House, Gurukul, Ahmedabad - 380 052

Audit Committee

Mr. Krushnakant Patel	Chairperson
Mr. Sanjeev Lodha	Member
Mrs. Sonalben Patel	Member

Stakeholders Grievance and Redressal Committee

Mr. Krushnakant Patel	Chairperson
Mr. Sanjeev Lodha	Member
Dr. Dineshbhai Patel	Member

Nomination and Remuneration Committee

Mr. Krushnakant Patel	Chairperson
Mr. Sanjeev Lodha	Member
Mrs. Siyona Jhanwar	Member

NOTICE OF 29TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the Twenty Ninth (29th) Annual General Meeting (AGM) of the Members of Hemo Organic Limited will be held on Wednesday, September 29, 2021 at 11:00 A.M. IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following businesses:

ORDINARY BUSINESSES:

1. To consider and adopt the audited financial statement of the Company for the financial year ended March 31, 2021 and the reports of the Board of Directors and Auditors thereon and in this regard, to consider and if thought fit, to pass, with or without modification(s), the following resolutions as an **Ordinary Resolution**.

"RESOLVED THAT the audited financial statement of the Company for the financial year ended March 31, 2021 and the reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby considered and adopted."

2. To appoint a Director in place of Mrs. Sonalben Patel (DIN 02848171) who retires by rotation and being eligible, seeks re-appointment.

Explanation: Based on the terms of appointment, executive directors and non-executive directors are subject to retirement by rotation. Mrs. Sonalben Patel (DIN 02848171), who was appointed as Executive Director for the current term, and is the longest-serving member on the Board, retires by rotation and, being eligible, seeks re-appointment.

To the extent that Mrs. Sonalben Patel (DIN 02848171) is required to retire by rotation, she would need to be reappointed as such. Therefore, shareholders are requested to consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT, pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, the approval of the members of the Company be and is hereby accorded for the re-appointment of Mrs. Sonalben Patel (DIN 02848171) as such, to the extent that she is required to retire by rotation."

SPECIAL BUSINESSES:

3. To regularize appointment of Mr. Sanjeev Lodha (DIN: 02719095) as Non-Executive Independent Director of the Company:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as **Ordinary Resolutions**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152, Schedule IV and any other applicable provisions of the Companies Act, 2013 and the rules made there under (including any statutory modifications or re-enactment thereof for the time being in force), Mr. Sanjeev Lodha (DIN: 02719095), who was appointed as an Additional (Non-Executive Independent) Director of the Company by the Board of Directors with effect from October 5, 2020 and who holds office till the date of this AGM in terms of Section 161 of the Companies Act, 2013, who is eligible for appointment and who meets the criteria for independence as provided in Section 149(6) of the Act along with the rules framed thereunder and who has submitted a declaration to that effect and declaration under Section 164 of the Companies Act, 2013 declaring that he is not disqualified to become the Director and in respect of whom the Company has received a notice in writing from a member under Section 160 of the Companies Act, 2013 signifying his intention to propose Mr. Sanjeev Lodha (DIN: 02719095) as a candidate for the office of a Non-Executive Independent Director of the Company and whose appointment has been recommended by Nomination and Remuneration Committee and Board of Directors of the Company, be and is hereby appointed as Non-Executive Independent Director of the Company to hold office as such for a period up to October 4, 2025, not liable to retire by rotation.

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to do all such acts, deeds, matters and things as may be deemed necessary to give effect to the above resolution and filing of necessary forms and documents with the Registrar of Companies."

4. To regularize appointment of Ms. Siyona Jhanwar (DIN: 07857945) as Non-Executive Director of the Company:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT, pursuant to the provisions of Sections 152 and all other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed thereunder, including any statutory modifications or re-enactment(s) thereof and any rules made thereunder, for the time being in force, Ms. Siyona Jhanwar (DIN: 07857945), who was appointed as Additional (Non-Executive) Director of the Company with effect from October 5, 2020, and whose term expires at this AGM, and in respect of whom the Company has received a notice in writing from a member proposing her candidature for the office of Non-Executive Director of the Company and whose appointment has been recommended by the Nomination and Remuneration Committee and Board of Directors, be and is hereby appointed as a Non-Executive Director of the Company whose office shall be liable to retire by rotation."

5. Re-appointment of Mrs. Sonalben Patel (DIN 02848171) as Executive Director of the Company and approval of the payment of remuneration:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as **Special Resolutions**:

"RESOLVED THAT in accordance with the provisions of Sections 196, 197 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as "the Board" which term shall be deemed to include the Nomination and Remuneration Committee of the Board), the approval of the Members of the Company be and is hereby accorded to the re-appointment of Mrs. Sonalben Patel (DIN 02848171) as Executive Director of the Company, liable to retire by rotations, for a period of 5 (Five) years with effect from August 11, 2021 as well as the payment of salary and perquisites (hereinafter referred to as "remuneration") and on the terms and conditions as set out in the explanatory statement attached hereto, with liberty to the Board of Directors to alter and vary the terms and conditions of the said appointment and / or remuneration as it may deem fit and as may be acceptable to Mrs. Sonalben Patel (DIN 02848171), subject to the same not exceeding the limits specified under Paragraph I (A) of Part II of Section II of Schedule V to the Companies Act, 2013 or any statutory modification(s) or re-enactment thereof.

RESOLVED FURTHER THAT in terms of Section 190 of the Companies Act, 2013, no formal contract of service with Mrs. Sonalben Patel (DIN 02848171) will be executed and this resolution along with its explanatory statement be considered as Memorandum setting out terms and conditions of re-appointment and remuneration of Mrs. Sonalben Patel (DIN 02848171) as Executive Director.

RESOLVED FURTHER THAT any of the Directors of the Company be and are hereby severally authorized to do all acts and take all such steps as may be necessary, proper or expedient to give effect to above resolutions."

6. Re-appointment of Dr. Dineshbhai Patel (DIN 00481641) as Chairman and Managing Director of the Company and approval of the payment of remuneration:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as **Special Resolutions**:

“RESOLVED THAT in accordance with the provisions of Sections 196, 197 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as “the Board” which term shall be deemed to include the Nomination and Remuneration Committee of the Board), the approval of the Members of the Company be and is hereby accorded to the re-appointment of Dr. Dineshbhai Patel (DIN 00481641) as Chairman and Managing Director of the Company, liable for retire by rotations, for a period of 5 (Five) years with effect from August 11, 2021 as well as the payment of salary and perquisites (hereinafter referred to as “remuneration”) and on the terms and conditions as set out in the explanatory statement attached hereto, with liberty to the Board of Directors to alter and vary the terms and conditions of the said appointment and / or remuneration as it may deem fit and as may be acceptable to Dr. Dineshbhai Patel (DIN 00481641), subject to the same not exceeding the limits specified under Paragraph I (A) of Part II of Section II of Schedule V to the Companies Act, 2013 or any statutory modification(s) or re-enactment thereof.

RESOLVED FURTHER THAT in terms of Section 190 of the Companies Act, 2013, no formal contract of service with Dr. Dineshbhai Patel (DIN 00481641) will be executed and this resolution along with its explanatory statement be considered as Memorandum setting out terms and conditions of re-appointment and remuneration of Dr. Dineshbhai Patel (DIN 00481641) as Chairman and Managing Director.

RESOLVED FURTHER THAT any of the Directors of the Company be and are hereby severally authorized to do all acts and take all such steps as may be necessary, proper or expedient to give effect to above resolutions.”

Registered office:

8-A, Gulnar, Chinar-Gulnar Appartment,
V V Nagar Road, Anand - 388 001, Gujarat

By order of the Board of Directors
For, **HEMO ORGANIC LIMITED**
CIN: L24231GJ1992PLC018224

Place: Anand

Date: August 11, 2021

Dr. Dinesh Patel
Chairman and Managing Director
DIN: 00481641

IMPORTANT NOTES

1. In view of the continuing COVID-19 pandemic, the Ministry of Corporate Affairs (“MCA”) has vide its General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 05, 2020, General Circular No. 22/2020 dated June 15, 2020, General Circular No. 33/2020 dated September 28, 2020, General Circular No. 39/2020 dated December 31, 2020, General Circular No. 02/2021 dated January 13, 2021 and General Circular No. 10/2021 dated June 23, 2021 (the “MCA Circulars”) read with Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, issued by SEBI (hereinafter collectively referred to as “the applicable Circulars”) have permitted the companies to hold their Annual General Meeting (“AGM”) through video conferencing / any other audio visual means (“VC facility”) without the physical presence of the members at a common venue. Hence, in compliance with these Circulars, the AGM of the Company is being held through VC facility. The deemed venue of the meeting shall be the registered office of the Company.
The detailed procedure for participation in the meeting through VC/OAVM is provided at the end of notice and available at the Company’s website www.hemoorganicltd.com. The deemed venue for the AGM shall be the Registered Office of the Company situated in Anand, Gujarat.
2. Information regarding appointment/re-appointment of Director(s) pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard II is annexed hereto.
3. Though, pursuant to the provisions of the Act, a Member is entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf, since this AGM is being held pursuant to the Circular No. 14/2020 dated April 8, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
4. Institutional/Corporate Shareholders (i.e. other than individuals/HUF, NRI, etc.) are required to send a scanned copy (PDF/JPEG Format) of its Board Resolution or governing body Resolution/Authorization etc., authorizing its representative to attend the Annual General Meeting through VC/OAVM on its behalf and to vote through remote e-voting. The said Resolution/Authorization shall be sent to the Scrutinizer by email through their registered email address to csanandlavingia@gmail.com with copies marked to the Company at drdineshpatel@rediffmail.com and to National Securities Depository Limited (NSDL) at evoting@nsdl.co.in. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
5. Since the AGM will be held through VC/OAVM, the route map of the venue of the Meeting is not annexed hereto.
6. In line with the aforesaid Ministry of Corporate Affairs (MCA) Circulars and SEBI Circular dated May 12, 2020 read with Circular dated January 15, 2021, the Notice of AGM along with Annual Report 2020-21 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. Member may note that Notice and Annual Report 2020-21 has been uploaded on the website of the Company at www.hemoorganicltd.com and the website of the Stock Exchange i.e. BSE Limited at www.bseindia.com. The Notice can also be accessed from the website of NSDL i.e. www.evoting.nsdl.com.
7. Those shareholders who have not yet registered their e-mail address are requested to get their e-mail addresses submitted, by following the procedure given below:
 - (a) In case shares are held in physical mode, please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), and AADHAR (self-attested scanned copy of Aadhar Card) by email to drdineshpatel@rediffmail.com.
 - (b) In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to drdineshpatel@rediffmail.com.

- (c) Alternatively member may send an e-mail request to evoting@nsdl.co.in for obtaining User ID and Password by proving the details mentioned in Point (a) or (b) as the case may be.
 - (d) In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.
 - (e) It is clarified that for permanent submission of e-mail address, the shareholders are however requested to register their email address, in respect of electronic holdings with the depository through the concerned depository participants and in respect of physical holdings with the Company's Registrar and Share Transfer Agent, MCS Share Transfer Agent Limited ("MSTPL"), having its office at 10, Aaram Apartment, 12, Sampatrao Colony, B/h. Laxmi Hall, Alkapuri, Vadodra - 390 007 by following the due procedure.
 - (f) Those shareholders who have already registered their e-mail address are requested to keep their e-mail addresses validated with their depository participants / the Company's Registrar and Share Transfer Agent, MCS Share Transfer Agent Limited to enable servicing of notices / documents / annual Reports electronically to their e-mail address.
8. Members seeking any information with regard to the accounts or any matter to be placed at the AGM or who would like to ask questions or registered themselves as Speaker, are requested to write to the Company mentioning their name demat account number/folio number, email id, mobile number at drdineshpatel@rediffmail.com on or before September 19, 2021 so as to enable the management to keep the information ready. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.
 9. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013 and all other documents referred to in the Notice will be available for inspection in electronic mode.
 10. Members holding the shares in dematerialized form are requested to notify immediately, the information regarding change of address and bank particulars to their respective Depository Participant.
 11. **PROCESS AND MANNER FOR MEMBERS OPTING FOR VOTING THROUGH ELECTRONIC MEANS AND PARTICIPATING AT THE ANNUAL GENERAL MEETING THROUGH VC/OAVM:**
 - i. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 8, 2020, April 13, 2020, May 5, 2020 and SEBI Circular dated May 12, 2020, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with NSDL, as the Authorized e-voting agency for facilitating voting through electronic means. The facility of casting votes by a member using remote e-voting as well as e-voting system on the date of the AGM will be provided by NSDL.
 - ii. The Register of Members and Share Transfer Books of the Company will remain close from Thursday, September 23, 2021 to Wednesday, September 29, 2021 (both days inclusive). Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off date i.e. Wednesday, September 22, 2021, shall be entitled to avail the facility of remote e-voting as well as e-voting system on the date of the AGM. Any recipient of the Notice, who has no voting rights as on the Cut-off date, shall treat this Notice as intimation only.
 - iii. A person who has acquired the shares and has become a member of the Company after the dispatch of the Notice of the AGM and prior to the Cut-off date i.e. Wednesday, September 22, 2021, shall be entitled to exercise his/her vote either electronically i.e. remote e-voting or e-voting system on the date of the AGM by following the procedure mentioned in this part.
 - iv. The remote e-voting will commence on 9:00 A.M. on Sunday, September 26, 2021 and will end on 5:00 P.M. on Tuesday, September 28, 2021. During this period, the members of the Company holding shares as on the Cut-off date i.e. Wednesday, September 22, 2021 may cast their vote electronically. The members will not be able to cast their vote electronically beyond the date and time mentioned above and the remote e-voting module shall be disabled for voting by NSDL thereafter.
 - v. Once the vote on a resolution is cast by the member, he/she shall not be allowed to change it subsequently or cast the vote again.
 - vi. The voting rights of the members shall be in proportion to their share in the paid up equity share capital of the Company as on the Cut-off date i.e. Wednesday, September 22, 2021.
 - vii. The Company has appointed CS Anand S Lavingia, Practicing Company Secretary, to act as the Scrutinizer for conducting the remote e-voting process as well as the e-voting system on the date of the AGM, in a fair and transparent manner.

INSTRUCTIONS FOR CASTING VOTES BY REMOTE E-VOTING

The remote e-voting period begins on 9:00 A.M. on Sunday, September 26, 2021 and will end on 5:00 P.M. on Tuesday, September 28, 2021. The remote e-voting module shall be disabled by NSDL for voting thereafter.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1. Access to NSDL e-Voting system.

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode:

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> 1. If you are already registered for NSDL IDEAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under "IDEAS" section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on options available against company name or e-Voting service provider - NSDL and you will be re-directed to NSDL e-Voting website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. If the user is not registered for IDEAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDEAS" Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on options available against company name or e-Voting service provider - NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Individual Shareholders holding securities in demat mode with CDSL	<ol style="list-style-type: none"> 1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. 2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote. 3. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.
--	--

Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Once login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on options available against company name or e-Voting service provider-NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
--	---

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 or 022-23058542-43

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***.

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the ‘initial password’ which was communicated to you. Once you retrieve your ‘initial password’, you need to enter the ‘initial password’ and the system will force you to change your password.
 - c) How to retrieve your ‘initial password’?
 - i. If your email ID is registered in your demat account or with the company, your ‘initial password’ is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your ‘User ID’ and your ‘initial password’.
 - ii. If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.
6. If you are unable to retrieve or have not received the “ Initial password” or have forgotten your password:
 - a) Click on “Forgot User Details/Password?”(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?” (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

Step 2. Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join General Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

HEMO ORGANIC LIMITED

GENERAL GUIDELINES FOR SHAREHOLDERS

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to csanandlavingia@gmail.com with a copy marked to evoting@nsdl.co.in.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request at evoting@nsdl.co.in.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join General meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at drdineshpatel@rediffmail.com. The same will be replied by the company suitably.

CONTACT DETAILS

Company	HEMO ORGANIC LIMITED Registered Office: 8-A, Gulnar, Chinar-Gulnar Apartment, V V Nagar Road, Anand - 388 001 Tel No. +91 2692 248 535; Email: drdineshpatel@rediffmail.com; Web: www.hemoorganicltd.com
Registrar and Transfer Agent	MCS SHARE TRANSFER AGENT LIMITED 10, Aaram Apartment, 12, Sampatrao Colony, B/h Laxmi Hall, Alkapuri, Vadodra - 390 007. Tel No.: 0265 2314757/2350490; Email: mcsltdbaroda@gmail.com
e-Voting Agency & VC / OAVM	Email: evoting@nsdl.co.in NSDL help desk 1800 1020 990 and 1800 22 44 30
Scrutinizer	Mr. Anand S Lavingia Email: csanandlavingia@gmail.com; Tel No.: +91 79 - 4005 1702

EXPLANATORY STATEMENT**(Pursuant to Section 102 (1) of the Companies Act 2013 and Secretarial Standard 2 on General Meetings)****Item No. 3:****To regularize appointment of Mr. Sanjeev Lodha (DIN: 02719095) as Non-Executive Independent Director of the Company: ORDINARY RESOLUTIONS**

Mr. Sanjeev Lodha (DIN 02719095) was appointed as an Additional (Non-Executive Independent) Director w.e.f. October 5, 2020 in accordance with the provisions of Section 161 of the Companies Act, 2013 by the Board of Directors.

Pursuant to the provisions of Section 161 of the Companies Act, 2013, Mr. Sanjeev Lodha (DIN 02719095) will hold office up to the date of the ensuing AGM. The Company has received notice in writing under the provisions of Section 160 of the Companies Act, 2013, from a member proposing the candidature of Mr. Sanjeev Lodha (DIN 02719095) for the office of Non-Executive Independent Director of the Company and to be appointed as such under the provisions of Section 149 of the Companies Act, 2013.

The Nomination and Remuneration Committee and the Board of Directors has, at their respective meetings held on August 11, 2021, considered and recommended the appointment of Mr. Sanjeev Lodha (DIN 02719095) as a Non-Executive Independent Director of the Company to hold office for a period up to October 4, 2025, not liable to retire by rotation. In the opinion of Nomination and Remuneration Committee and the Board, Mr. Sanjeev Lodha (DIN 02719095), the Non-Executive Independent Director proposed to be appointed, fulfills the conditions specified in the Companies Act, 2013 and the Rules made thereunder and he is independent of the Management.

Mr. Sanjeev Lodha (DIN 02719095), aged 44 years, has experience of foreign trade and allied activity. He is also involved in a various investment related activity and trading in a stock. He is actively working in a business research / expansion etc.

The Company has received from Mr. Sanjeev Lodha (DIN 02719095) (i) consent in writing to act as director in Form DIR 2 pursuant to Rule 8 of Companies (Appointment & Qualification of Directors) Rules 2014, (ii) intimation in Form DIR 8 in terms of Companies (Appointment & Qualification of Directors) Rules, 2014, to the effect that he is not disqualified under Sub-section (2) of Section 164 of the Companies Act, 2013, and (iii) a declaration to the effect that he meets the criteria of independence as provided in Sub-section (6) of Section 149 of the Companies Act, 2013.

A copy of the draft letter for the appointment of Mr. Sanjeev Lodha (DIN 02719095) as Non-Executive Independent Director setting out the terms and conditions is available for inspection of members in electronic form.

The resolution seeking the approval of members for the appointment of Mr. Sanjeev Lodha (DIN 02719095) as Non-Executive Independent Director of the Company to hold office for a period up to October 4, 2025, pursuant to Section 149 and other applicable provisions of the Companies Act, 2013 and the Rules made thereunder is proposed by the Board of Directors. Further, he will not be liable to retire by rotation.

The Board recommends the matter and the resolution set out under Item No. 3 for the approval of the Members by way of passing Ordinary Resolutions.

Except Mr. Sanjeev Lodha (DIN 02719095) himself and his relatives to the extent their shareholding in the Company, none of the Directors or Key Managerial Personnel and their immediate relatives are concerned or interested, financially or otherwise, except to their shareholding, in the aforesaid resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

Item No. 4:**To regularize appointment of Ms. Siyona Jhanwar (DIN: 07857945) as Non-Executive Director of the Company: ORDINARY RESOLUTIONS**

Ms. Siyona Jhanwar (DIN 07857945) was appointed as an Additional (Non-Executive) Director w.e.f. October 5, 2020 in accordance with the provisions of Section 161 of the Companies Act, 2013 by the Board of Directors.

Pursuant to the provisions of Section 161 of the Companies Act, 2013, Ms. Siyona Jhanwar (DIN 07857945) will hold office up to the date of the ensuing AGM. The Company has received notice in writing under the provisions of Section 160 of the Companies Act, 2013, from a member proposing the candidature of Ms. Siyona Jhanwar (DIN 07857945) for the office of Non-Executive Director of the Company and to be appointed as such under the provisions of Section 152 of the Companies Act, 2013.

Ms. Siyona Jhanwar (DIN 07857945), aged 35 years, is having experience of more than a decade in the field of business administration. She is also associates with various multinational companies for business management related services on freelancing basis. Further she has also a vast experience in the field of marketing, manufacturing, procurement of pharmaceutical and surgical items.

The Company has received from Ms. Siyona Jhanwar (DIN 07857945) (i) consent in writing to act as director in Form DIR 2 pursuant to Rule 8 of Companies (Appointment & Qualification of Directors) Rules 2014, (ii) intimation in Form DIR 8 in terms of Companies (Appointment & Qualification of Directors) Rules, 2014, to the effect that she is not disqualified under Sub-section (2) of Section 164 of the Companies Act, 2013.

A copy of the draft letter for the appointment of Ms. Siyona Jhanwar (DIN 07857945) as Non-Executive Director setting out the terms and conditions is available for inspection of members in electronic form.

The resolution seeking the approval of members is proposed for the appointment of Ms. Siyona Jhanwar (DIN 07857945) as Non-Executive Director of the Company pursuant to Section 152 and other applicable provisions of the Companies Act, 2013 and the Rules made thereunder. She will be liable to retire by rotation.

The Nomination and Remuneration Committee and the Board recommends the resolution set forth in Item no. 4 for the approval of the members.

HEMO ORGANIC LIMITED

Except Ms. Siyona Jhanwar (DIN 07857945) and her relatives, none of the Directors and Key Managerial Personnel of the Company and their respective relatives is, in any way, concerned or interested, in the Resolutions set out at Item No. 4 of the Notice.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

Item No. 5:

Re-appointment of Mrs. Sonalben Patel (DIN 02848171) as Executive Director of the Company and approval of the payment of remuneration: SPECIAL RESOLUTIONS

The Board of Directors of the Company, in their Meeting held on August 11, 2021, has re-appointed Mrs. Sonalben Patel (DIN 02848171) as Executive Director of the Company. It is in the best interest of the Company to appoint her for a further period of 5 (Five) years w.e.f. August 11, 2021, on the terms & conditions of re-appointment and remuneration as given here in after.

Moreover, the Nomination and Remuneration Committee, in their meeting held on August 11, 2021, has considered the matter and recommended the re-appointment of Mrs. Sonalben Patel (DIN 02848171) under Paragraph I (A) of Part II of Section II of Schedule V and approved the terms and condition of re-appointment and remuneration of Mrs. Sonalben Patel (DIN 02848171) w.e.f. August 11, 2021 subject to the approval of the Shareholders at this Annual General Meeting. The Committee has noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

General Information:

Nature of Industry: The Company is in Pharma products.

Date or expected date of commencement of commercial production: The Company has stated its manufacturing activities way back in the year 1992 i.e. soon after its incorporation.

In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus: Not Applicable

Financial performance based on given indicators:

(₹ in Thousands)

Particulars	F.Y. 2020-21	F.Y. 2019-20
Revenue from Operations	80.70	2,771.80
Other Income	-	-
Total Income	80.70	2,771.80
Operating Expenditure before Finance Cost, Depreciation and Amortization	559.43	2,990.06
Earnings before Finance Cost, Depreciation and Amortization	(478.73)	(218.26)
Less: Finance Cost	-	-
Depreciation and Amortization Expenses	-	-
Profit/(Loss) before Tax	(478.73)	(218.26)
Less: Tax Expense	-	-
Profit/(Loss) after Tax (PAT)	(478.73)	(218.26)

Foreign investments or collaborations, if any: No collaborations has been made by the Company with any of foreign entity. Further, as at March 31, 2021, total holding of NRI was 6400 Equity Shares.

Information about the appointee:

Background Details, Job Profile and her suitability: She has around 18 years of experience of general administration.

Past Remuneration: ₹ 1.47 Lakh for F.Y. 2020-21.

Recognition or awards: Nil.

Terms and conditions of Re-appointment and Remuneration:-

Term of re-appointment: 5 (Five) years with effect from August 11, 2021.

Remuneration Proposed:

Basic Salary up to ₹ 0.50 Lakh per month for a period of 5 years from the date of re-appointment with an increment of 10% every year;

Provided that Increment shall be applicable w.e.f. April 1 of every year and the first increment shall be applicable w.e.f. April 1, 2022.

Other information:

Reasons of loss or inadequate profits: The Company is finding difficulty in generating revenue and hence the Company is facing problem to generate adequate profit.

HEMO ORGANIC LIMITED

Steps taken or proposed to be taken for improvement: The Company is finding the reason and steps are being taken for generating the business revenue.

In compliance with the provisions of Sections 196, 197 and other applicable provisions of the Act, read with Schedule V to the Act, the terms of re-appointment and remuneration specified above are now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for payment for a period of 3 years from the date of re-appointment.

The Board of Directors is of the view that the re-appointment of Mrs. Sonalben Patel (DIN 02848171) as Executive Director will be beneficial to the operations of the Company and the remuneration payable to her is commensurate with her abilities and experience and accordingly commend the Resolution at Item No. 5 of the accompanying Notice for approval by the Members of the Company.

Except Mrs. Sonalben Patel (DIN 02848171) herself and her relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

Item No. 6:

Re-appointment of Dr. Dineshbhai Patel (DIN 00481641) as Chairman and Managing Director of the Company and approval of the payment of remuneration: SPECIAL RESOLUTIONS

The Board of Directors of the Company, in their Meeting held on August 11, 2021, has re-appointed Dr. Dineshbhai Patel (DIN 00481641) as Chairman and Managing Director of the Company.

Dr. Dineshbhai Patel (DIN 00481641) is responsible for managing the Company subject to the superintendence, control and direction of the Board of Directors. It is in the best interest of the Company to appoint him for a further period of 5 (Five) years w.e.f. August 11, 2021, on the terms & conditions of re-appointment and remuneration as given here in after.

Moreover, the Nomination and Remuneration Committee, in their meeting held on August 11, 2021, has considered the matter and recommended the re-appointment of Dr. Dineshbhai Patel (DIN 00481641) under Paragraph I (A) of Part II of Section II of Schedule V and approved the terms and condition of re-appointment and remuneration of Dr. Dineshbhai Patel (DIN 00481641) w.e.f. August 11, 2021 subject to the approval of the Shareholders at this Annual General Meeting. The Committee has noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

General Information:

Nature of Industry: The Company is in Pharma products.

Date or expected date of commencement of commercial production: The Company has stated its manufacturing activities way back in the year 1992 i.e. soon after its incorporation.

In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus: Not Applicable

Financial performance based on given indicators:

(₹ in Thousands)

Particulars	F.Y. 2020-21	F.Y. 2019-20
Revenue from Operations	80.70	2,771.80
Other Income	-	-
Total Income	80.70	2,771.80
Operating Expenditure before Finance Cost, Depreciation and Amortization	559.43	2,990.06
Earnings before Finance Cost, Depreciation and Amortization	(478.73)	(218.26)
Less: Finance Cost	-	-
Depreciation and Amortization Expenses	-	-
Profit/(Loss) before Tax	(478.73)	(218.26)
Less: Tax Expense	-	-
Profit/(Loss) after Tax (PAT)	(478.73)	(218.26)

Foreign investments or collaborations, if any: No collaborations has been made by the Company with any of foreign entity. Further, as at March 31, 2021, total holding of NRI was 6400 Equity Shares.

Information about the appointee:

Background Details: Academically he holds a science master degree. Afterwards he has completed his P.HD in chemistry area. He had started his industrial journey before 2 decade. Chemical, Pharmacy and other allied activity is a pillar of his career. He is regularly active in a various research activity which gives a better quality of pharmacy to the society.

Past Remuneration: ₹ 0.90 Lakh for F.Y. 2020-21.

Recognition or awards: Nil.

HEMO ORGANIC LIMITED

Job Profile and his suitability: Dr. Dineshbhai Patel (DIN 00481641) is responsible for managing the Company subject to superintendence, control and direction of the Board of Directors.

Terms and conditions of Re-appointment and Remuneration:-

Term of re-appointment: 5 (Five) years with effect from August 11, 2021.

Remuneration Proposed:

Basic Salary up to ₹ 0.50 Lakh per month for a period of 5 years from the date of re-appointment with an increment of 10% every year;

Provided that Increment shall be applicable w.e.f. April 1 of every year and the first increment shall be applicable w.e.f. April 1, 2022.

Other information:

Reasons of loss or inadequate profits: The Company is finding difficulty in generating revenue and hence the Company is facing problem to generate adequate profit.

Steps taken or proposed to be taken for improvement: The Company is finding the reason and steps are being taken for generating the business revenue.

In compliance with the provisions of Sections 196, 197 and other applicable provisions of the Act, read with Schedule V to the Act, the terms of re-appointment and remuneration specified above are now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for payment for a period of 3 years from the date of re-appointment.

The Board of Directors is of the view that the re-appointment of Dr. Dineshbhai Patel (DIN 00481641) as Chairman and Managing Director will be beneficial to the operations of the Company and the remuneration payable to him is commensurate with his abilities and experience and accordingly commend the Resolution at Item No. 6 of the accompanying Notice for approval by the Members of the Company.

Except Dr. Dineshbhai Patel (DIN 00481641) himself and his relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

Registered office:

8-A, Gulnar, Chinar-Gulnar Appartment,
V V Nagar Road, Anand - 388 001, Gujarat

By order of the Board of Directors
For, HEMO ORGANIC LIMITED
CIN: L24231GJ1992PLC018224

Place: Anand

Date: August 11, 2021

Dr. Dinesh Patel
Chairman and Managing Director
DIN: 00481641

HEMO ORGANIC LIMITED

DETAILS OF DIRECTOR SEEKING RE-APPOINTMENT/ APPOINTMENT AT THE 29TH ANNUAL GENERAL MEETING

(Pursuant to Regulation 36(3) of SEBI (LODR), Regulations, 2015 and Secretarial Standard II)

Name	Mr. Sanjeev Lodha	Ms. Siyona Jhanwar	Mrs. Sonalben Patel	Dr. Dineshbhai Patel
Date of Birth	September 01, 1977	November 11, 1986	March 19, 1966	July 1, 1961
Qualification	Mr. Sanjeev Lodha (DIN 02719095), aged 44 years, has experience of foreign trade and allied activity. He is also involved in a various investment related activity and trading in a stock. He is actively working in a business research / expansion etc.	Ms. Siyona Jhanwar (DIN 07857945), aged 35 years, is having experience of more than a decade in the field of business administration. She is also associates with various multinational companies for business management related services on freelancing basis. Further she has also a vast experience in the field of marketing, manufacturing, procurement of pharmaceutical and surgical items.	Graduate She has around 18 years of experience of general administration.	MSC (Chemistry), P.HD. Academically he holds a science master degree. Afterwards he has completed his P.HD in chemistry area. He had started his industrial journey before 2 decade. Chemical, Pharmacy and other allied activity is a pillar of his career. He is regularly active in a various research activity which gives a better quality of pharmacy to the society.
No. of Shares held	Nil	Nil	47000 Equity Shares	536940 Equity Shares
Terms & Conditions	As per Resolution No. 3 of the Notice.	As per Resolution No. 4 of the Notice.	As per Resolution No. 5 of the Notice.	As per Resolution No. 6 of the Notice.
Remuneration paid in FY 2020-21	Nil	Nil	₹ 1.47 Lakh	₹ 0.90 Lakh
Remuneration sought to be paid	Nil	Nil	As per Resolution No. 5 of the Notice.	As per Resolution No. 6 of the Notice.
Number of Board Meetings attended during the FY 2020-21	5 out of 5	5 out of 5	8 out of 8	8 out of 8
Date of Original Appointment	October 5, 2020	October 5, 2020	July 1, 1994	August 28, 1992
Date of Appointment in current terms	October 5, 2020	October 5, 2020	August 11, 2021	August 11, 2021
Directorships held in other public companies*	Nil	Nil	Nil	Nil
Memberships / Chairpersonships of committees of public companies*	Membership - 2 Committees	Nil	Membership - 1 Committee	Membership - 1 Committee
Inter-se Relationship with other Directors.	No Relation	No Relation	Mrs. Sonalben Patel is spouse of Dr. Dineshbhai Patel.	Dr. Dineshbhai Patel is spouse of Mrs. Sonalben Patel.

*Includes only Audit Committee and Stakeholders' Relationship Committee.

DIRECTOR'S REPORT

Your Directors take pleasure in presenting their report on the business and operations of your Company along with Audited Financial Statements for the year ended on March 31, 2021.

FINANCIAL PERFORMANCE (₹ in Thousands)

Particulars	F.Y. 2020-21	F.Y. 2019-20
Revenue from Operations	80.70	2,771.80
Other Income	-	-
Total Income	80.70	2,771.80
Operating Expenditure before Finance Cost, Depreciation and Amortization	559.43	2,990.06
Earnings before Finance Cost, Depreciation and Amortization	(478.73)	(218.26)
Less: Finance Cost	-	-
Depreciation and Amortization Expenses	-	-
Profit/(Loss) before Tax	(478.73)	(218.26)
Less: Tax Expense	-	-
Profit/(Loss) after Tax (PAT)	(478.73)	(218.26)

Review of Performance

In the financial year 2020-21, the Company has earned ₹ 8,07,000 from revenue from operations compared to ₹ 27,71,800 for the financial year 2019-20. Due to high employee expenses, the Company has incurred Loss after tax of ₹ 4,78,730 during the financial year 2020-21 as compared to loss after tax of ₹ 2,18,260 in the financial year 2019-20.

Dividend & Reserves

In view of the loss made during the year, your Directors regret to recommend any dividend for the year 2020-21 (previous year Nil).

During the year, the Company has not apportioned any amount to other reserve. The loss incurred during the year has been carried to the Balance Sheet.

Change in Nature of Business

During the year under review, there is no change in the Nature of business activities carried out by the Company.

Changes to Share Capital

At present the Authorized Share Capital of the Company stands at ₹ 3,50,00,000 divided into 3500000 Equity Shares of ₹ 10 each and the Paid-up Share Capital stands at ₹ 3,46,59,000 divided into 3465900 Equity Shares of ₹ 10 each. There has been no change in the share capital during the period ended March 31, 2021.

BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Constitution of Board

As on date of this report, the Board of the Company comprises of five Directors out of which two is Promoter Executive Director, one is Non-Promoter Non-Executive Director and rest of the Directors is Non-Promoter Non-Executive Independent Directors. As on the date of this report, the Board comprises following Directors.

Name of Director	Category Cum Designation	Date of Appointment at current term	Total Directorship	No. of Committee [^]		No. of Shares held as on March 31, 2021
				in which Director is Member	in which Director is Chairman	
Dr. Dineshbhai Patel	Chairman and Managing Director (Promoter)	August 28, 1992	1	1	-	5,36,940 Equity Shares
Mrs. Sonalben Patel	Executive Director (Promoter)	July 1, 1994	1	1	-	47,000 Equity Shares
Ms. Siyona Jhanwar	Non-Executive Director	October 5, 2020	1	-	-	-
Mr. Krushnakant Patel	Independent Director	September 30, 2006	1	2	2	-
Mr. Sanjeev Lodha	Independent Director	October 5, 2020	1	2	-	-

[^]Committee includes Audit Committee and Stakeholders Relationship Committee across all Public Companies.

HEMO ORGANIC LIMITED

None of the Directors of Board is a member of more than ten Committees or Chairman of more than five committees across all the Public companies in which they are Director. The necessary disclosures regarding Committee positions have been made by all the Directors.

None of the Director of the Company is serving as a Whole-Time Director in any Listed Company and is holding position of Independent Director in more than 3 Listed Companies. None of the Director of the Company is holding position as Independent Director in more than 7 Listed Companies. Further, none of the Directors of the Company is disqualified for being appointed as a Director pursuant to Section 164 (2) of the Companies Act, 2013.

Board Meeting

Regular meetings of the Board are held at least once in a quarter, inter-alia, to review the quarterly results of the Company. Additional Board meetings are convened to discuss and decide on various business policies, strategies and other businesses. During the year under review, Board of Directors of the Company met 8 (Eight) times viz; July 24, 2020; September 4, 2020; September 15, 2020; October 5, 2020; October 19, 2020; November 7, 2020; February 13, 2021 and March 31, 2021.

The details of attendance of each Director at the Board Meeting and Annual General Meeting are given below;

Name of Director	Dr. Dineshbhai Patel	Mrs. Sonalben Patel	Ms. Siyona Jhanwar	Mr. Krushnakant Patel	Mr. Sanjeev Lodha	Mr. Pankajbhai Patel	Mrs. Kinnariben Patel
Number of Board Meeting held	8	8	8	8	8	8	8
Number of Board Meetings Eligible to attend	8	8	5	8	5	3	3
Number of Board Meeting attended	8	8	5	8	5	3	3
Presence at the previous AGM	Yes	Yes	NA	No	NA	No	No

Changes in Directors

During the Financial year 2020-2021, Mrs. Kinnariben Patel and Mr. Pankajbhai Patel had tendered their resignation from the directorship of the Company w.e.f. October 5, 2020. The Board placed its appreciation to them for serving the Company during their tenure. The Board of Directors in their meeting held on, October 5, 2020, appointed Ms. Siyona Jhanwar as an Additional (Non-Executive) Director and Mr. Sanjeev Lodha as an Additional (Non-Executive Independent) Director of the Company.

In terms of Section 161 of the Companies Act, 2013, above directors hold office up to the date of ensuing Annual General Meeting of the Company. The Company has received the notice from Member under Section 160 of the Companies Act, 2013 signifying his intention to appoint above directors on the Board of the Company.

The Board of Directors and Nomination and Remuneration Committee have considered the profile of above directors and have recommended their appointment on the Board of the Company. Necessary resolutions for their appointment are proposed for the approval of the Members at the ensuing Annual General Meeting.

Further, the Board of Directors, in their meeting held on August 11, 2021, re-appointed Dr. Dineshbhai Patel and Mrs. Sonalben Patel as Chairman and Managing Director and Executive Director respectively for a period of 5 years w.e.f. August 11, 2021. Their terms of re-appointment and remuneration are proposed for the approval of the shareholders.

In accordance with the provisions of the Articles of Association and Section 152 of the Companies Act 2013, Mrs. Sonalben Patel, Executive Director of the Company, retires by rotation at the ensuing Annual General Meeting. She, being eligible, offers herself for re-appointment as such. The Board of Directors recommends her appointment on the Board.

Independent Directors

A separate meeting of Independent Directors was held on March 31, 2021 to review the performance of Non-Independent Directors and Board as whole and of the chairman and assess the quality, quantity and timeliness of flow of information between Company Management and Board. The terms and conditions of appointment of Independent Directors and Code for Independent Director are incorporated on the website of the Company at www.hemoorganicltd.com. The Company has received necessary declaration from each independent director under Section 149 (7) of the Companies Act, 2013 that they meet the criteria of independence laid down in Section 149 (6) of the Companies Act, 2013.

Details of Key Managerial Personnel

In accordance with Section 203 of the Companies Act, 2013, the Company has Mr. Dineshbhai Patel who is acting as Managing Director of the Company.

Addition to this during the Financial Year 2020-2021, the Company has appointed Ms. Payal Rishabh Shah as Company Secretary and Compliance Officer and Mr. Dipak Rajnikant Joshi as Chief Financial Officer of the Company.

Performance Evaluation

The Board of Directors has carried out an annual evaluation of its own performance, board committees and individual directors pursuant to the provisions of the Act.

- The performance of the board was evaluated by the board, after seeking inputs from all the directors, on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning etc.
- The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc.
- The board and the nomination and remuneration committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the performance of chairman was also evaluated on the key aspects of his role.
- Separate meeting of independent directors was held to evaluate the performance of non-independent directors, performance of the board as a whole and performance of the chairman, taking into account the views of executive directors and non-executive directors. The same was discussed in the board meeting that followed the meeting of the independent directors, at which the performance of the board, its committees and individual directors was also discussed. Performance evaluation of independent directors was done by the entire board, excluding the independent director being evaluated.

Directors Responsibility Statement

Pursuant to section 134(5) of the Companies Act, 2013, the board of directors, to the best of their knowledge and ability, confirm that:

- a) In preparation of annual accounts for the year ended March 31, 2021, the applicable accounting standards have been followed and that no material departures have been made from the same;
- b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that year;
- c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) The Directors had prepared the annual accounts for the year ended March 31, 2021 on going concern basis.
- e) The Directors had laid down the internal financial controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively; and
- f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

COMMITTEES OF BOARD

Your Company has constituted several Committees in compliance with the requirements of the relevant provisions of applicable laws and statutes, details of which are given hereunder.

1. Audit Committee

Audit Committee meeting is generally held once in quarter for the purpose of recommending the quarterly/half yearly/yearly financial results and the gap between two meetings did not exceed one hundred and twenty days. The Audit Committee met Five (5) times during the financial year 2020-2021 viz; July 24, 2020; September 4, 2020; September 15, 2020; November 7, 2020 and February 13, 2021.

The composition of the Committee and the details of meetings attended by its members are given below:

Name of Members	Category	Designation in Committee	Number of meetings during the financial year 2020-21		
			Held	Eligible to attend	Attended
Mr. Pankajbhai Patel [^]	Independent Director	Chairperson	5	3	3
Mr. Krushnakant Patel*	Independent Director	Chairperson	5	5	5
Mrs. Sonalben Patel	Executive Director	Member	5	5	5
Mr. Sanjeev Lodha-	Independent Director	Member	5	2	2

[^] resigned w.e.f. October 5, 2020 * re-designated and appointed as Chairperson w.e.f. October 5, 2020

- Appointed w.e.f. October 5, 2020

The Company Secretary of the Company is acting as Secretary to the Audit Committee.

Recommendations of Audit Committee, wherever/whenever given, have been accepted by the Board of Directors. Further, the terms of reference, roles and powers of the Audit Committee is as per Section 177 of the Companies Act, 2013 (as amended).

Vigil Mechanism

The Company has established a vigil mechanism and accordingly framed a Whistle Blower Policy. The policy enables the employees to report to the management instances of unethical behavior, actual or suspected fraud or violation of company's Code of Conduct. Further the mechanism adopted by the Company encourages the Whistle Blower to report genuine concerns or grievances and provide for adequate safe guards against victimization of the Whistle Blower who avails of such mechanism and also provides for direct access to the Chairman of the Audit Committee, in exceptional cases. The functioning of vigil mechanism is reviewed by the Audit Committee from time to time. None of the Whistle blowers has been denied access to the Audit Committee of the Board. The Whistle Blower Policy of the Company is available on the website of the Company at www.hemoorganicltd.com.

2. Nomination and Remuneration Committee

The Company has formed Nomination and Remuneration committee in line with the provisions Section 178 of the Companies Act, 2013. Nomination and Remuneration Committee meetings are generally held for identifying the person who is qualified to become Directors and may be appointed in senior management and recommending their appointments and removal.

During the year under review, the Nomination and Remuneration Committee met Four (4) times viz; September 4, 2020; October 5, 2020; October 19, 2020 and March 31, 2021 to recommend the appointment of Director and KMPs and to review the performance of Directors of the Company.

The composition of the Committee and the details of meetings attended by its members are given below:

Name of Members	Category	Designation in Committee	Number of meetings during the financial year 2020-21		
			Held	Eligible to attend	Attended
Mr. Krushnakant Patel	Independent Director	Chairperson	4	4	4
Mr. Pankajbhai Patel [^]	Independent Director	Member	4	1	1
Mrs. Sonalben Patel [@]	Executive Director	Member	4	2	2
Mr. Sanjeev Lodha ⁻	Independent Director	Member	4	2	2
Ms. Siyona Jhanwar ⁻	Non-Executive Director	Member	4	2	2

[^] resigned w.e.f. October 5, 2020 [@] removed w.e.f. October 5, 2020 ⁻ Appointed w.e.f. October 5, 2020

Further, the terms of reference of the Nomination and Remuneration Committee is as per Section 178 of the Companies Act, 2013 (as amended).

Nomination and Remuneration Policy

The Company has, in order to attract motivated and retained manpower in competitive market and to harmonize the aspirations of human resources consistent with the goals of the Company and in terms of the provisions of the Companies Act, 2013 devised a policy on Nomination and Remuneration of Directors, Key Managerial Personnel and Senior Management. Key points of the Policy are:

A. Policy on Appointment of Directors, Key Managerial Personnel and Senior Management Personnel

- The policy is formulated to identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP and Senior Management personnel and recommend to the Board for his / her appointment.
- A person should possess adequate qualification, expertise and experience for the position he/ she is considered for appointment.
- In case of appointment of Independent Director, the Committee shall satisfy itself with regard to the independent nature of the Director vis-à-vis the Company so as to enable the Board to discharge its function and duties effectively.

B. Policy on remuneration of Director, key managerial personnel and senior management personnel

The Company remuneration policy is driven by the success and performance of the Director, KMP and Senior Management Personnel vis-à-vis the Company. The Company philosophy is to align them and provide adequate compensation with the Objective of the Company so that the compensation is used as a strategic tool that helps us to attract, retain and motivate highly talented individuals who are committed to the core value of the Company. The Nomination and Remuneration Policy, as adopted by the Board of Directors, is placed on the website of the Company at www.hemoorganicltd.com.

Remuneration of Directors:

(₹ in Lakh)

Name of Directors	Designation	Salary	Sitting Fees	Perquisite	Total
Dr. Dineshbhai Patel	Chairman and Managing Director	0.90	-	-	0.90
Mrs. Sonalben Patel	Executive Director	1.47	-	-	1.47

3. Stakeholders' Grievances and Relationship Committee

The Company has constituted Stakeholder's Grievance & Relationship Committee mainly to focus on the redressal of Shareholders' / Investors' Grievances, if any, like Transfer / Transmission / Demat of Shares; Loss of Share Certificates; Non-receipt of Annual Report; Dividend Warrants; etc.

During the year under review, Stakeholders Relationship Committee met Four times during the financial year 2020-21 on July 24, 2020; September 4, 2020; November 7, 2020 and February 13, 2021.

The composition of the Committee and the details of meetings attended by its members are given below:

Name of Members	Category	Designation in Committee	Number of meetings during the financial year 2020-21		
			Held	Eligible to attend	Attended
Mr. Krushnakant Patel*	Independent Director	Chairperson	4	1	1
Dr. Dineshbhai Patel*	Executive Director	Member	4	4	4
Mr. Pankajbhai Patel^	Independent Director	Member	4	2	2
Mr. Sanjeev Lodha-	Independent Director	Member	4	2	2

* re-designated and appointed w.e.f. October 5, 2020

^ resigned w.e.f. October 5, 2020

- Appointed w.e.f. October 5, 2020

Company Secretary and Compliance officer of the Company provides secretarial support to the Committee.

During the year under review, the Company had received Nil complaints from the Shareholders. There was no complaint pending for resolution as on March 31, 2021. Further, the terms of reference of the Stakeholder's Grievance & Relationship Committee is as per Section 178 of the Companies Act, 2013 (as amended).

Public Deposits

The Company has not accepted any deposits from Shareholders and Public falling within the ambit of Section 73 of the Companies Act, 2013 and rules made there under. There were no deposits, which were claimed and remained unpaid by the Company as on March 31, 2021.

Risk Management

A well-defined risk management mechanism covering the risk mapping and trend analysis, risk exposure, potential impact and risk mitigation process is in place. The objective of the mechanism is to minimize the impact of risks identified and taking advance actions to mitigate it. The mechanism works on the principles of probability of occurrence and impact, if triggered. A detailed exercise is being carried out to identify, evaluate, monitor and manage both business and non-business risks.

Sexual Harassment of Women at Workplace

To foster a positive workplace environment, free from harassment of any nature, we have institutionalized the Anti-Sexual Harassment Initiative (ASHI) framework, through which we address complaints of sexual harassment at the all workplaces of the company. Our policy assures discretion and guarantees non-retaliation to complainants. We follow a gender-neutral approach in handling complaints of Sexual Harassment and we are complaint with the law of the land where we operate.

During the year under review, there were no incidences of sexual harassment reported.

Management Discussion and Analysis Report

Your attention is drawn to the perception and business outlook of your management for your company for current year and for the industry in which it operates including its position and perceived trends in near future. The Management Discussion and Analysis Report as stipulated under Schedule V of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 is attached and forms part of this Directors Report.

Particulars of Loans, Guarantees and Investments

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statement.

Annual Return

The Annual Return for the financial year 2020-21 is uploaded on the website of the Company at www.hemoorganicltd.com and also given in Annexure - A.

Contracts and Arrangements with Related Parties

During the financial year 2020-21, the company has not entered into any transactions with related parties as defined under Section 2(76) of the Companies Act, 2013, within the meaning of Section 188 of the Companies Act, 2013.

Material changes and commitment affecting financial position of the Company

There are no material changes and commitments, affecting the financial position of the Company which has occurred between the end of financial year of the Company and the date of this report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

A. Conservation of Energy -

- i.) The steps taken or impact on conservation of energy: None
- ii.) The steps taken by the Company for utilizing alternate sources of energy: None
- iii.) The capital investment on energy conservation equipment: None

B. Technology Absorption -

- i.) The effort made towards technology absorption: None
- ii.) The benefit derived like product improvement, cost reduction, product development or import substitution: None
- iii.) In case of imported technology (imported during the last three years reckoned from the beginning of the financial year) -
 - a. The details of technology imported: None
 - b. The year of import: None
 - c. Whether the technology has been fully absorbed: None
 - d. If not fully absorbed, areas where absorption has not taken place, and the reasons thereof: None
- iv.) The expenditure incurred on Research and Development: None

C. Foreign Exchange Earnings & Expenditure:

- i.) Details of Foreign Exchange Earnings: Nil
- ii.) Details of Foreign Exchange Expenditure: Nil

Particular of Employees

The ratio of the remuneration of each whole-time director to the median of employees' remuneration as per Section 197(12) of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this Report as Annexure - B.

Internal Financial Control

Your Company has laid down the set of standards, processes and structure which enables to implement internal financial control across the Organization and ensure that the same are adequate and operating effectively.

Statutory Auditors

M/s. M A A K & Associates, Chartered Accountants (FRN: 135024W) were appointed as Statutory Auditors of your Company at the 25th Annual General Meeting held on September 30, 2017, for a term till the conclusion of 30th Annual General Meeting to be held in the calendar year 2022, subject to ratification of appointment at every subsequent annual general meeting.

The Report given by the Auditors on the financial statement of the company is a part of this Annual Report. There are certain adverse remarks or disclaimer given by the Auditors in their Report related to i) they have not been provided with the balance confirmation or any other details for the trade receivable and trade payable shown in the books of accounts and ii) they have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to them for verification.

Your Directors state that i) the Company has already started process of obtaining the balance confirmation from trade receivable and trade payable and once received, the same will be provided to the Auditor; ii) further, since some of the accounts of the Company are dormant and accordingly, the same have not been collected from the Bank.

Secretarial Audit

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed Ms. Payal Dhamecha proprietor of M/s. Payal Dhamecha & Associates, Practising Company Secretary (Unique Code: S2020GJ735800), Ahmedabad, to undertake the Secretarial Audit of the Company for the financial year 2020-21. The Secretarial Audit Report is annexed herewith as Annexure - C.

Reporting of Fraud

The Auditors of the Company have not reported any fraud as specified under Section 143(12) of the Companies Act, 2013.

Corporate Governance

Your Company strives to incorporate the appropriate standards for corporate governance. However, pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is not required to mandatorily comply with the provisions of certain regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and therefore the Company has not provided a separate report on Corporate Governance, although few of the information are provided in this report of Directors under relevant heading.

Compliance with the provisions of SS 1 and SS 2

The applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively, have been duly complied by your Company.

General Disclosure

Your Directors state that the Company has made disclosures in this report for the items prescribed in section 134 (3) of the Act and Rule 8 of The Companies (Accounts) Rules, 2014 and other applicable provisions of the act and listing regulations, to the extent the transactions took place on those items during the year. Your Directors further state that no disclosure or reporting is required in respect of the following items as there were no ₹ transactions occur on these items during the year under review;

- (i) Details relating to deposits covered under Chapter V of the Act;
- (ii) Issue of Equity Shares with differential rights as to dividend, voting or otherwise;
- (iii) Issue of shares (including sweat equity shares) to employees of the Company under any scheme save and ESOS;
- (iv) Annual Report and other compliances on Corporate Social Responsibility;
- (v) There is no revision in the Board Report or Financial Statement;
- (vi) No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and company's operations in future;
- (vii) Information on subsidiary, associate and joint venture companies.

Acknowledgment

Your company & Directors wish to place on record their appreciation of the assistance and co-operation extended by Investors, Bankers, Business Associates, and Government. We are deeply grateful to shareholders for their continued faith, confidence and support to the company.

Registered office:
8-A, Gulnar, Chinar-Gulnar Appartment,
V V Nagar Road, Anand - 388 001, Gujarat

By order of the Board of Directors
For, **HEMO ORGANIC LIMITED**
CIN: L24231GJ1992PLC018224

Place: Anand
Date: August 11, 2021

Dr. Dinesh Patel
Chairman and Managing Director
DIN: 00481641

FORM NO. MGT-7

[Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of rule 11of the Companies (Management and Administration) Rules, 2014]



सत्यमेव जयते

Annual Return (other than OPCs and Small Companies)

Form language English Hindi

Refer the instruction kit for filing the form.

I. REGISTRATION AND OTHER DETAILS

(i) * Corporate Identification Number (CIN) of the company

L24231GJ1992PLC018224

Pre-fill

Global Location Number (GLN) of the company

* Permanent Account Number (PAN) of the company

AAACD6900D

(ii) (a) Name of the company

HEMO ORGANIC LIMITED

(b) Registered office address

8-A, GULNAR, CHINAR - GULNAR APPT.
V V NAGAR ROAD
ANAND
Gujarat
388001

(c) *e-mail ID of the company

drdineshpatel@rediffmail.com

(d) *Telephone number with STD code

02692248535

(e) Website

www.hemoorganicltd.com

(iii) Date of Incorporation

28/08/1992

Type of the Company	Category of the Company	Sub-category of the Company
Public Company	Company limited by shares	Indian Non-Government company

(v) Whether company is having share capital

Yes No

(vi) *Whether shares listed on recognized Stock Exchange(s)

Yes No

(a) Details of stock exchanges where shares are listed

S. No.	Stock Exchange Name	Code
1	BSE Limited	1

(b) CIN of the Registrar and Transfer Agent

U67120WB2011PLC165872

Pre-fill

Name of the Registrar and Transfer Agent

MCS SHARE TRANSFER AGENT LIMITED

Registered office address of the Registrar and Transfer Agents

383 LAKE GARDENS
1ST FLOOR

(vii) *Financial year From date 01/04/2020 (DD/MM/YYYY) To date 31/03/2021 (DD/MM/YYYY)

(viii) *Whether Annual general meeting (AGM) held Yes No

(a) If yes, date of AGM

(b) Due date of AGM

30/09/2021

(c) Whether any extension for AGM granted

Yes No

(f) Specify the reasons for not holding the same

To Be Held on 29/09/2021

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

*Number of business activities

1

S.No	Main Activity group code	Description of Main Activity group	Business Activity Code	Description of Business Activity	% of turnover of the company
1	C	Manufacturing	C6	Chemical and chemical products, pharmaceuticals, medicinal chemical and	100

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

*No. of Companies for which information is to be given

0

Pre-fill All

S.No	Name of the company	CIN / FCRN	Holding/ Subsidiary/Associate/ Joint Venture	% of shares held
1				

IV. SHARE CAPITAL, DEBENTURES AND OTHER SECURITIES OF THE COMPANY

(i) *SHARE CAPITAL

(a) Equity share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Total number of equity shares	3,500,000	3,465,900	3,465,900	3,465,900
Total amount of equity shares (in Rupees)	35,000,000	34,659,000	34,659,000	34,659,000

Number of classes

1

Class of Shares	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Equity Shares				
Number of equity shares	3,500,000	3,465,900	3,465,900	3,465,900
Nominal value per share (in rupees)	10	10	10	10
Total amount of equity shares (in rupees)	35,000,000	34,659,000	34,659,000	34,659,000

(b) Preference share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid-up capital
Total number of preference shares	0	0	0	0
Total amount of preference shares (in rupees)	0	0	0	0

Number of classes

0

Class of shares	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Number of preference shares				
Nominal value per share (in rupees)				
Total amount of preference shares (in rupees)				

(c) Unclassified share capital

Particulars	Authorised Capital
Total amount of unclassified shares	0

(d) Break-up of paid-up share capital

Class of shares	Number of shares			Total nominal amount	Total Paid-up amount	Total premium
	Physical	DEMAT	Total			
Equity shares						
At the beginning of the year	182,160	3,283,740	3465900	34,659,000	34,659,000	
Increase during the year	0	800	800	0	0	0
i. Public Issues	0	0	0	0	0	0
ii. Rights issue	0	0	0	0	0	0
iii. Bonus issue	0	0	0	0	0	0
iv. Private Placement/ Preferential allotment	0	0	0	0	0	0
v. ESOPs	0	0	0	0	0	0
vi. Sweat equity shares allotted	0	0	0	0	0	0
vii. Conversion of Preference share	0	0	0	0	0	0
viii. Conversion of Debentures	0	0	0	0	0	0
ix. GDRs/ADRs	0	0	0	0	0	0
x. Others, specify	0	800	800	0	0	0
Demat of Physical Shares						
Decrease during the year	800	0	800	0	0	0
i. Buy-back of shares	0	0	0	0	0	0
ii. Shares forfeited	0	0	0	0	0	0
iii. Reduction of share capital	0	0	0	0	0	0
iv. Others, specify	800	0	800	0	0	
Demat of Physical Shares						
At the end of the year	181,360	3,284,540	3465900	34,659,000	34,659,000	
Preference shares						
At the beginning of the year	0	0	0	0	0	
Increase during the year	0	0	0	0	0	0
i. Issues of shares	0	0	0	0	0	0
ii. Re-issue of forfeited shares	0	0	0	0	0	0

iii. Others, specify						
Decrease during the year	0	0	0	0	0	0
i. Redemption of shares	0	0	0	0	0	0
ii. Shares forfeited	0	0	0	0	0	0
iii. Reduction of share capital	0	0	0	0	0	0
iv. Others, specify						
At the end of the year	0	0	0	0	0	

ISIN of the equity shares of the company

(ii) Details of stock split/consolidation during the year (for each class of shares)

Class of shares		(i)	(ii)	(iii)
Before split / Consolidation	Number of shares			
	Face value per share			
After split / Consolidation	Number of shares			
	Face value per share			

(iii) Details of shares/Debentures Transfers since closure date of last financial year (or in the case of the first return at any time since the incorporation of the company) *

Nil

[Details being provided in a CD/Digital Media]

Yes No Not Applicable

Separate sheet attached for details of transfers

Yes No

Note: In case list of transfer exceeds 10, option for submission as a separate sheet attachment or submission in a CD/Digital Media may be shown.

Date of the previous annual general meeting	<input type="text"/>
---	----------------------

Date of registration of transfer (Date Month Year)	<input type="text"/>
--	----------------------

Type of transfer	<input type="text"/>	1 - Equity, 2- Preference Shares,3 - Debentures, 4 - Stock
------------------	----------------------	--

Number of Shares/ Debentures/ Units Transferred	<input type="text"/>	Amount per Share/ Debenture/Unit (in Rs.)	<input type="text"/>
---	----------------------	---	----------------------

Ledger Folio of Transferor	<input type="text"/>
----------------------------	----------------------

Transferor's Name	<input type="text"/>	<input type="text"/>	<input type="text"/>
	Surname	middle name	first name

Ledger Folio of Transferee	<input type="text"/>
----------------------------	----------------------

Transferee's Name	<input type="text"/>	<input type="text"/>	<input type="text"/>
	Surname	middle name	first name

Date of registration of transfer (Date Month Year)	<input type="text"/>
--	----------------------

Type of transfer	<input type="text"/>	1 - Equity, 2- Preference Shares,3 - Debentures, 4 - Stock
------------------	----------------------	--

Number of Shares/ Debentures/ Units Transferred	<input type="text"/>	Amount per Share/ Debenture/Unit (in Rs.)	<input type="text"/>
---	----------------------	---	----------------------

Ledger Folio of Transferor	<input type="text"/>
----------------------------	----------------------

Transferor's Name	<input type="text"/>	<input type="text"/>	<input type="text"/>
	Surname	middle name	first name

Ledger Folio of Transferee	<input type="text"/>
----------------------------	----------------------

Transferee's Name	<input type="text"/>	<input type="text"/>	<input type="text"/>
	Surname	middle name	first name

(iv) *Debentures (Outstanding as at the end of financial year)

Particulars	Number of units	Nominal value per unit	Total value
Non-convertible debentures	0	0	0
Partly convertible debentures	0	0	0
Fully convertible debentures	0	0	0
Total			0

Details of debentures

Class of debentures	Outstanding as at the beginning of the year	Increase during the year	Decrease during the year	Outstanding as at the end of the year
Non-convertible debentures	0	0	0	0
Partly convertible debentures	0	0	0	0
Fully convertible debentures	0	0	0	0

(v) Securities (other than shares and debentures)

0

Type of Securities	Number of Securities	Nominal Value of each Unit	Total Nominal Value	Paid up Value of each Unit	Total Paid up Value
Total					

V. *Turnover and net worth of the company (as defined in the Companies Act, 2013)

(i) Turnover

807,000

(ii) Net worth of the Company

658,020

VI. (a) *SHARE HOLDING PATTERN - Promoters

S. No.	Category	Equity		Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	583,940	16.85	0	
	(ii) Non-resident Indian (NRI)	0	0	0	
	(iii) Foreign national (other than NRI)	0	0	0	

2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	
3.	Insurance companies	0	0	0	
4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	
6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	0	0	0	
10.	Others	0	0	0	
	Total	583,940	16.85	0	0

Total number of shareholders (promoters)

2

(b) *SHARE HOLDING PATTERN - Public/Other than promoters

S. No.	Category	Equity		Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	2,559,477	73.85	0	
	(ii) Non-resident Indian (NRI)	6,400	0.18	0	
	(iii) Foreign national (other than NRI)	0	0	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	
3.	Insurance companies	0	0	0	

4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	
6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	316,083	9.12	0	
10.	Others	0	0	0	
	Total	2,881,960	83.15	0	0

Total number of shareholders (other than promoters)

1,353

**Total number of shareholders (Promoters+Public/
Other than promoters)**

1,355

**VII. *NUMBER OF PROMOTERS, MEMBERS, DEBENTURE HOLDERS
(Details, Promoters, Members (other than promoters), Debenture holders)**

Details	At the beginning of the year	At the end of the year
Promoters	2	2
Members (other than promoters)	1,369	1,353
Debenture holders	0	0

VIII. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

(A) *Composition of Board of Directors

Category	Number of directors at the beginning of the year		Number of directors at the end of the year		Percentage of shares held by directors as at the end of year	
	Executive	Non-executive	Executive	Non-executive	Executive	Non-executive
A. Promoter	2	0	2	0	16.85	0
B. Non-Promoter	0	3	0	3	0	0
(i) Non-Independent	0	1	0	1	0	0
(ii) Independent	0	2	0	2	0	0
C. Nominee Directors representing	0	0	0	0	0	0

(i) Banks & FIs	0	0	0	0	0	0
(ii) Investing institutions	0	0	0	0	0	0
(iii) Government	0	0	0	0	0	0
(iv) Small share holders	0	0	0	0	0	0
(v) Others	0	0	0	0	0	0
Total	2	3	2	3	16.85	0

Number of Directors and Key managerial personnel (who is not director) as on the financial year end date

7

(B) (i) *Details of directors and Key managerial personnel as on the closure of financial year

Name	DIN/PAN	Designation	Number of equity share(s) held	Date of cessation (after closure of financial year : If any)
DINESHBHAI SHANAB	00481641	Managing Director	536,940	
SONALBEN PATEL	02848171	Director	47,000	
KRUSHNAKANT RAME	00507736	Director	0	
SANJEEV LODHA	02719095	Additional director	0	
SIYONAA MOHAN LAL	07857945	Additional director	0	
PAYAL RISHABH SHAH	BCPPD2090F	Company Secretar	0	
DIPAK RAJNIKANT JO	AFVPJ5439A	CFO	0	

(ii) Particulars of change in director(s) and Key managerial personnel during the year

6

Name	DIN/PAN	Designation at the beginning / during the financial year	Date of appointment/ change in designation/ cessation	Nature of change (Appointment/ Change in designation/ Cessation)
PANKAJ RAMESHBHA	02889398	Director	05/10/2020	Cessation
KINNARIBEN PATEL	02889405	Director	05/10/2020	Cessation
SANJEEV LODHA	02719095	Additional director	05/10/2020	Appointment
SIYONAA MOHAN LAL	07857945	Additional director	05/10/2020	Appointment
PAYAL RISHABH SHAH	BCPPD2090F	Company Secretar	19/10/2020	Appointment
DIPAK RAJNIKANT JO	AFVPJ5439A	CFO	19/10/2020	Appointment

IX. MEETINGS OF MEMBERS/CLASS OF MEMBERS/BOARD/COMMITTEES OF THE BOARD OF DIRECTORS

A. MEMBERS/CLASS /REQUISITIONED/NCLT/COURT CONVENED MEETINGS

Number of meetings held

1

Type of meeting	Date of meeting	Total Number of Members entitled to attend meeting	Attendance	
			Number of members attended	% of total shareholding
AGM	30/09/2020	1,365	21	52.41

B. BOARD MEETINGS

*Number of meetings held

8

S. No.	Date of meeting	Total Number of directors associated as on the date of meeting	Attendance	
			Number of directors attended	% of attendance
1	24/07/2020	5	5	100
2	04/09/2020	5	5	100
3	15/09/2020	5	5	100
4	05/10/2020	5	5	100
5	19/10/2020	5	5	100
6	07/11/2020	5	5	100
7	13/02/2021	5	5	100
8	31/03/2021	5	5	100

C. COMMITTEE MEETINGS

Number of meetings held

14

S. No.	Type of meeting	Date of meeting	Total Number of Members as on the date of the meeting	Attendance	
				Number of members attended	% of attendance
1	Audit Committee	24/07/2020	3	3	100
2	Audit Committee	04/09/2020	3	3	100
3	Audit Committee	15/09/2020	3	3	100

S. No.	Type of meeting	Date of meeting	Total Number of Members as on the date of the meeting	Attendance	
				Number of members attended	% of attendance
4	Audit Committee	07/11/2020	3	3	100
5	Audit Committee	13/02/2021	3	3	100
6	Stakeholders'	04/09/2020	3	3	100
7	Stakeholders'	15/09/2020	3	3	100
8	Stakeholders'	07/11/2020	3	3	100
9	Stakeholders'	13/02/2021	3	3	100
10	Independent Director	31/03/2021	2	2	100

D. *ATTENDANCE OF DIRECTORS

S. No.	Name of the director	Board Meetings			Committee Meetings			Whether attended AGM held on
		Number of Meetings which director was entitled to attend	Number of Meetings attended	% of attendance	Number of Meetings which director was entitled to attend	Number of Meetings attended	% of attendance	
		(Y/N/NA)						
1	DINESHBHAI	8	8	100	4	4	100	
2	SONALBEN P	8	8	100	9	9	100	
3	KRUSHNAKA	8	8	100	14	14	100	
4	SANJEEV LOI	5	5	100	6	6	100	
5	SIYONAA MO	5	5	100	2	2	100	

X. *REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Nil

Number of Managing Director, Whole-time Directors and/or Manager whose remuneration details to be entered

1

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/Sweat equity	Others	Total Amount
1	DINESHBHAI SHAN	Managing Director	90,000	0	0	0	90,000
	Total		90,000	0	0	0	90,000

Number of CEO, CFO and Company secretary whose remuneration details to be entered

1

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/Sweat equity	Others	Total Amount
--------	------	-------------	--------------	------------	---------------------------	--------	--------------

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Mrs. Sonal Patel	Executive Director	147,000	0	0	0	147,000
	Total		147,000	0	0	0	147,000

Number of other directors whose remuneration details to be entered

0

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1							0
	Total						

XI. MATTERS RELATED TO CERTIFICATION OF COMPLIANCES AND DISCLOSURES

* A. Whether the company has made compliances and disclosures in respect of applicable provisions of the Companies Act, 2013 during the year Yes No

B. If No, give reasons/observations

The Company has not appointed Internal Auditor for the financial year 2020-21 and as such is non-compliant of Section 138 of the Companies Act, 2013 and 4. The Company has not maintained functional website as required under Regulation 46 of the Securities and Exchange Board of India

XII. PENALTY AND PUNISHMENT - DETAILS THEREOF

(A) DETAILS OF PENALTIES / PUNISHMENT IMPOSED ON COMPANY/DIRECTORS /OFFICERS Nil

Name of the company/ directors/ officers	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which penalised / punished	Details of penalty/ punishment	Details of appeal (if any) including present status

(B) DETAILS OF COMPOUNDING OF OFFENCES Nil

Name of the company/ directors/ officers	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which offence committed	Particulars of offence	Amount of compounding (in Rupees)

XIII. Whether complete list of shareholders, debenture holders has been enclosed as an attachment

Yes No

XIV. COMPLIANCE OF SUB-SECTION (2) OF SECTION 92, IN CASE OF LISTED COMPANIES

In case of a listed company or a company having paid up share capital of Ten Crore rupees or more or turnover of Fifty Crore rupees or more, details of company secretary in whole time practice certifying the annual return in Form MGT-8.

Name

Anand Lavingia

Whether associate or fellow

Associate Fellow

Certificate of practice number

11410

I/We certify that:

(a) The return states the facts, as they stood on the date of the closure of the financial year aforesaid correctly and adequately.

(b) Unless otherwise expressly stated to the contrary elsewhere in this Return, the Company has complied with all the provisions of the Act during the financial year.

Declaration

I am Authorised by the Board of Directors of the company vide resolution no. ..

04

dated

29/05/2018

(DD/MM/YYYY) to sign this form and declare that all the requirements of the Companies Act, 2013 and the rules made thereunder in respect of the subject matter of this form and matters incidental thereto have been complied with. I further declare that:

1. Whatever is stated in this form and in the attachments thereto is true, correct and complete and no information material to the subject matter of this form has been suppressed or concealed and is as per the original records maintained by the company.
2. All the required attachments have been completely and legibly attached to this form.

Note: Attention is also drawn to the provisions of Section 447, section 448 and 449 of the Companies Act, 2013 which provide for punishment for fraud, punishment for false statement and punishment for false evidence respectively.

To be digitally signed by

Director

DIN of the director

00481641

To be digitally signed by

Company Secretary

Company secretary in practice

Membership number

Certificate of practice number

Attachments

- 1. List of share holders, debenture holders
- 2. Approval letter for extension of AGM;
- 3. Copy of MGT-8;
- 4. Optional Attachement(s), if any

Attach
Attach
Attach
Attach

List of attachments

--

Remove attachment

Modify

Check Form

Prescrutiny

Submit

This eForm has been taken on file maintained by the Registrar of Companies through electronic mode and on the basis of statement of correctness given by the company

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
Indian Clearing Corporation Ltd				110000100011370	86246	EQUITY SHARES
MITAXI HEMANTKUMAR GANDHI				1201040000016376	200	EQUITY SHARES
UTSAV UTTAM BAGRI				1201040000049256	100	EQUITY SHARES
USHA RAVINDRA MODI				1201060000486839	10	EQUITY SHARES
PRAKASHCHANDRA BABULAL MEHTA				1201060000672380	25	EQUITY SHARES
PUKHRAJ M JAIN				1201060002280460	400	EQUITY SHARES
SADHU BHAVANABEN JAYESHKUMAR				1201060002436898	4960	EQUITY SHARES
AEROTECH IMPEX INFOSOLUTION PRIVATE LIMITED				1201060002441207	7451	EQUITY SHARES
Batukarai Nyalchandbhai Kamdar				1201060100017564	100	EQUITY SHARES
Pushpa Batukbhai Kamdar				1201060100017583	100	EQUITY SHARES
Rajesh Batukbhai Kamdar				1201060100017598	100	EQUITY SHARES
MITESH DAHYABHAI PATEL				1201070000063878	2425	EQUITY SHARES
HITESH VITHALBHAI POKAR				1201070000144617	50	EQUITY SHARES
RAJANIKANT ISHVERLAL SHALIA				1201070000149731	30	EQUITY SHARES
SANJAY RAJNIKANT SHAH				1201070000166052	10	EQUITY SHARES
SAGARIKA INFRASTRUCTURE PRIVATE LIMITED				1201070000446125	3448	EQUITY SHARES
RAMA RAJIV JAGDALE				1201070000446131	300	EQUITY SHARES
RAJIV R JAGDALE HUF				1201070000446159	1999	EQUITY SHARES
DEEPAK MANHARLAL MEHTA				1201070000545861	1000	EQUITY SHARES
BABUBHAI SHAH				1201070000548201	3000	EQUITY SHARES
PRATAP KESHAVLAL SHAH				1201080000054543	2750	EQUITY SHARES
RASKIN TRIKAMLAL BAROT				1201080000058402	500	EQUITY SHARES
MEHULKUMAR RAJENDRABHAI SONI				1201080000078195	100	EQUITY SHARES
MADAN KISANGOPAL RATHI				1201090000078671	4	EQUITY SHARES
NARENDRA PANDURANG NAWALE				1201090001530958	100	EQUITY SHARES
HEMANG HARSHAD DOSHI				1201090001758971	300	EQUITY SHARES
HARSHAD KESHAVJI DOSHI				1201090001765881	1890	EQUITY SHARES
ASHISH AMRUTLAL PATEL				1201090003059703	740	EQUITY SHARES
JAYSHREE RAMESH LAKHANI				1201090003801717	790	EQUITY SHARES
ABHISEKHA PATTNAYAK				1201090004107040	90	EQUITY SHARES
SHAIKESH J MEHTA				1201090004191541	1000	EQUITY SHARES
JIGNESHKUMAR ARVINDBHAI PATEL				1201090004684642	500	EQUITY SHARES
RAGA FINVEST LIMITED				1201090005554791	1	EQUITY SHARES
BHARAT CHHOTALAL KALYANI				1201090006559780	110	EQUITY SHARES
PARESHKUMAR BANSILAL KHAMAR				1201090009359240	200	EQUITY SHARES
GOPAL PRASAD				1201090009942215	1	EQUITY SHARES
PAWAN KUMAR JAGDISHPRASAD GOENKA				1201090011351981	35	EQUITY SHARES
VIPUL JITENDRA PAREKH				1201090016315061	200	EQUITY SHARES
ASHABEN RAJENDRAKUMAR SHETH				1201090019136990	214	EQUITY SHARES
KARTIK SANDEEP KULKARNI				1201091900174557	435	EQUITY SHARES
KEYUR KANUBHAI THAKKAR				1201120000352363	200	EQUITY SHARES
BIJAL JIGNESH SHAH				1201120100046471	250	EQUITY SHARES
ALPABEN LAXMANBHAI KUNDALIA				1201130000075782	700	EQUITY SHARES
JAGESH A SHAH HUF				1201130000153136	100	EQUITY SHARES
JYOTI KAMLESH PATEL				1201130000269179	200	EQUITY SHARES
PATEL VINUBHAI R				1201130000356831	1000	EQUITY SHARES
JASHBHAI NARANBHAI PATEL				1201130000613659	2727	EQUITY SHARES
SANJAYKUMAR RATILAL SHAH				1201130000698613	175	EQUITY SHARES
JAYESHBHAI ROHITBHAI KACHHIYA				1201130000833177	94	EQUITY SHARES
RAMESH LAXMANRAJ VANIGOTTA				1201210000077636	500	EQUITY SHARES
DAL BAHADUR SINGH				1201210100346524	1	EQUITY SHARES
ASHOK VITHALDAS MARTHAH				1201260000015411	200	EQUITY SHARES
HIREN R AMIN				1201260000052868	500	EQUITY SHARES
JITESH RAGHAVAN CHURAKKAT				1201260000099647	15	EQUITY SHARES
BHAVDEEP JAGDISHBHAI SHAH				1201260000156314	100	EQUITY SHARES
JITENDRA CHANDULAL SHAH				1201290000042065	200	EQUITY SHARES
ANIL AMRUTLAL PARMAR				1201320000204490	500	EQUITY SHARES
JAYANTILAL C CHOUDHARI				1201330000664671	200	EQUITY SHARES
DEEP CHAND JAIN				1201330000853321	600	EQUITY SHARES
SHUBHAM JAIN				1201330001202960	1000	EQUITY SHARES
PRAGYA JAIN				1201330001320797	1000	EQUITY SHARES
NEMICHAND JAIN				1201330001333221	2000	EQUITY SHARES
PANDURANG SHANKAR BIBAVE				1201370000158163	100	EQUITY SHARES
PRAMILA SUNIL SHETTY				1201370000309039	175	EQUITY SHARES
ALPANA DUTT				1201410000022471	10	EQUITY SHARES
GAURAV BHARADWAJ				1201640000181647	120	EQUITY SHARES
KOMAL				1201700000310980	1401	EQUITY SHARES
TEJAS DILIPBHAI PATEL				1201750000296183	233	EQUITY SHARES
VIJAY HEMANT LAKHANI				1201770100522451	25	EQUITY SHARES
YOGESH KANTILAL POPAT				1201800000308467	11	EQUITY SHARES
ASHOK KUMAR MODI HUF				1201860000161408	299	EQUITY SHARES
AVANI MITULBHAI SHAH				1201860000621350	200	EQUITY SHARES
JIMEET GAUTAMBHAI SHETH				1201910100355408	26	EQUITY SHARES
PALLAVI SAMIR PATHAK				1201910101757290	500	EQUITY SHARES
TARUNA KHEMCHANDANI				1201910102066718	189	EQUITY SHARES
SADHNA SINGH				1201910103124397	1000	EQUITY SHARES
SACHINKUMAR BIPINCHANDRA BHATT				1201910103853872	200	EQUITY SHARES
PRAFULLAKIRAN PURUSHOTTAM BOKIL				1201910104064253	1000	EQUITY SHARES
SWATICHANDRA PRIYATAMBHAI ACHARYA				1201980000163387	50	EQUITY SHARES
AMIT NATVARBHAI PATEL				1202000000020719	10	EQUITY SHARES
NIMISHA DILIP SANGHANI				1202000000021328	129	EQUITY SHARES
AMIT KUMAR JOSHI				1202060000346517	350	EQUITY SHARES
PRADEEP SATYANARAYAN KABRA				1202300000024964	1000	EQUITY SHARES
BIJAL BAHADUR KAPADIA				1202300000095956	100	EQUITY SHARES
NAGENDRA SATYANARAYAN BHUTRA				1202300000516639	1000	EQUITY SHARES
SADASHIV DHANAJI MAHAJAN				1202300000669551	500	EQUITY SHARES
SWARNJIT KOUR				1202300001037981	200	EQUITY SHARES
ASHISH AMRUTLAL MUTHA				1202350000268146	1	EQUITY SHARES
VISHAL N MANSETA				1202400000016016	200	EQUITY SHARES
GAURANG SHANKERLAL DESAI				1202470000474074	100	EQUITY SHARES
HARAKCHAND PREMJI BHAI SHAH				1202550000132088	10850	EQUITY SHARES
HEMLATA HARAKCHAND SHAH				1202550000132092	700	EQUITY SHARES
BELA JAYESHBHAI SHAH				1202550000132109	3000	EQUITY SHARES
CHINTAN BIPINCHANDRA PUJARA				1202550000132113	300	EQUITY SHARES
KAVIT DILIPBHAI VARMA				1202550000155895	220	EQUITY SHARES
NITIN RUNGTA HUF				1202650100019761	3309	EQUITY SHARES
RONAK NARESHBHAI ARORA				1202680000025020	1000	EQUITY SHARES
KAMLADEVI CHANDULAL ARORA				1202680000072544	800	EQUITY SHARES
ANKIT ARVINDBHAI SHAH				1202680000095889	500	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
MUKESHKUMAR CHHOTABHAI PATEL				1202680000097930	1000	EQUITY SHARES
ILABEN NALINBHAI PATEL				1202680000099524	4000	EQUITY SHARES
AMBALAL JETHABHAI PRAJAPATI				1202680000107063	200	EQUITY SHARES
NIHIR ARVINDBHAI PATEL				1202680000124009	500	EQUITY SHARES
MEHUL DHIRAJLAL SHAH				1202870000043897	750	EQUITY SHARES
NAYANABEN MANGALBHAI PATEL				1202870000061192	500	EQUITY SHARES
JAYANTILAL SARDARMAL JAIN HUF				1202870000093541	2500	EQUITY SHARES
AMITBHAI MUKESHBHAI BHAVSAR				1202870000114195	50	EQUITY SHARES
PARASHOTTAMBHAI SHIVARAMDAS PATEL				1202870000121504	50	EQUITY SHARES
BHAVDIPKUMAR PARSOTTAMBHAI PATEL				1202870000121654	20	EQUITY SHARES
RAMESHKUMAR VIRAMDAS PATEL				1202870000147757	20480	EQUITY SHARES
HARSHADKUMAR SOMABHAI PATEL				1202870000276175	500	EQUITY SHARES
DARSHAN SATISH SHAH				1202890000484486	3000	EQUITY SHARES
AXIT DILIP SHAH				12028900000940571	2430	EQUITY SHARES
VIDHI AXIT SHAH				12028900000940586	4770	EQUITY SHARES
ANJANA VIPUL SHAH				12028900000951617	475	EQUITY SHARES
NISARG R SHAH				12028900000953082	3550	EQUITY SHARES
KETAN A PANCHAMIA HUF				12028900000978084	900	EQUITY SHARES
REENA BIRJU MODI				12028900000995091	800	EQUITY SHARES
CHETAN BABULAL SHAH				12028900001052510	700	EQUITY SHARES
SHRADDHA KETAN PANCHAMIA				12028900001092497	1000	EQUITY SHARES
SEJAL PRAGNESH SHAH				12028900001107618	500	EQUITY SHARES
ASHA HARSHAD SHAH				12028900001107622	705	EQUITY SHARES
PRACHI KRUNAL SHAH				12028900001140297	5508	EQUITY SHARES
VIPUL JIVRAJBHAI SAVANI				12028900001145242	900	EQUITY SHARES
ANSHUMAN NARENDRAKUMAR JAIN				12028900001145597	200	EQUITY SHARES
ANANTRAI VANMALIDAS PANCHAMIA				12028900001145850	3000	EQUITY SHARES
AJAY S MUCHHALA HUF				12028900001231802	1000	EQUITY SHARES
NIYATI HARSHAD SHAH				12028900001234457	500	EQUITY SHARES
VIDHI NISARG SHAH				12028900001246612	2	EQUITY SHARES
SAMIRKUMAR NAVINCHANDRA SHAH				12028900001522256	2000	EQUITY SHARES
DINESH B RATHOD HUF BASTIMAL RATHOD				1202900000016382	800	EQUITY SHARES
ALKA MITTAL				1202920000042567	100	EQUITY SHARES
RAJEEV AGRAWAL				1202920000048174	123	EQUITY SHARES
SANJEEV AGRAWAL				1202920000141866	140	EQUITY SHARES
PRANAY SURESH KAPADIA				1202970000139991	1	EQUITY SHARES
ATUL HAKAMCHAND SHAH				1202970000219131	200	EQUITY SHARES
MAHENDRAKUMAR ZAVERBHAI PATEL				1202970000241410	5530	EQUITY SHARES
KIRANKUMAR BABULAL PATEL				1202970000241425	3530	EQUITY SHARES
PATEL HIMANSHU BALDEVPRASAD				1203000000615167	800	EQUITY SHARES
PRATIK D JOSHI				1203000000769425	663	EQUITY SHARES
JIGNESH GIRISHKUMAR RANA				1203000000962212	192	EQUITY SHARES
SHASHIKANT MAHASUKHLAL SHAH				1203000001044042	25	EQUITY SHARES
AARTIBEN UDAYKUMAR DOSHI				1203030000047347	200	EQUITY SHARES
KRUTIKA KETANKUMAR DESAI				1203030000051621	25	EQUITY SHARES
NITINBHAI VINODCHANDRA SHAH				1203030000065529	650	EQUITY SHARES
VIMALKUMAR VASANTLAL CHAHWALA				1203150000119659	6500	EQUITY SHARES
VIMALKUMAR VASANTLAL CHAHWALA HUF				1203150000135886	63	EQUITY SHARES
URVASHI V JARIWALA				1203150000137387	50	EQUITY SHARES
HEZELIN P GANDHI				1203150000145590	5500	EQUITY SHARES
NIKITA MEHUL VAKHARIA				1203150000148901	100	EQUITY SHARES
USHABEN BIPINCHANDRA KHAMBHATI				1203150000149314	1000	EQUITY SHARES
BIPINCHANDRA NATVERLAL KHAMBHATI				1203150000149329	1000	EQUITY SHARES
HEMANTKUMAR NATVERLAL KHAMBHATI				1203150000149371	1000	EQUITY SHARES
ROYBYEN JASHVANTLAL MODI				1203150000150862	100	EQUITY SHARES
BIPINCHANDRA NATVERLAL KHAMBHATI				1203150000151146	1000	EQUITY SHARES
AVINASHGIRI JAGANNATHGIRI MEHTA				1203150000160767	145	EQUITY SHARES
RAJESH VINODCHANDRA DABAWALA				1203150000161606	1000	EQUITY SHARES
ANITA JAGDISH UNAGAR				1203150000176741	35	EQUITY SHARES
DINESHBHAI JANAKBHAI VANSESA				1203150000187903	185	EQUITY SHARES
NILESH B PATEL				1203150000195756	181	EQUITY SHARES
SAGARKUMAR P GANDHI				1203150000207397	2800	EQUITY SHARES
BHAKTIBEN RAKESHKUMAR GANDHI				1203150000232092	20700	EQUITY SHARES
PRAJAPATI MITESH AMRUTLAL				1203230001037559	60	EQUITY SHARES
SUTHAR MANISH R				1203230002818908	250	EQUITY SHARES
WEALTH MANTRA LIMITED				1203270000153053	100	EQUITY SHARES
ESHANEE HYDER KAZI				1203300000009096	600	EQUITY SHARES
HYDER HOSSAIN KAZI				1203300000017747	600	EQUITY SHARES
SURESHCHANDRA JAYANTILAL PATEL				1203320000001509	400	EQUITY SHARES
DAHYABHAI SHIVGANBHAI PATEL				1203320000003510	6300	EQUITY SHARES
NAYAN JAYANTILAL SANGHAVI				1203320000099314	1050	EQUITY SHARES
KETAN NARSINBHAI PATEL				1203320000113454	2150	EQUITY SHARES
PRANAY KUMAR BALDEV PRASHAD PANCHOLI				1203320000777187	50	EQUITY SHARES
VINOD GORDHANDAS PANCHASARA				1203320000829361	1427	EQUITY SHARES
JAYESH HARAKHCHAND SHAH				1203320000851976	200	EQUITY SHARES
JAIMIN KANTIBHAI PATEL				1203320001201865	400	EQUITY SHARES
ILABEN NALINBHAI PATEL				1203320001284229	8000	EQUITY SHARES
CHETANABEN B SANGHAVI				1203320001560721	118	EQUITY SHARES
MITABEN R SANGHAVI				1203320001566565	100	EQUITY SHARES
PATEL CHANDRIKABEN JITENDRABHAI				1203320001642169	83	EQUITY SHARES
DHANJIBHAI NARSINHDAS PATEL				1203320002052031	1650	EQUITY SHARES
NILESHKUMAR PATEL				1203320003990470	5998	EQUITY SHARES
BAROT SUNILBHAI A				1203320004573636	2204	EQUITY SHARES
HETALBEN ASHISHKUMAR MAHETA				1203320004880868	200	EQUITY SHARES
PRABODH SHANTILAL MEHTA				1203320005105096	300	EQUITY SHARES
ATUL PRABHULAL MEHTA				1203320005503210	100	EQUITY SHARES
SANKET SUBANDHUBHAI PATEL				1203320005987359	2000	EQUITY SHARES
RUPESH NITIN MORABIA				1203320006278039	200	EQUITY SHARES
ANILKUMAR TIRTHDAS LEKHWANI				1203320006860261	76	EQUITY SHARES
PURNIMA SHUKLA				1203320007109526	650	EQUITY SHARES
NAYANA AFRAM DESAI				1203320007757844	1000	EQUITY SHARES
AFRAIM PURSOTTAMDAS DESAI				1203320007759803	1000	EQUITY SHARES
NIRAV SURESHBHAI PATEL				1203320007893531	2874	EQUITY SHARES
SUNIL TIRATHDAS LAKHWANI				1203320007918384	259	EQUITY SHARES
PANCHASARA SADHANABEN V				1203320009086901	400	EQUITY SHARES
Jiten Durgaprasad Patel				1203330000017516	200	EQUITY SHARES
DINESHBHAI LALJIBHAI NAIK				1203330000202463	100	EQUITY SHARES
APEKSHA S PUNEKAR				1203330000483195	200	EQUITY SHARES
VINUBHAI BACHUBHAI GOHEL				1203330000617433	400	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
GANDHI TRUPESH ASHOKKUMAR				1203330000906158	800	EQUITY SHARES
RAJIV MAHESHWARI				1203350001406079	15	EQUITY SHARES
AKHILESH KUMAR				1203350001536041	50	EQUITY SHARES
ABHAY KUMAR WORAH				1203360000000404	200	EQUITY SHARES
PRAFUL MANILAL SHAH				1203400000002089	100	EQUITY SHARES
RUCHI CHUNILAL PATEL				1203410000483985	1000	EQUITY SHARES
JYOTSANABEN RAMESHKUMAR PATEL				1203410000484974	4860	EQUITY SHARES
LATABEN NARENDRA CHAUHAN				1203440000134435	100	EQUITY SHARES
MAULIK REVASHANKAR JOSHI				1203440000272698	100	EQUITY SHARES
DALWADI DIPAKKUMAR R				1203440000728788	900	EQUITY SHARES
DAXABEN BHARATBHAI PATEL				1203440000735736	800	EQUITY SHARES
JINANG M BOKHANI				1203440000744341	3750	EQUITY SHARES
JAYABEN P GURUNANI				1203440000758593	47	EQUITY SHARES
PRITI HIREN VAKIL				1203440000770361	250	EQUITY SHARES
RABARI KIRANKUMAR HARTANBHAI				1203440000771591	500	EQUITY SHARES
PANDYA VIPULRAI V				1203440000804060	300	EQUITY SHARES
PATEL NIRAV SURESHBHAI				1203440000817823	3071	EQUITY SHARES
ARCADIA SHARE AND STOCK BROKERS PVT LTDPROPRIETARY AC				1203440001056669	1	EQUITY SHARES
VIVIAN VICTOR DSOUZA				1203440001059032	10	EQUITY SHARES
JAWAHAR CHIMANLAL DESAI				1203460000401862	250	EQUITY SHARES
SATISH RAMGOPAL ANCHAN				1203460000415305	503	EQUITY SHARES
NAYNABEN R LALAN				1203460000436754	238	EQUITY SHARES
NITA DEVENDRA SHAH				120349000015313	200	EQUITY SHARES
GIRA KIRTIKUMAR SHAH				1203500001118098	200	EQUITY SHARES
ANILKUMAR MADANLAL MEHTA				120350001172819	1000	EQUITY SHARES
HETAL JITENDRAKUMAR MADIA				1203500001667045	6011	EQUITY SHARES
RASHMIKABEN R PATEL				1203510000099806	90	EQUITY SHARES
T D PATEL				1203510000389689	1000	EQUITY SHARES
BIJALBEN K PARMAR				1203510000391303	50	EQUITY SHARES
VIPUL SURYAKANT VAKHARIA				1203550000012173	150	EQUITY SHARES
BAROT PRIMALKUMAR P				1203600000563788	300	EQUITY SHARES
NITINBHAI GANDALAL SHAH				1203600000675321	500	EQUITY SHARES
VIMLESH MAHENDRAKUMAR MODH				1203600000959627	1620	EQUITY SHARES
YAGNIK DIPEN DEVENDRABHAI				1203600001203040	4000	EQUITY SHARES
MAHENDRAKUMAR VITHALDAS MODH				1203600001250091	1500	EQUITY SHARES
RAJENDRAKUMAR RANCHHODBHAI PRAJAPATI				1203600001363213	6500	EQUITY SHARES
JAVIA TEJASH CHIMANLAL				1203600001472761	15	EQUITY SHARES
DAVE PUSHPABEN K				1203600001517571	5000	EQUITY SHARES
ARPANA BHAVINBHAI SHAH				1203600005476067	975	EQUITY SHARES
SUNIL KUMAR JAIN				1203680000090630	3	EQUITY SHARES
NARSINHBHAI LAKHUBHAI PATEL				1203760000163895	2100	EQUITY SHARES
KALPESH KUMAR RAMESHCHANDRA RAVAL				1203760000415575	500	EQUITY SHARES
DINESH JAIN				1203800000135641	100	EQUITY SHARES
HARDIK DINESHCHANDRA SHAH				120400000174361	200	EQUITY SHARES
PARAG SEVANTILAL SHAH				1204130000019564	200	EQUITY SHARES
BHAVISHA ABHAY SHAH				1204130000020700	400	EQUITY SHARES
ANULATA DHANSUKHLAL PATEL PATEL				1204150000003875	24	EQUITY SHARES
SUMITRA NARESH KOTHARI				1204150000025044	50	EQUITY SHARES
PAYAL PRADIPBHAI SHAH				1204150000070731	25	EQUITY SHARES
SEJAL VIPUL SHAH				1204150000091154	500	EQUITY SHARES
SHRENIKBHAI RAJMALBHAI VOHERA				1204150000118920	1000	EQUITY SHARES
VAISHALIBEN SHRENIKBHAI VOHERA				1204150000148624	100	EQUITY SHARES
HIREN HARESHBHAI VAKIL				1204150000152170	100	EQUITY SHARES
ARUN CHAUDHARY				1204150000219885	801	EQUITY SHARES
PARTHESH VIRESHKUMAR PAREKH				1204150000312424	20	EQUITY SHARES
SAROJBEN PRAKASHKUMAR SHAH				1204150000315518	100	EQUITY SHARES
HIMALI ANKURBHAI SHAH				1204150000338400	1000	EQUITY SHARES
VALAY PRAKASHKUMAR SHAH				1204150000370812	2550	EQUITY SHARES
AMIT DINESHLAL MODI				1204150000447296	100	EQUITY SHARES
MADHUBEN BHARATBHAI SHAH				1204150000447716	2250	EQUITY SHARES
PRAKASHKUMAR KANTILAL SHAH				1204150000449390	800	EQUITY SHARES
DAXA HARSHAD PATEL				1204150000471889	4300	EQUITY SHARES
PARTH HARSHAD PATEL				1204150000714161	254	EQUITY SHARES
HEMANG PRAMODBHAI MEHTA				1204150001356212	200	EQUITY SHARES
VIKRAMKUMAR RAJNIKANT SADHANI				1204150001496717	200	EQUITY SHARES
MINAL JIGAR SHAH				1204150001639474	700	EQUITY SHARES
DILIP ANANTRAI DESAI				1204200000059193	400	EQUITY SHARES
SHAH GAUTAM PRAVINBHAI				1204200000123051	1848	EQUITY SHARES
VIMALABEN R SHAH				1204200000137725	4000	EQUITY SHARES
MANUBHAI NAGINDAS SHAH				1204200000140259	4500	EQUITY SHARES
UNNATIBEN CHIRAGKUMAR KACHHIA				1204200000158682	1000	EQUITY SHARES
LEUA RAHULKUMAR MANILAL				1204200000168739	1600	EQUITY SHARES
KETANKUMAR RAMANLAL PATEL				1204200000178935	1000	EQUITY SHARES
HIRAGAR DHANESHBHAI K				1204210000094396	100	EQUITY SHARES
HIREN MUKESHBHAI PAREKH				1204210000103120	168	EQUITY SHARES
VIMAL JITENDRABHAI DALAL				1204210000103743	10	EQUITY SHARES
HEMANTKUMAR JAGDISHCHANDRA PUROHIT				1204220000009359	250	EQUITY SHARES
MANISHA GIRISHKUMAR PATEL				1204220000021131	1000	EQUITY SHARES
SUNITA SUNILKUMAR DUGAR				1204220000089471	1300	EQUITY SHARES
JALPABEN DARSHITKUMAR PATEL				1204220000101181	1500	EQUITY SHARES
MAMTA KISHORKUMAR SHARMA				1204220000106306	35	EQUITY SHARES
SAGAR SHETH				1204220000158661	800	EQUITY SHARES
MAYURIKA SURESH SHAH				1204220000183960	375	EQUITY SHARES
DILKHUSH JOITARAM RATHOD				1204230000178396	24	EQUITY SHARES
NARESH HARICHAND SHAH				1204320000044426	200	EQUITY SHARES
SARASWATIBEN JIGARKUMAR PATEL				1204370000364641	215	EQUITY SHARES
JIGARKUMAR KIRITBHAI PATEL				1204370000385974	1000	EQUITY SHARES
ANISH RAMESHCHANDRA SHAH				1204440000002405	800	EQUITY SHARES
SURENDRA MANGALDAS MARFATIA				1204440000005771	1	EQUITY SHARES
PARIKSHITBHAI RAVJIBHAI AMIN				1204440000065177	1000	EQUITY SHARES
KARAMATALI MEHMUDALI SAIYAD				1204440000067290	20	EQUITY SHARES
NITA NITINKUMAR DAVE				1204440000097997	1914	EQUITY SHARES
PARVEZ M KAZI				1204440000124844	39	EQUITY SHARES
RAKESHKUMAR KANTIBHAI PATEL				1204440000189051	7075	EQUITY SHARES
USHABEN GAUTAMKUMAR SHAH				1204440000218599	2018	EQUITY SHARES
SAFYUDDIN NURMIYA SAIYAD				1204440000219058	210	EQUITY SHARES
FIRADOSHBANU MAHEBUBKHAN PATHAN				1204440000221202	27	EQUITY SHARES
JYOTSANABEN BABULAL PATEL				1204440000221498	1000	EQUITY SHARES
SAJIDHUSEN MAHMADALI SAIYAD				1204440000222829	3	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
HIMANSHU BALDEVPRASAD PATEL				1204440000226253	5650	EQUITY SHARES
MANUBHAI NAGINDAS SHAH				1204440000232489	4400	EQUITY SHARES
RAKESHBHAI BABULAL PATEL				1204470000639145	2000	EQUITY SHARES
ASHISH AMRUTLAL PATEL				1204470001802779	3700	EQUITY SHARES
ANITA T TILWANI				1204470002185340	3162	EQUITY SHARES
CHANDRAKANT D VANKAR				1204470002902357	907	EQUITY SHARES
KEYUR CHETANBHAI SHAH				1204470003886601	931	EQUITY SHARES
NEHA JAINISHBHAI PANCHAL				1204470004715481	1000	EQUITY SHARES
PANCHAL DHARMSHTHABEN SANJAYBHAI				1204470004772515	2500	EQUITY SHARES
RAKESHKUMAR L RATHOD				1204470005914371	200	EQUITY SHARES
SUDERSHAN KUMAR KASHYAP				1204470006697384	199	EQUITY SHARES
SHIVAM DESAI				1204470007160249	1000	EQUITY SHARES
KHELAN B SHAH				1204470007185261	50	EQUITY SHARES
JAYESHKUMAR H PANCHAL				1204470007392108	1100	EQUITY SHARES
VIREN VIJAYKUMAR PANCHAL				1204470008604958	2500	EQUITY SHARES
KETAN AMRATLAL KOTECHA				1204540000020993	100	EQUITY SHARES
RAJEEV KISHOR DOSHI				1204710000025235	500	EQUITY SHARES
VIJAYBHAI YASHARAMBHAI PALADIYA				1204720000621123	69	EQUITY SHARES
OM BABU GUPTA				1204720000857063	100	EQUITY SHARES
SANJAY KUMAR				1204720005272664	10	EQUITY SHARES
MANVIR SINGH				1204720012753080	23	EQUITY SHARES
SUSHIL KUMAR				1204720013470831	300	EQUITY SHARES
JAIPAL SINGH				1204720020872989	10	EQUITY SHARES
MOHAMMED FASIHUDDIN				1204780000096011	52144	EQUITY SHARES
DHIRESH NAROTTAMDAS ZINZUVADIA				1204780000167707	300	EQUITY SHARES
JYOTSNA KISHOR THAKKAR				1204830000030250	5	EQUITY SHARES
VINABEN RAJENDRAKUMAR SONI				1204840000007401	50	EQUITY SHARES
REENA RAMANLAL SHARMA				1204840000158838	50	EQUITY SHARES
PRASHANT UDAYANBHAI CHINUBHAI				1204840000164022	4750	EQUITY SHARES
RAJ NARENDRABHAI PUROHIT				1204840000170963	15350	EQUITY SHARES
MAJIDKHAN ZAFRULLA KHAN PATHAN				1204840000192231	250	EQUITY SHARES
MAULIN GAURANG BHAI SHAH				1204840000349865	200	EQUITY SHARES
NARESH ISHWARLAL THAKKAR				1204840000429385	250	EQUITY SHARES
RCKANKARIA				1204880000151216	1764	EQUITY SHARES
VANITA BALDEV MEHRA				1204990000004453	1000	EQUITY SHARES
PIYUSH MAHASUKHLAL SHETH				1205150000075800	16	EQUITY SHARES
PURVI NIKUNJ SHAH				1205430000036568	200	EQUITY SHARES
JANARDHAN A G				1205670000430717	25	EQUITY SHARES
LAKSHMISHREE INVESTMETN SECURITIES PVT LTD				1205910000010396	9000	EQUITY SHARES
UJJVALKUMAR YOGENDRABHAI PATEL				1206040000020640	1260	EQUITY SHARES
NILESHKUMAR RAJESHKUMAR DESAI				1206040000041671	150	EQUITY SHARES
GIRRAJ SHARAN BANSAL				1206120000043369	200	EQUITY SHARES
VIJAY KUMAR MUNDHRA HUF				1206160000013809	1500	EQUITY SHARES
VIJAY KUMAR MUNDHRA				1206160000013813	8509	EQUITY SHARES
BHAVESH AMRUTLAL RAYCHA				1206380000032445	50	EQUITY SHARES
VINODKUMAR ISHWARPURI DESAI				1206380000035131	500	EQUITY SHARES
POOJA PRATIK JOSHI				1206380000110673	60	EQUITY SHARES
RAMESHBHAI RAMDAS PATEL				1206380000129420	110	EQUITY SHARES
HARISH CHAND JAIN				1206590000021564	100	EQUITY SHARES
ANIL PRANLAL SHAH				1206720000003768	500	EQUITY SHARES
MAYURKUMAR DINESHCHANDRA SHAH				1206720000031561	175	EQUITY SHARES
KINJALBEN MAYURKUMAR SHAH				1206720000031576	795	EQUITY SHARES
DIPAKKUMAR KISHANLAL DHINGRA				1206720000031941	1000	EQUITY SHARES
DHAVALKUMAR HASMUKHBHAI PATEL				1206740000185127	9985	EQUITY SHARES
VAIBHAVI BIPINCHANDRA VAKHARIA				12067900000006627	150	EQUITY SHARES
JAYVEERSINH CHAVDA				1206850000135875	900	EQUITY SHARES
KHUSHIBEN NILESH DARYANANI				1207010000015628	5573	EQUITY SHARES
NATHURMAL BHOJRAJMAL UTWANI				1207010000018574	200	EQUITY SHARES
USHA NATHURAMAL UTWANI				1207010000019700	200	EQUITY SHARES
SHAH ANILABEN				1207020000051011	1404	EQUITY SHARES
HARSHA MAYURBHAI SHETH				1207020000057617	2500	EQUITY SHARES
CHAITANYA RAMESHCHANDRA MEHTA				1207020000069732	1000	EQUITY SHARES
DHVANI HARDIK ARORA				1207020000212837	1	EQUITY SHARES
ANILBHAI DALPATRAM BUDHBHATTI				1207020000244411	1	EQUITY SHARES
CHETANABEN BIPINKUMAR SANGHAVI				1207020000324024	10675	EQUITY SHARES
SONALBEN BHADRESHKUMAR SANGHAVI				1207020000324155	9994	EQUITY SHARES
HETAL MAULIK TRIPATHI				1207020000616795	500	EQUITY SHARES
RAJENDRA INDRAMAL SOMAIYA				1207020001469030	2	EQUITY SHARES
TARACHAND VARUMALBHAI TILVANI				1207100000045025	4157	EQUITY SHARES
TARABEN CHANDRAKANT THAKKAR				1207130000036117	100	EQUITY SHARES
TEJAL GUNVANT SHETH				1207170000030637	100	EQUITY SHARES
VASANTI N MAKHANIA				1207170000034116	50	EQUITY SHARES
HARSHKUMAR SUNILBHAI PARIKH				1207270000007986	450	EQUITY SHARES
JAYDEEP CHIRAGBHAI SUTARIA				12072900000009242	41	EQUITY SHARES
HEMAL NIRANJANBHAI PATEL				1207480000004472	2480	EQUITY SHARES
ANIL KUMAR KEJRIWAL				1207650000212432	400	EQUITY SHARES
JAYSHRIBEN DHIRENDRAKUMAR MANIAR				12076700000000030	100	EQUITY SHARES
DHARMRAJ SURENDRASINH ZALA				12079000000004170	500	EQUITY SHARES
BHAVESH KIRITKUMAR CHOKSI HUF				1208020000008146	3433	EQUITY SHARES
ROHAN FABTEX PRIVATE LIMITED				1208150000017545	6000	EQUITY SHARES
SARAVANAN C				12081600000513369	3	EQUITY SHARES
YOGESH RATHANKUMAR				1208160005012995	10	EQUITY SHARES
UMESH GONDHALI				1208160008791230	1	EQUITY SHARES
ANILBHAI DALPATRAM BUDHBHATTI				1208160010194347	50	EQUITY SHARES
RAVIKUMAR JAGJIVANRAM SUTHAR				1208160010288429	1000	EQUITY SHARES
DEEPAK KUMAR GUPTA				1208160012401362	1257	EQUITY SHARES
ABHISHEK JHA				1208160012932594	10	EQUITY SHARES
GOVINDA SHAW				1208160012938581	201	EQUITY SHARES
SUMIT SHARMA				1208160013322803	100	EQUITY SHARES
KETAN SHRIRAM PATIL				1208160013353403	100	EQUITY SHARES
PARTH ANILBHAI SONI				1208160013888279	1	EQUITY SHARES
SHEETAL KUMARI				1208160016049407	10	EQUITY SHARES
ANUP VILASRAO PEDNEKAR				1208160017368819	100	EQUITY SHARES
K UMAMAHESWARA RAO				1208160018085639	270	EQUITY SHARES
DIPANKER DAS				1208160019466490	1	EQUITY SHARES
MANOHAR KISAN AMBEKAR				1208160019535872	3	EQUITY SHARES
SUNILBHAI ARVINDBHAI BAROT				1208160032813983	2586	EQUITY SHARES
VIKAS SALECHA				1208160033274082	185	EQUITY SHARES
VEER SINGH MEHTA				1208160037505605	100	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
SHAILESH FATECHAND SHAH				1208160038891951	100	EQUITY SHARES
PEETA CHANAKYA				1208160055838189	10	EQUITY SHARES
BHAVNA ROHIT SHAH				1208160057643143	1900	EQUITY SHARES
THIRUNAVUKKARASU BHUVANESH RAJA				1208160058585351	1	EQUITY SHARES
HEMANTKUMAR NAGINBHAI PATEL				1208180000417244	2	EQUITY SHARES
AJINKYA MOHAN YADAV				1208180026146919	2	EQUITY SHARES
MOHAMMADSALIM BURHANMIA SAIYAD				1208180026202994	6	EQUITY SHARES
RATNESHWARI DEVI RATANLAL JAITLEIA				1208320000050494	200	EQUITY SHARES
SACHIN SOGANI				1208490000009648	1000	EQUITY SHARES
AMARCHAND BHERULAL BOHRA				1208620000000655	2000	EQUITY SHARES
MANJUDEVI JAIN				1208620000000674	500	EQUITY SHARES
HARMEET SINGH				1208870008574484	1	EQUITY SHARES
KAVINDRA KUMAR				1208880000312591	251	EQUITY SHARES
BINOD KUMAR DHANWAR				1208880000569184	12	EQUITY SHARES
SUDHIR MADHAVRAO BHOITE				1301190300045461	100	EQUITY SHARES
RAHUL KUMAR				1301240004651183	20	EQUITY SHARES
KANUBHAI BABUBHAI PATEL				1301520000021190	5000	EQUITY SHARES
ASMITA NILESH JANI				1301520000092222	50	EQUITY SHARES
RINA KETANBHAI SHAH				1301520000150155	200	EQUITY SHARES
KAILASHCHANDRA HIMATLAL FADIA				1301520000170144	173	EQUITY SHARES
TRUPTI RAKESH PATHAK				1301520000183322	500	EQUITY SHARES
HEMAL JAGDISHBHAI SARAIYA				1301520000187031	300	EQUITY SHARES
GURDEEP SINGH SABHARWAL				1301540000091417	200	EQUITY SHARES
MAHENDRA RAJMAL GADIA				1301540000093281	11	EQUITY SHARES
PRAKASH VITHALDAS SARAIYA				1301540000126151	100	EQUITY SHARES
KINJAL JAGDISH SHAH				1301670000280185	100	EQUITY SHARES
KALAVATIBEN H THAKKAR				1301670000646525	100	EQUITY SHARES
HARDIPBHAI M PATEL				1301670000674202	200	EQUITY SHARES
HIMANSHU A TRIVEDI				1301670000688192	10	EQUITY SHARES
RUPAL ATUL HIRANI				1301990000011971	100	EQUITY SHARES
ATUL MANSUKHLAL HIRANI				1301990000011999	200	EQUITY SHARES
KUMARPAL MEHTA				1301990000167684	800	EQUITY SHARES
GHUSABHAI HARJIBHAI SAKHIYA				1301990000173983	500	EQUITY SHARES
GEETABEN DEEPAK DAMANI				1302080000225751	300	EQUITY SHARES
JAYESH NARENDRA KESHARIA				130295000008195	5	EQUITY SHARES
CHANDRAKANT DWARKABHAI PATEL				1304140001513943	50	EQUITY SHARES
SANGEETA SHAH				1304140001869664	450	EQUITY SHARES
KANTILAL BABALDAS PATEL				1304140002091785	15	EQUITY SHARES
VIKRANT KUMAR				1304140006802418	18	EQUITY SHARES
PARESH KANTIBHAI PATEL				1304140006842109	10	EQUITY SHARES
CHETAN MANSUKHLAL SOMAIYA				1304140008043661	400	EQUITY SHARES
KALYAN KUMAR JAGNANY				1601010000360532	1	EQUITY SHARES
VARMA KAVIT DILIPBHAI				1601430102044397	35	EQUITY SHARES
INDIAN CLEARING CORPORATION LIMITED				IN00115010000004	193704	EQUITY SHARES
NARI A BHARWANI				IN30001110018617	2700	EQUITY SHARES
HAREN H SHETH				IN30002010198885	400	EQUITY SHARES
Indra Kumar Bagri				IN30009511415372	104	EQUITY SHARES
Ritesh P Kothari				IN30009512128318	200	EQUITY SHARES
SAIBAL KUMAR DUTT				IN30011810927172	11	EQUITY SHARES
RAMABHAI VIRABHAI PATEL				IN30011811367270	22	EQUITY SHARES
HARMOHAN SINGH SAWHNEY				IN30011811508900	100	EQUITY SHARES
JAYANT SHRIRIKISHNA PATANKAR				IN30012610097725	100	EQUITY SHARES
HIREN D SHETH				IN30012610423517	100	EQUITY SHARES
SUDHIR KUMAR MAYAWALA				IN30015910638304	100	EQUITY SHARES
SUSHIL FINANCIAL SERVICES PRIVATE LIMITED				IN30015910851745	200	EQUITY SHARES
DIMENSIONAL SECURITIES PRIVATE LTD				IN30015910852553	100	EQUITY SHARES
RAM SINGH RAJPUROHIT				IN30015911101180	100	EQUITY SHARES
DHANASEKARAN A				IN30017510104679	400	EQUITY SHARES
NITA COLACO				IN30018310008935	50	EQUITY SHARES
SAYED ABRAR ALI				IN30018310776445	200	EQUITY SHARES
SOHANLAL VADERA				IN30018311255408	100	EQUITY SHARES
SANATKUMAR VILAS DUNUNG				IN30018311291688	500	EQUITY SHARES
B RAVINDRA PAI				IN30018311575238	200	EQUITY SHARES
SATYAMURTHY S V				IN30021411166413	610	EQUITY SHARES
NILESH HASMUKH KHICHADIA				IN30021411724006	500	EQUITY SHARES
SAROJ DUGAR				IN30021412585979	1000	EQUITY SHARES
AJAY RAMCHAND AHUJA				IN30021412677824	1894	EQUITY SHARES
ANIL KUMAR PODDAR				IN30021415506436	8	EQUITY SHARES
BHAVI RAKESH AGARWAL				IN30021419590462	250	EQUITY SHARES
AJITCHANDRA VIJAYJI				IN30021420740184	1	EQUITY SHARES
VISHAL CHHAPARIA HUF				IN30021421653956	100	EQUITY SHARES
TARA PANKAJ BHANUSHALI				IN30021421975210	1200	EQUITY SHARES
VINUBHAI BACHUBHAI GOHEL				IN30021426588265	700	EQUITY SHARES
SUNILKUMAR VINUBHAI GOHEL				IN30021426588388	500	EQUITY SHARES
RAJENDRAKUMAR NARSINHBHAI PATEL				IN30021432899739	2150	EQUITY SHARES
MADUCOLIL MATHAI KUNJACHAN				IN30023910000203	500	EQUITY SHARES
LAVU RAM KOKATE				IN30023911073222	255	EQUITY SHARES
MATHEW ABRAHAM				IN30023911775325	3	EQUITY SHARES
JAYASIMHAN K				IN30023913708307	100	EQUITY SHARES
ATUL KANTILAL MANIYAR				IN30023950020091	100	EQUITY SHARES
KRISHNENDU DAS				IN30026310064688	3	EQUITY SHARES
MINESH CHANDULAL SHAH				IN30034310209915	300	EQUITY SHARES
DINESHKUMAR CHINUBHAI SHAH				IN30034310217032	500	EQUITY SHARES
PATEL KANAIYALAL				IN30034310303514	200	EQUITY SHARES
POOJA RAHUL PATEL				IN30034310326106	300	EQUITY SHARES
SONI ILABEN BHARATKUMAR				IN30034310813239	1000	EQUITY SHARES
KIRTIKUMAR RAMANLAL PATEL				IN30034310886970	200	EQUITY SHARES
SHAIKH MAYUDDIN				IN30034310899143	500	EQUITY SHARES
NILESH ROHITBHAI SHAH				IN30034311014435	150	EQUITY SHARES
SARLADEVI SANTOSHKUMAR KEDIA				IN30034311014693	100	EQUITY SHARES
SHAH JAYANTILAL DUNGARDAS				IN30034311015382	30	EQUITY SHARES
BHARAT CHUNILAL PATEL				IN30034311235859	299	EQUITY SHARES
NAKUL RAMESHBHAI KURSJIJA				IN30034311327181	143	EQUITY SHARES
KALYANI HARESH SURTI				IN30034311330780	300	EQUITY SHARES
PAVAN RAMESHCHANDRA KHURSHIJA				IN30034311334700	100	EQUITY SHARES
DHAVALKUMAR H PATEL				IN30034311485545	14075	EQUITY SHARES
DESAI JAYARAMBHAI AMTHABHAI				IN30034320044168	200	EQUITY SHARES
HITESH RAMJI JAVERI				IN30036020087818	500	EQUITY SHARES
PRAKASH ARVIND VIJAYAKAR				IN30036020500205	1	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
RAVIRAJ SHEENA SHETTY				IN30036022467764	400	EQUITY SHARES
MAHENDRA RATANSHI SHAH				IN30038610034031	3200	EQUITY SHARES
GIRIBALA NARENDRA SHAH				IN30038610037714	500	EQUITY SHARES
BIJAL BAHADUR KAPADIA				IN30038610052674	150	EQUITY SHARES
MAHESH MOHANLAL SHAH				IN30038610071484	100	EQUITY SHARES
BRAHMBHATT CHANDRAKANT MOHANLAL				IN30039413860629	1900	EQUITY SHARES
MANISHKUMAR R PRAJAPATI				IN30042510109014	220	EQUITY SHARES
JASHODA R PRAJAPATI				IN30042510184482	100	EQUITY SHARES
SOUDHA YOUSUF				IN30044110624912	500	EQUITY SHARES
DEEPAK RAMGOPAL KARIWALA				IN30045013127432	400	EQUITY SHARES
VEERANJANEYA PRASAD T				IN30045014389741	1	EQUITY SHARES
VILAS KESHAV SHIGVAN				IN30047610093832	1900	EQUITY SHARES
SANJAY KUMAR				IN30047610099397	1	EQUITY SHARES
MOHINDER NARULA				IN30047610102255	300	EQUITY SHARES
MISTRY MAMTA ASHWIN				IN30047610397974	500	EQUITY SHARES
USHA HARSHAD MEHTA				IN30047640357068	400	EQUITY SHARES
PARAG JITENDRA GANDHI				IN30047640699700	100	EQUITY SHARES
HDFC SECURITIES LIMITED				IN30047641012590	6100	EQUITY SHARES
PUNBAI D PANDAV				IN30047641686448	500	EQUITY SHARES
ALPESHBHAI MULCHANDBHAI PATEL				IN30047642444094	1440	EQUITY SHARES
BACHANI BHAGWAN				IN30047643497042	300	EQUITY SHARES
VALJIBHAI P VIRADIA HUF				IN30048412784683	200	EQUITY SHARES
NARENDRA BABULAL PATEL				IN30051310002464	600	EQUITY SHARES
LEENA NARENDRA PATEL				IN30051310002489	600	EQUITY SHARES
SMT CHANDRA K BAPNA				IN30051310151263	500	EQUITY SHARES
SAMIR AVANITKUMAR SHAH				IN30051310171307	280	EQUITY SHARES
VIJAY BALKRISHNA KADAM				IN30051310736720	300	EQUITY SHARES
RAMAN DEEP MALIK				IN30051311904605	1840	EQUITY SHARES
PUSHPA DEVI				IN30051311915212	860	EQUITY SHARES
DHAVAL DOSHI				IN30051312172912	17	EQUITY SHARES
R V Y NAGENDRA KUMAR				IN30051312226207	400	EQUITY SHARES
NIMISHA VIPUL VAKHARIA				IN30051312238559	800	EQUITY SHARES
NANDLAL H SINGH				IN30051312286610	82	EQUITY SHARES
SHALINI GUPTA				IN30051313478625	50	EQUITY SHARES
BHAVESH DHIRAJLAL SHAH				IN30051314792397	3000	EQUITY SHARES
PANKAJ KEWALRAM MAKDE				IN30051315005834	7	EQUITY SHARES
VIPUL S VAKHARIA				IN30051315425297	2000	EQUITY SHARES
GANVANI AMRUTBHAI D				IN30051316866042	42	EQUITY SHARES
ANJANA V SHAH				IN30051318066260	1000	EQUITY SHARES
MALTI KUMARI				IN30051318593834	1000	EQUITY SHARES
SHAH KHUSHBU JAIMINKUMAR				IN30051320064613	1000	EQUITY SHARES
KAMLESH K AMLANI				IN30051320430164	96	EQUITY SHARES
LINABEN P CHALUHAN				IN30051320540216	100	EQUITY SHARES
KISHORKUMAR BACHULAL GOHEL				IN30051320720948	2000	EQUITY SHARES
RAUNAK KUMAR				IN30051320796130	10	EQUITY SHARES
ASHISH KUMAR SHARMA				IN30051321658499	100	EQUITY SHARES
HIMABEN PRADIP GAJJAR				IN30051321707994	100	EQUITY SHARES
DINESH KUMAR				IN30055610048508	25	EQUITY SHARES
MAFATBHAI CHHOTABHAI PATEL				IN30063610024531	1000	EQUITY SHARES
KAILASHBEN NAVINBHAI PATEL				IN30063610202785	6489	EQUITY SHARES
DINESHBHAI SHANABHAI PATEL				IN30063610222318	536940	EQUITY SHARES
SONALBEN DINESHBHAI PATEL				IN30063610222825	47000	EQUITY SHARES
KIRAN RAMESHBHAI PATEL				IN30063610257745	100	EQUITY SHARES
GOPALDAS MANILAL MEHTA				IN30063610272814	1790	EQUITY SHARES
AMIT NAVINCHANDRA PATEL				IN30063610275433	400	EQUITY SHARES
VIJAYKUMAR BABUBHAI THAKKAR				IN30063610275668	1	EQUITY SHARES
SHREYASKUMAR DILIPBHAI PATEL				IN30063610278235	10	EQUITY SHARES
NISHA S PATEL				IN30063640009272	7061	EQUITY SHARES
KALPANABEN GIRISHBHAI PATEL				IN30063640045935	885	EQUITY SHARES
DEVANG RAMESHBHAI GOHEL				IN30063640049632	100	EQUITY SHARES
JINESHKUMAR JAYANTIBHAI PATEL				IN30063640063204	282	EQUITY SHARES
VIKRAM MADHUBHAI SHAH				IN30065210000391	1500	EQUITY SHARES
PATEL HANSABEN RAMESHBHAI				IN30065210006716	463	EQUITY SHARES
BHADRAYU AJAYKUMAR SHAH				IN30065210050012	1000	EQUITY SHARES
SHAH MAYURKUMAR DINESHCHANDRA				IN30065210136817	2100	EQUITY SHARES
PATEL BHAILAL DAHYABHAI				IN30065210137459	204578	EQUITY SHARES
MUKESH H PRAJAPATI				IN30065210168182	250	EQUITY SHARES
YOGESHKUMAR RAMANLAL PATEL				IN30065210207359	9749	EQUITY SHARES
DIPAK CHANDUBHAI PATEL				IN30065210217203	7405	EQUITY SHARES
RITESH VIKRAMBHAI SHAH				IN30065210220636	950	EQUITY SHARES
NIYATI BHADRAYU SHAH				IN30065210223455	1000	EQUITY SHARES
PATEL YOGESH SOMABHAI HUF				IN30065210223752	87477	EQUITY SHARES
JENIL RAJESHBHAI KHAMAR				IN30065210244760	2050	EQUITY SHARES
PATEL SITABEN DILIPBHAI				IN30065210245246	11043	EQUITY SHARES
UPENDRA SHANTILAL DALAL				IN30065210250940	1000	EQUITY SHARES
VINAYAK YASHWANT APKARE				IN30065210253727	1075	EQUITY SHARES
AMOL JANU GONDAL				IN30065210255541	10000	EQUITY SHARES
HARASIL BHAILALBHAI PATEL				IN30065210259985	5400	EQUITY SHARES
DHARMISHTHA SATISH PATEL				IN30065210265060	1697	EQUITY SHARES
CHANDRIKA PARESHBHAI KHAMAR				IN30065210265834	500	EQUITY SHARES
CHANDUBHAI ARJANBHAI PATEL				IN30065210265906	2000	EQUITY SHARES
RAJESH ANOPCHAND SHAH				IN30065210269401	1049	EQUITY SHARES
MEHULKUMAR HARSHDBHAI SHAH				IN30065210269895	20	EQUITY SHARES
GAURANG CHIMANBHAI PATEL				IN30065210270924	1998	EQUITY SHARES
SANTOSHI SHASHAVATKUMAR VARMA				IN30065210272737	2100	EQUITY SHARES
SUCHITABEN PANKAJKUMAR PATEL				IN30065210274860	11400	EQUITY SHARES
MEET YOGESHKUMAR PATEL				IN30065210275897	20583	EQUITY SHARES
DUSHYANT CHANDUBHAI SADARIYA				IN30065210277330	2000	EQUITY SHARES
MUKESHBHAI BABUBHAI PATEL				IN30065210283311	6700	EQUITY SHARES
BHARGAV BHAVANBHAI SONGARA				IN30065210284417	1500	EQUITY SHARES
PRATIK RAJESHBHAI KHAMAR				IN30065210285305	300	EQUITY SHARES
CHANDULAL KEVALDAS PATEL HUF				IN30065210285356	1350	EQUITY SHARES
VIJAY MANUBHAI SHAH				IN30065210285565	100	EQUITY SHARES
ULKABEN BHAILALBHAI PATEL				IN30065210285879	48441	EQUITY SHARES
BHAVANA ANAND PATEL				IN30065210286076	4000	EQUITY SHARES
JYOTIDHAR HARISHCHANDRA PANCHAL				IN30065210289509	250	EQUITY SHARES
DEEP PATEL				IN30065210291776	57570	EQUITY SHARES
KRUPA BHAILALBHAI PATEL				IN30065210292011	45500	EQUITY SHARES
NITA SHRADBHAI MEHTA				IN30065210294201	2986	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
AYUSHI KANSARA				IN30065210297040	100	EQUITY SHARES
YOGESH SOMABHAI PATEL				IN30065210304065	118799	EQUITY SHARES
SOMABHAI ISHWARDAS PATEL				IN30065210304161	58150	EQUITY SHARES
JYOTIBEN SOMABHAI PATEL				IN30065210304215	113383	EQUITY SHARES
RAMANLAL RATILAL DESAI				IN30065210308204	120795	EQUITY SHARES
MITALBEN RUPESHBHAI DESAI				IN30065210308212	121002	EQUITY SHARES
VIJAY BHIKABHAI SHETH				IN30065210308622	59651	EQUITY SHARES
SANGITABEN VIJAYKUMAR SHETH				IN30065210308639	59345	EQUITY SHARES
SAGAR SHETH				IN30065210308647	60509	EQUITY SHARES
MANSUKHLAL CHHOTALAL SHAH				IN30065210309115	87044	EQUITY SHARES
KARISHMA KANSARA				IN30065210315017	200	EQUITY SHARES
JYOTI DAHYABHAI PATEL				IN30065210318322	6078	EQUITY SHARES
HETAL YOGESHKUMAR PATEL				IN30065210329136	111154	EQUITY SHARES
ANANDKANT PRAKASHCHAND GUPTA				IN30065210340488	100	EQUITY SHARES
BHARATKUMAR RAMANLAL RAVAL				IN30065210343736	500	EQUITY SHARES
SHUBHAM BAVISKAR				IN30065210364693	1	EQUITY SHARES
SANSKRITI SHASHVATKUMAR VARMA				IN30065210366156	501	EQUITY SHARES
NAMRA ALPESHBHAI PATEL				IN30065210372118	2	EQUITY SHARES
HASMUKH BHOLABHAI PATEL				IN30065210377427	100	EQUITY SHARES
RAJCHANDRA CAPITAL SERVICES PVT LTD				IN30074910184111	300	EQUITY SHARES
DHARMISHTHA SANJAYKUMAR SHAH				IN30074910926395	1000	EQUITY SHARES
NIRMALA CHHADVA				IN30074910973918	500	EQUITY SHARES
JAYESH H SHAH				IN30074910981942	1000	EQUITY SHARES
RAMESH M DEDHIA				IN30075710716838	200	EQUITY SHARES
SHAIKH SHABBIR YAKUB				IN30082910411532	200	EQUITY SHARES
SHOBHA D BHAT				IN30082910424147	500	EQUITY SHARES
JAIN DILIPKUMAR NENMALJI				IN30082910717995	300	EQUITY SHARES
SHAH HEMLATA RASIKLAL				IN30082911007969	1000	EQUITY SHARES
BIPIN JAYANTILAL SHAH				IN30082911883591	500	EQUITY SHARES
ANKIT HARIN SHAH				IN30082911971786	500	EQUITY SHARES
HASMUKHRAI R SHAH				IN30084510561044	5000	EQUITY SHARES
VARDHIBHAI V GADHECHA				IN30084510589513	250	EQUITY SHARES
SURESHCHANDRA R TRIPATHI				IN30085312104203	500	EQUITY SHARES
BHAVESH MAHENDRA PARIKH				IN30087010193635	300	EQUITY SHARES
CHANDRAPRAKASH KABRA				IN30087030023494	225	EQUITY SHARES
SHAILESH VAJUBHAI GADHVI				IN30088813630545	100	EQUITY SHARES
SUMATI CHANDRA MEHTA				IN30088813732700	225	EQUITY SHARES
DHIRENDRA KESHAVLAL DOSHI				IN30088813924628	197	EQUITY SHARES
CHE TAN SHAH				IN30088814008422	300	EQUITY SHARES
JAYANTILAL MAJITHIA				IN30088814031969	500	EQUITY SHARES
SAUREN HARISH PATEL				IN30088814046297	500	EQUITY SHARES
VANITA PRAKASH KAJARI				IN30088814705628	200	EQUITY SHARES
KAMALAKANNAN N				IN30089610241575	400	EQUITY SHARES
RAMESH ROSHAN BORANA				IN30089610266603	2	EQUITY SHARES
MRS NAYNA SHAILESH MASARANI				IN30097410033990	200	EQUITY SHARES
GEETABEN JAIKISHANBHAI UNADKAT				IN30097410045361	100	EQUITY SHARES
SHAILESH LALBHAI MASARANI				IN30097410055765	400	EQUITY SHARES
CHARU SANGHVI				IN30097410244664	500	EQUITY SHARES
NIRUPABEN KUMANDAS KHANAPARA				IN30097410274918	900	EQUITY SHARES
HEMAL RAJNIKANT GANGADIYA				IN30097410298963	250	EQUITY SHARES
KUNTAL RAJNIKANT GANGADIA				IN30097410311320	1250	EQUITY SHARES
RAJNIKANT M GANGADIYA				IN30097410311338	1000	EQUITY SHARES
SALLA JAGDISH BHUPATBHAI				IN30097410649780	150	EQUITY SHARES
RAJNIKANT M GANGADIYA HUF				IN30097411452370	2000	EQUITY SHARES
PRAFUL S KANAKIA				IN30097411549443	500	EQUITY SHARES
KOMAL JANARDAN SHUKLA				IN30097411693618	1000	EQUITY SHARES
UKABHAI KHIMJIBHAI KHIMSURIA				IN30097411700693	200	EQUITY SHARES
DARJI ASHWINBHAI JADAVBHAI				IN30097411708925	10	EQUITY SHARES
JAYANTILAL V BAMBHANIA				IN30097411717872	20	EQUITY SHARES
ABHAYKUMAR RAVINDRAKUMAR SHAH				IN30097412070735	1000	EQUITY SHARES
MAYANKUMAR RAVINDRAKUMAR SHAH				IN30097412077476	3000	EQUITY SHARES
BIPIN VALLABHBHAI MAKHASANA				IN30097412342404	500	EQUITY SHARES
MADHABHAI DHULABHAI DATANIA				IN30098210123414	105	EQUITY SHARES
MUKESHCHANDRA VAIKUNTLAL PATEL				IN30098210816881	25	EQUITY SHARES
VELJIBHAI MONABHAI PHALKIA				IN30103924352904	200	EQUITY SHARES
NEEPA SHAH				IN30112715885093	200	EQUITY SHARES
AMRISH B DHOLAKIA				IN30112715920100	200	EQUITY SHARES
PADMA J PAI				IN30113526707598	200	EQUITY SHARES
ARUN KUMAR MALHOTRA				IN30114310116924	400	EQUITY SHARES
M H GURNANI				IN30114311061052	400	EQUITY SHARES
INVENTURE GROWTH SECURITIES LTD				IN30115112079453	1000	EQUITY SHARES
SURESH AGARWAL				IN30115112621426	500	EQUITY SHARES
PANKAJA K GAJARIA				IN30115113017380	300	EQUITY SHARES
NAIK SANKET DINESHBHAI				IN30115121816738	200	EQUITY SHARES
VANDANA CHOPRA				IN30115122938984	50	EQUITY SHARES
PRATAVANI SURENDRASING B				IN30115124548931	990	EQUITY SHARES
MUKUNDA RAO SANGARU				IN30115125810984	50	EQUITY SHARES
URMILA DINESH SEETHA				IN30115128640711	2900	EQUITY SHARES
SONI GAUTAMKUMAR MAFATLAL				IN30123310284933	1000	EQUITY SHARES
MODI KALABEN VASANTKUMAR				IN30123310375518	100	EQUITY SHARES
SHAH HEMANTBHAI BABULAL				IN30123310389206	2250	EQUITY SHARES
HARESH RAMANLAL DESAI				IN30127610212234	50	EQUITY SHARES
RAJESH V SHAH				IN30127630140309	600	EQUITY SHARES
DILIP SINGH GAUR				IN30127630743522	50	EQUITY SHARES
BELA SANJIV JHAVERI				IN30131321660390	200	EQUITY SHARES
HASUMATIBEN PIYUSHBHAI PATEL				IN30132110696095	998	EQUITY SHARES
JIGNESH VINUBHAI GOHEL				IN30132110710138	300	EQUITY SHARES
ARUNABEN BHARATBHAI PATEL				IN30132110711608	3251	EQUITY SHARES
CHITRANG VISHNUBHAI PATEL				IN30132110714258	500	EQUITY SHARES
GHEWARCHAND L JOGANI				IN30133017276542	100	EQUITY SHARES
AJIT KUMAR AGRAWAL				IN30133019856672	100	EQUITY SHARES
LKP SECURITIES LTD				IN30133020662091	100	EQUITY SHARES
ANANT RAM SONPALI				IN30133020832267	50	EQUITY SHARES
MUSHTAQUE G ANSARI				IN30135620448147	50	EQUITY SHARES
VINOD NANIARAM BHAMBHANI				IN30135620501250	200	EQUITY SHARES
MANOJ GAUR				IN30136410219700	200	EQUITY SHARES
ADIL VIRAF MIRZAN				IN30143610638417	1000	EQUITY SHARES
PARAG SANATKUMAR OZA				IN30146910007689	1000	EQUITY SHARES
ASHABEN BHARAT KOSTI				IN30146910105681	45	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
HITESH N SHAH				IN30146910111252	4	EQUITY SHARES
BONANZA PORTFOLIO LTD				IN30147710068355	865	EQUITY SHARES
BIREWAR PRADIP				IN30148510021189	500	EQUITY SHARES
RAKSHA GANDHI				IN30148510071012	50	EQUITY SHARES
ANITHA R NAIR				IN30148510118695	500	EQUITY SHARES
MINABEN NARENDRA SHAH				IN30148510276150	200	EQUITY SHARES
SANDIP ANILBHAI SHAH				IN30148510339814	500	EQUITY SHARES
PATEL BRIJESH GOVINDBHAI				IN30148510359703	200	EQUITY SHARES
KIRAN KOTHARI				IN30148510411582	375	EQUITY SHARES
PANDYA DAKSHA ARPAN				IN30148510672910	2	EQUITY SHARES
PRABHABEN SHIVKUMAR VARMA				IN301485111334844	5905	EQUITY SHARES
MANJULABEN SADHU				IN30148511138072	18914	EQUITY SHARES
RONAK SHAH				IN30148511143953	300	EQUITY SHARES
MAHESH KUMAR SANGHAI				IN30154914126050	500	EQUITY SHARES
RAJNI TANWANI				IN30154916204865	500	EQUITY SHARES
VIPUL VINAYCHANDRA DOSHI				IN30154917286760	203	EQUITY SHARES
SHEFALI NILESH SHAH				IN30154917988141	100	EQUITY SHARES
NARAYAN G SHETTY				IN30154931774552	800	EQUITY SHARES
MURALIKUMAR UDUMALAI SREEKANTAN				IN30154937773431	502	EQUITY SHARES
HIRESH ARJUN GONDAL				IN30154951956819	5000	EQUITY SHARES
RADHABEN TIRATHDAS LEKHWANI				IN30154957027493	1662	EQUITY SHARES
AHTASHAM AHMAD				IN30154957058821	100	EQUITY SHARES
PATEL DIKSHIT NARESHBHAI				IN30154958687752	2500	EQUITY SHARES
PRAMILA PRABHAKAR MANIKPURKAR				IN30154962676205	1000	EQUITY SHARES
HEM CHANDRA				IN30155720088383	3	EQUITY SHARES
RASHMIKANT ANUPCHAND DOSHI				IN30160410021680	2112	EQUITY SHARES
SANDHYA RASHMIKANT DOSHI				IN30160410082109	350	EQUITY SHARES
LALITA NEMANI				IN30160410396673	30	EQUITY SHARES
MAHENDRA BANWARILAL LALPURIA				IN30160410408590	100	EQUITY SHARES
DIPAKKUMAR R HALANI				IN30160410728275	100	EQUITY SHARES
JIGARKUMAR CHANDRAKANT SHAH				IN30160410756755	7750	EQUITY SHARES
SURESH KUMAR SINGHANIA				IN30160410764415	1500	EQUITY SHARES
MINESHKUMAR CHANDUBHAI PATEL				IN30160410794066	500	EQUITY SHARES
MEENABEN GIRISHKUMAR SHAH				IN30160410905630	1989	EQUITY SHARES
HASMUKH RAMBHAI PATEL				IN30160410976364	500	EQUITY SHARES
PRAVINBHAI KANTIBHAI PATEL				IN30160411064608	100	EQUITY SHARES
GIRISHBHAI M PATEL				IN30160411345106	250	EQUITY SHARES
PURNIMA DHIRU SHAH				IN30160411384948	200	EQUITY SHARES
BHARATKUMAR NARANDAS PAREKH				IN30160411737671	450	EQUITY SHARES
JAGDISH PRASAD BANKA				IN30160412122474	400	EQUITY SHARES
VIJAYKUMAR PARASHRAM PRADHAN				IN30160412232074	4000	EQUITY SHARES
MANISHABEN SHAH				IN30164510170709	300	EQUITY SHARES
ALPESHBHAI RASIKLAL SHAH				IN30164510458779	100	EQUITY SHARES
DINESHBHAI KANTILAL BHAYSAR				IN30164510483642	1000	EQUITY SHARES
UTTAM SHARE BROKERS PVT LTD				IN30165310009009	200	EQUITY SHARES
MUDITA KARWA				IN30165310340349	100	EQUITY SHARES
PARESHKUMAR RATILAL PATEL				IN30169610804374	7000	EQUITY SHARES
SURAJ MAL SHARMA				IN30169611465504	740	EQUITY SHARES
JAY PARMAR				IN30174010045823	100	EQUITY SHARES
Rajeev Maini				IN30177410085569	300	EQUITY SHARES
Tulsidas Anant Tilve				IN30177410186143	10	EQUITY SHARES
MOHAMMAD SUHAIL NAUMANI				IN30177411113434	500	EQUITY SHARES
VINODKUMAR CHIMANLAL PANCHAL				IN30177411299498	2500	EQUITY SHARES
KUMKUMBEN INDRAVADANBHAI PATEL				IN30177412197095	4690	EQUITY SHARES
DAKSHABEN ASHVINKUMAR PATEL				IN30177412402769	100	EQUITY SHARES
BHARATBHAI SOMABHAI PATEL				IN30177412771488	10	EQUITY SHARES
MANOJKUMAR VINODKUMAR PANCHAL				IN30177414033106	2500	EQUITY SHARES
ASHOKKUMAR MULCHAND KABA				IN30177414875173	1000	EQUITY SHARES
KUNJAL MAHESH PALAKHIWALA				IN30177415041700	100	EQUITY SHARES
NITIN VASANTLAL JAIN				IN30177416128463	1000	EQUITY SHARES
CHINTAN A PATEL				IN30177416809792	300	EQUITY SHARES
VIJAY SHANTARAM KULKARNI				IN30177417166301	20	EQUITY SHARES
DINESHBHAI B RATHOD				IN30177417393457	65	EQUITY SHARES
SINGURU GOPI CHAND				IN30177417393800	11	EQUITY SHARES
GULAMFARID N SHAIKH				IN30177417882528	1500	EQUITY SHARES
GIRISHKUMAR KANTILAL PATEL				IN30177418634813	810	EQUITY SHARES
JAYESH HASMUKHRAI SHAH HUF				IN30185410100290	900	EQUITY SHARES
SUMIT SHARMA				IN30198310107632	33	EQUITY SHARES
MAHESH ROHRA				IN30198310528635	100	EQUITY SHARES
PARU DHANESH BUCH				IN30198311073168	219	EQUITY SHARES
RUCHITA GIRISH PATEL				IN30199110049497	1500	EQUITY SHARES
SANDIPKUMAR MAGANBHAI PARMAR				IN30199110121561	1000	EQUITY SHARES
PRABHUSINGH R RATHORE				IN30199110209766	1500	EQUITY SHARES
KETANBHAI DASADIA				IN30199110238962	400	EQUITY SHARES
PRAVIN B PATEL				IN30199110507138	100	EQUITY SHARES
DHARMESH C KA PATEL				IN30199110580259	3207	EQUITY SHARES
PATEL PINALKUMAR NAGINBHAI				IN30199110722873	400	EQUITY SHARES
RAJESHKUMAR SOMABHAI MAKWANA				IN30199110788092	66	EQUITY SHARES
SAURABH MAHENDRABHAI PATEL				IN30199110850326	27028	EQUITY SHARES
KAUSHIKBHAI MANUBHAI PATEL				IN30199110931596	1	EQUITY SHARES
KIRITKUMAR KESHAVLAL KACHHIA				IN30199110965503	225	EQUITY SHARES
GANDHI MUKESH CHHAGANLAL				IN30199110995045	300	EQUITY SHARES
VATSAL DILIPKUMAR DOSHI				IN30199111160122	400	EQUITY SHARES
DIPALI KAUSHIKKUMAR PATEL				IN30199111416965	1	EQUITY SHARES
SUJATA CHAKRABORTY				IN30210510518122	150	EQUITY SHARES
RANJANA KHAITAN				IN30214810591765	100	EQUITY SHARES
NASEERUDDIN SHAIK				IN30214810658629	500	EQUITY SHARES
SHARMILA P JAIN				IN30216410061550	4000	EQUITY SHARES
BHADRESH BANSILAL SHAH				IN30220110169360	1000	EQUITY SHARES
NITIN AMRUTLAL MEHTA				IN30220110248595	200	EQUITY SHARES
SHAH PARAS HARESHKUMAR				IN30220110559565	2600	EQUITY SHARES
HASMUKHRAI RATILAL SHAH				IN30220111002445	1000	EQUITY SHARES
JIMIT R SHAH				IN30220111142052	200	EQUITY SHARES
SURAJ MAL SHARMA				IN30220111476585	326	EQUITY SHARES
SARVAIYA KAMLESH J				IN30220111497991	200	EQUITY SHARES
PATEL JYOTIKA SUBANDHU				IN30220111523896	11239	EQUITY SHARES
BHAVNA PINAKIN SATIA				IN30223610369805	30	EQUITY SHARES
ANJU SINGLA				IN30223610754402	600	EQUITY SHARES
RAHUL SHAH				IN30223610808645	1000	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
IIFL SECURITIES LIMITED				IN30226910000005	67	EQUITY SHARES
MANOJ R SODHANI				IN30226910030540	1	EQUITY SHARES
HARSHAD R BHIRUD				IN30226910372004	66	EQUITY SHARES
JAYARAMAN KRISHNAN CHITTOR				IN30226910772951	65	EQUITY SHARES
SHAILESHKUMAR VITTHALBHAI HINGARAJIYA				IN30226911124220	1	EQUITY SHARES
BAROT PRIMALKUMAR PRAVINKUMAR				IN30226911374759	347	EQUITY SHARES
PATEL PRAGNESHKUMAR KANUBHAI				IN30226912014917	16111	EQUITY SHARES
ZALA SURENDRA SINGH				IN30226912407221	5533	EQUITY SHARES
SHITALKUMAR HASMUKHBHAI PATEL				IN30226912505614	2	EQUITY SHARES
PURSHOTTAM RAVJIBHAI PATEL				IN30226912616776	150	EQUITY SHARES
BAROT LILABEN ARVINDBHAI				IN30226912940655	4900	EQUITY SHARES
HIRAK PRARTHAN SHAH				IN30226913092578	150	EQUITY SHARES
JITENDRAKUMAR MANILAL PATEL				IN30226913380329	500	EQUITY SHARES
JADAV PRIYANKABEN TEJESHWAR				IN30226913929363	1000	EQUITY SHARES
DINESH HARESHBHAI GURNANI				IN30226914461022	2140	EQUITY SHARES
ANIL HAZARIMAL GUPTA				IN30226914735161	557	EQUITY SHARES
BHAVNA HITESH SHAH				IN30229310136879	75	EQUITY SHARES
DR TRIBHUVANDAS M PATEL				IN30233210038182	600	EQUITY SHARES
SYED HILAL AHMAD				IN30234910320793	11	EQUITY SHARES
VINOD JAIN				IN30246110011612	300	EQUITY SHARES
MEHUL M SHAH				IN30246110068725	200	EQUITY SHARES
VAGHAJIBHAI VORA				IN30246110073684	75	EQUITY SHARES
LEENA SURESH SHAH				IN30246110118062	500	EQUITY SHARES
VIMLABEN RATILAL SHAH				IN30246110194754	1000	EQUITY SHARES
JAIMINI PARESH SHAH				IN30246110282623	1000	EQUITY SHARES
CHINTAK KAMLESHBHAI SONI				IN30246110288532	200	EQUITY SHARES
FALGUNI KAMLESH SONI				IN30246110288566	300	EQUITY SHARES
KAMLESH RASIKLAL SONI				IN30246110288575	300	EQUITY SHARES
PRAVINABEN JITENDRABHAI MODI				IN30246110289088	150	EQUITY SHARES
RUPAL HETALBHAI SHAH				IN30246110349956	200	EQUITY SHARES
HETALBHAI BHARATBHAI SHAH				IN30246110349964	400	EQUITY SHARES
RAKSHA SHAILESH GANDHI				IN30246110411055	100	EQUITY SHARES
SADIKHUSEN REHMANBHAI SHAIKH				IN30246110459168	2000	EQUITY SHARES
SAROJBEN GUNVANTBHAI SHAH				IN30246110581999	300	EQUITY SHARES
ANJANA PRANAVKUMAR PATEL				IN30246110730784	1500	EQUITY SHARES
TRIBHOVANDAS M PATEL				IN30246110734622	600	EQUITY SHARES
DARSHIT TRIBHOVANDAS PATEL				IN30246110734647	600	EQUITY SHARES
JAGRUTI NILESH PATWA				IN30246110822960	900	EQUITY SHARES
SONAL SANJAY PATWA				IN30246110822994	13700	EQUITY SHARES
MANOJ SHYAMLAL SHARMA				IN30247010362415	6500	EQUITY SHARES
AWANINDRA PRATAP SINGH				IN30267932627708	245	EQUITY SHARES
SANJAY CHANDNA				IN30267933479333	1699	EQUITY SHARES
BINA ATULBHAI SHAH				IN30267933506127	3550	EQUITY SHARES
CHETAN JAIN				IN30267933506168	500	EQUITY SHARES
KAILASH MALPANI				IN30267936832801	50	EQUITY SHARES
RAMALINGAM P				IN30267937266529	100	EQUITY SHARES
RAGHWESH MISHRA				IN30267938893670	600	EQUITY SHARES
Alkaben Sanjaykumar Dave				IN30281411499399	250	EQUITY SHARES
LAKSHMINARAYANAN R				IN30290242890162	1	EQUITY SHARES
V SAIKRISHNAN				IN30290244823902	100	EQUITY SHARES
S SIVAKUMAR				IN30290246315076	100	EQUITY SHARES
SHANKAR KUMAR				IN30290247473803	75	EQUITY SHARES
SREEJITH S S				IN30290248656658	7	EQUITY SHARES
Bhavin Hitendrabhai Shah				IN30292710067909	1000	EQUITY SHARES
NIRALI JIGNESH GOHEL				IN30292710149431	4000	EQUITY SHARES
DEEPAK KUMAR DESAI				IN30294310106560	500	EQUITY SHARES
JOHNY GEORGE THEKKETHALA				IN30302851282852	70	EQUITY SHARES
C PRADEEP KUMAR REDDY				IN30302851462163	113	EQUITY SHARES
VINAY VISHWANATH VARTAK				IN30302851475690	100	EQUITY SHARES
MAYANK SHUKLA				IN30302851795967	490	EQUITY SHARES
GOLEGAONKAR VILAS V				IN30302854776213	10	EQUITY SHARES
PARTH RUSHABHKUMAR SHAH				IN30302859811156	1000	EQUITY SHARES
NAVEEN ROYAN				IN30302862010340	101	EQUITY SHARES
KARTIK RAO				IN30302874806057	1000	EQUITY SHARES
SATYAMURTHY S V				IN30302875400767	250	EQUITY SHARES
MANISHA MEHUL MEHTA				IN30304410037775	746	EQUITY SHARES
MEHUL PRANLAL MEHTA				IN30304410039437	2400	EQUITY SHARES
AMIT PRAMODKUMAR MEHTA				IN30305210123650	1000	EQUITY SHARES
RAMANLAL ISHWARLAL PATEL				IN30305210216323	800	EQUITY SHARES
HARSHA MAYURBHAI SHETH				IN30305210253184	2500	EQUITY SHARES
RAJESHKUMAR AADAJI PRAJAPATI				IN30305210308887	50	EQUITY SHARES
PRAKASH BHALAJI PRAJAPATI				IN30305210518632	50	EQUITY SHARES
KALPESHBHAI RASIKLAL SHAH				IN30305210638138	4250	EQUITY SHARES
JYOTI MAYURKUMAR GOHIL				IN30305210640173	3100	EQUITY SHARES
DHARNI RAVI KAPADIA				IN30305210661305	250	EQUITY SHARES
GAJENDRA BHIMSINH CHHASATIYA				IN30305210779314	200	EQUITY SHARES
PATEL NAVIN MANILAL				IN30305210830172	1000	EQUITY SHARES
TAPASI AGARWALLA				IN30307710711243	3	EQUITY SHARES
MAHESH KESHAVLAL SHETH				IN30311610400770	126	EQUITY SHARES
VIKRAM S MODI				IN30311611061069	100	EQUITY SHARES
NILESH HARIVADAN SHAH				IN30311611161184	251	EQUITY SHARES
UJJVAL KISHOR MEHTA				IN30311613198830	700	EQUITY SHARES
ANILKUMAR RAMANLAL SHAH				IN30311613326521	100	EQUITY SHARES
MEETA ANILKUMAR SHAH				IN30311613326732	200	EQUITY SHARES
MADHUKANTA RAMANLAL SHAH				IN30311613344679	200	EQUITY SHARES
BINITA CHHALANI				IN30340310012144	1000	EQUITY SHARES
MATALIA STOCK BROKING PVT LTD				IN30357510268716	100	EQUITY SHARES
SHEKH AIYUBBHAI VALIBHAI				IN30359110034259	20	EQUITY SHARES
HIRENKUMAR RAMESHCHANDRA SHAH				IN30365510014335	600	EQUITY SHARES
CHANDULAL PREMCHAND SHAH				IN30396410014222	50	EQUITY SHARES
SHAILESHKUMAR D SUTARIYA				IN30412310010823	1875	EQUITY SHARES
MIRZA JAVEDBHAI ASHRAF BHAI				IN30412310014327	2100	EQUITY SHARES
MUKESHBHAI NATHABHAI PATEL				IN304182100003963	5445	EQUITY SHARES
HEMANT JAYANT AMIN				IN30418210022118	100	EQUITY SHARES
DEVEN PRANLAL SHAH				IN30429512673460	300	EQUITY SHARES
SUNIL KUMAR SHETTY				IN30429512939346	225	EQUITY SHARES
CHINMAY VYOMESHKUMAR DOCTOR				IN30429519268630	1395	EQUITY SHARES
ROHINTON FRAMROZE BATIWALA				IN30611490067222	30	EQUITY SHARES
JEHANGIR ROHINTON BATIWALA				IN30611490109668	15	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
SODHAN	N	PATEL	00000002		10	EQUITY SHARES
MRUDULABEN	K	PATEL	00000003		10	EQUITY SHARES
KANTIBHAI	C	PATEL	00000004		10	EQUITY SHARES
RAJNIKANT	M	PATEL	00000005		10	EQUITY SHARES
HITENDRA	N	PATEL	00000006		10	EQUITY SHARES
JAYANTILAL	M	PATEL	00000007		10	EQUITY SHARES
NARANGIBEN	NATAVERLAL	SHAH	00001008		200	EQUITY SHARES
JAYESH	BHAI	KANTIBHAI PATEL	00001032		400	EQUITY SHARES
MILIND		ANTANI	00001042		400	EQUITY SHARES
JAGDISHBHAI	RAMANBHAI	PATEL	00001045		200	EQUITY SHARES
VIJAY	KUMAR	PAREKH	00001050		200	EQUITY SHARES
MINALBEN	MAYANKBHAI	PATEL	00001103		200	EQUITY SHARES
RAJENDRA	JAYANTILAL	KAPADIA	00001117		200	EQUITY SHARES
BHANUBEN	J	PATEL	00001144		300	EQUITY SHARES
PRATIPAL	SINGH	SETHI	00001202		100	EQUITY SHARES
SUKHPAL	SINGH	SETHI	00001203		100	EQUITY SHARES
RAJPAL	SINGH	SETHI	00001206		400	EQUITY SHARES
YOGI	JAYABEN	BABUBHAI	00001211		400	EQUITY SHARES
NILESH	V	DALSANIA	00001229		200	EQUITY SHARES
ALKA	B	SHAH	00001261		300	EQUITY SHARES
PARESH	U	SHETH	00001265		200	EQUITY SHARES
KESHAVLAL	K	SHETH	00001267		200	EQUITY SHARES
VANDNA	N	VASAUADA	00001273		100	EQUITY SHARES
URMILA	RATANLAL	BAGMAR	00001287		300	EQUITY SHARES
CHANDRAKANT		THAKKAR	00001292		300	EQUITY SHARES
KALPANA		THAKKAR	00001294		200	EQUITY SHARES
MAHENDRA	L	RUPAREL	00001319		300	EQUITY SHARES
SUNITA	G	LAL CHANDANI	00001320		100	EQUITY SHARES
CHANCHAL	N	RUPAREL	00001321		300	EQUITY SHARES
BHUPATBHAI		BHAYANI	00001325		100	EQUITY SHARES
REKHA	PANKAJ	THAKKAR	00001331		300	EQUITY SHARES
KAVITA	DEEPAK	THAKKAR	00001333		100	EQUITY SHARES
JAGDISHBHAI	S	PATEL	00001337		1500	EQUITY SHARES
TARABEN	J	PATEL	00001338		1500	EQUITY SHARES
PANKAJ	BHAGWANDAS	THAKKAR	00001339		100	EQUITY SHARES
YOUSUF	HATIMBHAI	LAKDAWALA	00001382		2500	EQUITY SHARES
BHUPESH	C	KANADIA	00001419		100	EQUITY SHARES
SRIRAM		K	00001420		100	EQUITY SHARES
SHAILESH		PATEL	00001424		200	EQUITY SHARES
SHASHI	PRABHA	R JAIN	00001425		100	EQUITY SHARES
KANTILAL	K	SOLANKI	00001426		200	EQUITY SHARES
KALPANA		LATHIA	00001430		100	EQUITY SHARES
HITENDRA	N	PATEL	00001434		300	EQUITY SHARES
SHODHAN	N	PATEL	00001436		200	EQUITY SHARES
KETAN	J	SHAH	00001441		200	EQUITY SHARES
UMESH	P	PAREKH	00001443		100	EQUITY SHARES
DHIRAJLAL	C	SHAH	00001446		200	EQUITY SHARES
SUNIL		AGRAWAL	00001452		100	EQUITY SHARES
RAMPURI		GOSAI	00001453		100	EQUITY SHARES
AMIT		SATA	00001454		100	EQUITY SHARES
PRAKASH	B	KHETAN	00001475		200	EQUITY SHARES
IQBAL	SINGH	BAMBAH	00001478		100	EQUITY SHARES
MAYA		VATNANI	00001481		200	EQUITY SHARES
RATANBEN	B	GALA	00001483		400	EQUITY SHARES
VIJAY	R	PALANDE	00001485		200	EQUITY SHARES
SUKHDEO		AGARAWAL	00001487		400	EQUITY SHARES
BIPINBHAI	POPATLAL	PATEL	00001496		100	EQUITY SHARES
HEMANT	H	BHAYANI	00001505		300	EQUITY SHARES
N	M	JOSHI	00001507		400	EQUITY SHARES
SANDIP	D	PATEL	00001508		100	EQUITY SHARES
SRIKANTHAN		S	00001512		100	EQUITY SHARES
LALITA	ARVINDKUMAR	PANCHAL	00001513		200	EQUITY SHARES
SANDIP	D	PATEL	00001519		100	EQUITY SHARES
HITESH	M	BUCH	00001523		100	EQUITY SHARES
VIPUL		PANDYA	00001526		100	EQUITY SHARES
TARIQ		SAYED	00001537		300	EQUITY SHARES
DHANKUMAR		GADIA	00001544		600	EQUITY SHARES
ROHIT	L	MEHTA	00001549		300	EQUITY SHARES
MANOJ		MOTIWALA	00001551		400	EQUITY SHARES
RAMESH	K	BHRUGUSHASTRI	00001558		400	EQUITY SHARES
MAHENDRA	KUMAR	MEHTA	00001560		100	EQUITY SHARES
S	SATISHCHANDRA	PRABHU	00001561		100	EQUITY SHARES
KETAN	ISHWARLAL	SHAH	00001565		100	EQUITY SHARES
RAJESH		NAGPAL	00001569		100	EQUITY SHARES
NANDLAL	S	CHANDWANI	00001579		200	EQUITY SHARES
TAJPAL	B	SHAH	00001580		100	EQUITY SHARES
PRADIP	CHHABILDAS	SHAH	00001584		100	EQUITY SHARES
HENA		BOSE	00001592		200	EQUITY SHARES
SAVITABEN	NEMCHAND	SHAH	00001594		100	EQUITY SHARES
DAXAY	ISHVARLAL	DESAI	00001596		200	EQUITY SHARES
BIPIN	KUMAR	JAIN	00001597		200	EQUITY SHARES
DINESH	K	JAIN	00001600		200	EQUITY SHARES
JITENDRA	H	JAIN	00001601		200	EQUITY SHARES
SANMATI	K	JAIN	00001602		300	EQUITY SHARES
GOPALAKRISHNA		IYER	00001618		200	EQUITY SHARES
PANDYA	MANGLESH	DEVENDRAPRASAD	00001622		200	EQUITY SHARES
SEVANTILAL	M	SHAH	00001624		100	EQUITY SHARES
DHARMESH	R	SHAH	00001627		200	EQUITY SHARES
ZARNA		SANGHVI	00001629		400	EQUITY SHARES
RASIKLAL	VITHALDAS	GANDHI	00001632		100	EQUITY SHARES
PRAFUL	MANILAL	SHAH	00001638		100	EQUITY SHARES
SANDIP	D	PATEL	00001641		300	EQUITY SHARES
VINOD	J	SHAH	00001645		300	EQUITY SHARES
JITENDRA	R	SHAH	00001648		200	EQUITY SHARES
MANGLABEN	K	THAKKAR	00001649		100	EQUITY SHARES
KETAN	J	SHAH	00001651		300	EQUITY SHARES
NEETA	RAJESH	MEHTA	00001655		100	EQUITY SHARES
SAVITA		RAMI	00001656		200	EQUITY SHARES
RAJU		MENON	00001658		100	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
ANKUR		SANGHVI	00001660		400	EQUITY SHARES
ZARNA		SANGHVI	00001661		100	EQUITY SHARES
ASHOK	NARAYANDAS	TRIVEDI	00001665		100	EQUITY SHARES
USHA	ASHOK	TRIVEDI	00001666		100	EQUITY SHARES
KANHAIYA	LAL	B SISODIYA	00001675		200	EQUITY SHARES
MUKESH		MADHUKAR	00001684		100	EQUITY SHARES
MANOJ	KUMAR	DOKANIA	00001685		100	EQUITY SHARES
RAJENDRA	AMBALAL	PATEL	00001690		100	EQUITY SHARES
KAMLESH	A	SHAH	00001694		200	EQUITY SHARES
RUPEL	HITESH	SHAH	00001704		200	EQUITY SHARES
AMRAT	ISHWAR	PATEL	00001705		400	EQUITY SHARES
RASHID	AHMAD	KHAN	00001715		100	EQUITY SHARES
SAVITABEN	NEMCHAND	SHAH	00001720		400	EQUITY SHARES
BHARAT	C	DOSHI	00001728		200	EQUITY SHARES
P	R	MANJUNATH	00001729		100	EQUITY SHARES
ASHOK	P	JETHANI	00001748		100	EQUITY SHARES
PRAKASH		JAIN	00001756		100	EQUITY SHARES
SHILPA	M	RATHORE	00001764		200	EQUITY SHARES
DILIP		ZAVERI	00001775		200	EQUITY SHARES
MEENA	RAJESH	KOTADIA	00001776		400	EQUITY SHARES
RENU		KARNAWAT	00001777		200	EQUITY SHARES
JANAK	L	PATEL	00001779		400	EQUITY SHARES
JANAK	L	PATEL	00001780		300	EQUITY SHARES
HASMUKH	N	JETHWA	00001788		100	EQUITY SHARES
HASMUKH	N	JETHWA	00001789		100	EQUITY SHARES
SHAILESH	R	PUROHIT	00001794		300	EQUITY SHARES
BHAVIN	DHIREN	SHAH	00001797		100	EQUITY SHARES
MUKESH		AHUJA	00001798		400	EQUITY SHARES
ABDULLAH	T	SHAIKH	00001807		200	EQUITY SHARES
SUHAS	S	SAMANT	00001810		100	EQUITY SHARES
SUDHA		KHEMKA	00001811		200	EQUITY SHARES
NEETABEN	K	SHAH	00001816		200	EQUITY SHARES
PRITESH	B	PATEL	00001818		100	EQUITY SHARES
RITESH	B	PATEL	00001819		100	EQUITY SHARES
PARINDA	N	PAREKH	00001831		200	EQUITY SHARES
SHITAL	A	MEHTA	00001832		200	EQUITY SHARES
INDULAL		DESAI	00001833		300	EQUITY SHARES
MIHIR	A	ADANI	00001839		200	EQUITY SHARES
SNEHAL	H	SHAH	00001840		200	EQUITY SHARES
SAMIULLAH		KHAN	00001841		200	EQUITY SHARES
CHHATARSINGH		BHANSALI	00001848		200	EQUITY SHARES
ATUL	P	PAREKH	00001850		200	EQUITY SHARES
BHARATI	P	PAREKH	00001856		300	EQUITY SHARES
DILSHAD		LOKHANDWALA	00001857		100	EQUITY SHARES
SHERBANU		KASSAM	00001858		100	EQUITY SHARES
DILSHAD		LOKHANDWALA	00001859		100	EQUITY SHARES
SHAILESH	R	PUROHIT	00001864		200	EQUITY SHARES
INDULAL		DESAI	00001868		300	EQUITY SHARES
AJAY		GAUTAM	00001869		300	EQUITY SHARES
RICHA	R	CHRISTIAN	00001871		100	EQUITY SHARES
GITA	ASHOK	SHAH	00001874		100	EQUITY SHARES
SONAL	M	SANGHANI	00001876		300	EQUITY SHARES
SUDHIR	KUMAR	GOYAL	00001881		100	EQUITY SHARES
RAJKUMAR		DOSHI	00001882		100	EQUITY SHARES
BABULAL	C	KOTHARI	00001885		200	EQUITY SHARES
NAYANA	V	PAI	00001901		200	EQUITY SHARES
RAVINDRA	KUMAR	KOTHARI	00001902		100	EQUITY SHARES
PAYAL	JAYANT	CHITALIA	00001909		1000	EQUITY SHARES
MAHESH	KUMAR	CHOUDHARY	00001911		200	EQUITY SHARES
KRISHNA	S	JAMBALE	00001913		200	EQUITY SHARES
ARUNA	PARASURAM	IYER	00001914		200	EQUITY SHARES
AMITA	D	GANDHI	00001915		200	EQUITY SHARES
NAIMISH	N	GODIAWALA	00001919		200	EQUITY SHARES
HITESH	DHIRAJLAL	PAREKH	00001921		300	EQUITY SHARES
GAJENDRA		MEHTA	00001923		200	EQUITY SHARES
GAURANG	KANTILAL	PARIKH	00001927		100	EQUITY SHARES
PRAVINA	N	KOTADIA	00001929		200	EQUITY SHARES
BHARATI	R	VORA	00001944		100	EQUITY SHARES
GOPAL	A	RANGA	00001946		100	EQUITY SHARES
SULABHA	SATISH	VAIDYA	00001947		100	EQUITY SHARES
VIRENDRASINGH	A	CHAUHAN	00001949		100	EQUITY SHARES
MANOJ		MEHTA	00001955		200	EQUITY SHARES
SHANTILAL	M	SAVALIYA	00001958		200	EQUITY SHARES
ALOK		KOTHARI	00001966		200	EQUITY SHARES
HITESH		JAIN	00001972		300	EQUITY SHARES
SANTHA	K	KINI	00001978		100	EQUITY SHARES
MOTIBHAI		TALREJA	00001987		100	EQUITY SHARES
ASHWIN	R	RANA	00001992		100	EQUITY SHARES
ABHAIRAJ	JOGIRAM	YADAV	00001995		200	EQUITY SHARES
LATHA		SASIDHARAN	00002011		300	EQUITY SHARES
JITENDRA	CHANDULAL	SHAH	00002012		200	EQUITY SHARES
SHIV	HARI	SARAF	00002018		200	EQUITY SHARES
ANJANABEN	R	KAPADIA	00002019		300	EQUITY SHARES
DHARMENDRA		AHUJA	00002028		200	EQUITY SHARES
PURSHOTAM	D	FATNANI	00002037		300	EQUITY SHARES
LEELA		JEYAKUMAR	00002041		100	EQUITY SHARES
ARUN		SURANA	00002054		300	EQUITY SHARES
CHETNA	H	DANI	00002058		200	EQUITY SHARES
ANAND	K	DANDEKAR	00002064		100	EQUITY SHARES
ABDULLA	MOHAMED	MADRE	00002077		200	EQUITY SHARES
KHUSHAL		DHARAMSEY	00002078		100	EQUITY SHARES
SURINDER		KOUR	00002079		200	EQUITY SHARES
UTPAL	R	DOSHI	00002080		200	EQUITY SHARES
KALPESH	R	SHAH	00002082		100	EQUITY SHARES
MANOJ	N	SHAH	00002083		300	EQUITY SHARES
SANJAY	P	SHAH	00002088		100	EQUITY SHARES
PANKAJ	C	SHAH	00002090		100	EQUITY SHARES
JAYSUKH	K	SHAH	00002091		100	EQUITY SHARES
ARUNA	DHIRAJ	SHAH	00002092		200	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
NIKITA		PAREKH	00002093		100	EQUITY SHARES
CHIRAG		PAREKH	00002094		100	EQUITY SHARES
MADHUKAR		SHETH	00002095		300	EQUITY SHARES
SURYAKUMAR		SABOO	00002096		100	EQUITY SHARES
KAVITA		JAIN	00002108		100	EQUITY SHARES
JAI	BHAGWAN	MITTAL	00002111		200	EQUITY SHARES
HEMEN	PANKAJ	KUMBHANI	00002123		200	EQUITY SHARES
BALDEV	RAJ	BHARDWAJ	00002125		100	EQUITY SHARES
MONA	D	JAIN	00002135		400	EQUITY SHARES
GIRIJA		BALACHANDRAN	00002140		300	EQUITY SHARES
NIPABEN		PAREKH	00002146		400	EQUITY SHARES
PRAMILA		KATIYAR	00002150		200	EQUITY SHARES
PRASHANT		AGARWAL	00002158		100	EQUITY SHARES
KETAN	T	RAJDEV	00002166		100	EQUITY SHARES
GITA	K	RAJDEV	00002167		100	EQUITY SHARES
RAJENDRAN		V	00002177		100	EQUITY SHARES
ARUN		THANVI	00002178		300	EQUITY SHARES
ASIF	A	NATHANI	00002180		200	EQUITY SHARES
RAGINI	I	THAKER	00002185		200	EQUITY SHARES
KALPESH	D	SHETH	00002190		100	EQUITY SHARES
PRAVINCHANDRA	VALJI	PATEL	00002192		100	EQUITY SHARES
NISHA	MANISH	DOSHI	00002196		200	EQUITY SHARES
SATYANARAYAN	R	UPADHYE	00002199		100	EQUITY SHARES
HEMENDRA		MODI	00002203		100	EQUITY SHARES
RENUKA		MODI	00002204		100	EQUITY SHARES
NANDLAL	RAMJIBHAI	SWAMI	00002214		100	EQUITY SHARES
KARTIK	B	JAIN	00002218		100	EQUITY SHARES
AMIT	D	MODI	00002219		200	EQUITY SHARES
NARESH		MINDA	00002220		200	EQUITY SHARES
RAMAN	V	DALAL	00002231		100	EQUITY SHARES
AMIT	R	SHAH	00002254		200	EQUITY SHARES
KETAN	S	SHAH	00002269		200	EQUITY SHARES
BHAWNA		SHAH	00002270		400	EQUITY SHARES
ANAND		SHRISHRIMAL	00002288		100	EQUITY SHARES
RAJESH	J	RAMBHIA	00002296		200	EQUITY SHARES
JAYESHKUMAR	ISHWARLAL	TOLIA	00002302		100	EQUITY SHARES
PAWAN	KUMAR	SHARMA	00002304		100	EQUITY SHARES
SONAL	P	ASHER	00002307		100	EQUITY SHARES
BHARAT	K	GADHVI	00002315		100	EQUITY SHARES
RANJAN	R	SAVLA	00002316		300	EQUITY SHARES
BHARAT		MASRANI	00002317		300	EQUITY SHARES
MANOJ	J	GOLECHA	00002318		200	EQUITY SHARES
RAJENDRA	KRUSHNARAO	MESHARAM	00002321		200	EQUITY SHARES
CHANDRESHKUMAR	INDRAVADAN	KHAMAR	00002328		100	EQUITY SHARES
MOOLCHAND		MEHTA	00002330		100	EQUITY SHARES
JITENDRA		SHAH	00002332		100	EQUITY SHARES
HEENA	R	SHETH	00002336		200	EQUITY SHARES
DAMODAR	S	SUVARNA	00002339		100	EQUITY SHARES
TARALIKA		SHAH	00002340		300	EQUITY SHARES
KETAN	S	SHAH	00002343		200	EQUITY SHARES
VILASBEN		DAFTARI	00002350		400	EQUITY SHARES
GULAB		MERANI	00002352		100	EQUITY SHARES
KISHOR		SOTA	00002357		200	EQUITY SHARES
ASHOKKUMAR		MAHAJAN	00002363		100	EQUITY SHARES
NEELAM		MAHAJAN	00002364		100	EQUITY SHARES
JAYESH	YASHVANT	SHETH	00002368		200	EQUITY SHARES
SAIKESH	GOVARDHANDAS	GANDHI	00002369		300	EQUITY SHARES
PRAFUL	MANILAL	SHAH	00002372		100	EQUITY SHARES
MANILAL	K	DARJI	00002376		300	EQUITY SHARES
ANILKUMAR		GARG	00002377		200	EQUITY SHARES
DINESH		RATHOD	00002379		200	EQUITY SHARES
ASWIN	KUMAR	RASIKLAL DAVE	00002385		100	EQUITY SHARES
RAJENDER		SINGH	00002398		300	EQUITY SHARES
KANCHAN		VISHNANI	00002403		200	EQUITY SHARES
MAHESH	RAMESH	PORE	00002406		200	EQUITY SHARES
KISHORE	ISHWARLAL	DAMANIA	00002410		300	EQUITY SHARES
SUJAY	B	JHAVERI	00002411		200	EQUITY SHARES
DISHA	K	PARMAR	00002412		200	EQUITY SHARES
PRASHANT	MANHAR	ITALIA	00002414		400	EQUITY SHARES
TATAVEERA		RAGHAVULU	00002416		100	EQUITY SHARES
SANTHI		XAVIER	00002417		200	EQUITY SHARES
KAUSHIK	S	UDANI	00002422		100	EQUITY SHARES
ASHISH		ARYA	00002425		200	EQUITY SHARES
KASHYAP	P	MODY	00002432		200	EQUITY SHARES
MOHAMMED	SAJID	AHMED HUSAIN	00002435		100	EQUITY SHARES
BIPIN	B	SHAH	00002438		100	EQUITY SHARES
TARUN	B	RAMANI	00002440		300	EQUITY SHARES
ARUNKUMAR		JAISWAL	00002454		100	EQUITY SHARES
RAMAN		KOHLI	00002456		200	EQUITY SHARES
MILAN	KANTILAL	MEHTA	00002457		100	EQUITY SHARES
KALYANJI		RAVJI	00002459		300	EQUITY SHARES
HASMUKH	CHAMPSHI	SATRA	00002460		400	EQUITY SHARES
PAWAN	KUMAR	AGARWAL	00002465		100	EQUITY SHARES
SIS	SHARE	STOCK BROKERS PVT LTD	00002474		800	EQUITY SHARES
PUSHPA		JAIN	00002488		300	EQUITY SHARES
PARASMAL		JAIN	00002489		400	EQUITY SHARES
MAHAVEER		JAIN	00002491		300	EQUITY SHARES
KISHOR	D	GORE	00002496		100	EQUITY SHARES
DIVYESH	KALIDAS	GAVIT	00002502		100	EQUITY SHARES
ATUL		GODHA	00002510		200	EQUITY SHARES
ANURAG		JAIN	00002511		300	EQUITY SHARES
LALITA	L	PAPAT	00002516		300	EQUITY SHARES
BHARAT	K	GADHVI	00002520		100	EQUITY SHARES
GURPREET	SINGH	KABLI	00002521		300	EQUITY SHARES
NILESH	M	PATWA	00002523		200	EQUITY SHARES
RAVINDER	KUMAR	GUPTA	00002543		300	EQUITY SHARES
SRIMAN	SECURITIES	FISCAL LTD	00002544		300	EQUITY SHARES
NILESH	DHIRAJLAL	PAREKH	00002552		200	EQUITY SHARES
MOOLCHAND	TRILLOCKCHAND	MEHTA	00002554		100	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
MADAN	M	JAIN	00002558		200	EQUITY SHARES
ANANTRAY		SHANTILAL	00002559		100	EQUITY SHARES
SARTHAK	A	DOSHI	00002568		200	EQUITY SHARES
DINESH		SHARMA	00002569		100	EQUITY SHARES
KISHOR	N	PATEL	00002571		200	EQUITY SHARES
BALKISHAN	D	DEVDA	00002573		400	EQUITY SHARES
BIPIN	L	MAGIYA	00002576		200	EQUITY SHARES
RAMPRASAD		AGARWAL	00002581		100	EQUITY SHARES
RAJENDRA		PATEL	00002593		400	EQUITY SHARES
CHANDRAKANT	C	MEHTA	00002605		2700	EQUITY SHARES
RENU		BHAGTANI	00002610		300	EQUITY SHARES
RASHMIKANT	M	SHAH	00002611		2400	EQUITY SHARES
KARNATI		PRASAD	00002613		100	EQUITY SHARES
ATUL	KUMAR	SARAF	00002614		1000	EQUITY SHARES
JITENDRA	J	DOSHI	00002616		400	EQUITY SHARES
KANTILAL	K	SOLANKI	00002618		1000	EQUITY SHARES
DILIP		TIWARI	00002620		100	EQUITY SHARES
MEENA	H	DOSHI	00002621		700	EQUITY SHARES
GANESH	KUMAR	KHANDELWAL	00002622		400	EQUITY SHARES
KAISER	ISMAIL	ANSARI	00002624		300	EQUITY SHARES
MITA	L	SHAH	00002625		1000	EQUITY SHARES
INDIRABEN	B	SHAH	00002626		800	EQUITY SHARES
RAHUL	SINGH	RAGHAVA	00002628		200	EQUITY SHARES
PHILOMENA	R	FERNANDES	00002629		200	EQUITY SHARES
RAJESH	T	JAIN	00002631		100	EQUITY SHARES
REKHA	R	KADAM	00002633		1000	EQUITY SHARES
VIMALKUMAR		JOSHI	00002634		900	EQUITY SHARES
RAJESH	T	JAIN	00002640		1900	EQUITY SHARES
KIRIT	KUMAR	SHAH	00002643		500	EQUITY SHARES
SATENDER	KUMAR	GUPTA	00002646		500	EQUITY SHARES
JAYESHKUMRA	I	TOLIA	00002653		200	EQUITY SHARES
SURYA	PRAKASH	TIBREWAL	00002658		800	EQUITY SHARES
T		BALACHANDER	00002659		1000	EQUITY SHARES
DEEPAK	R	GANDHI	00002660		100	EQUITY SHARES
BHAVIKA	D	GANDHI	00002661		100	EQUITY SHARES
NILESH	R	GANDHI	00002662		100	EQUITY SHARES
DILIPKUMAR	V	SANGHVI	00002664		200	EQUITY SHARES
RAKHI	KAMALKUMAR	JAIN	00002675		500	EQUITY SHARES
HASMUKHBHAI	M	MODI	00002680		600	EQUITY SHARES
MADHU	N	MODI	00002683		200	EQUITY SHARES
HETAL		SHAH	00002684		100	EQUITY SHARES
RAJESH	J	SHAH	00002689		500	EQUITY SHARES
GHANSHYAM		LOHIA	00002692		200	EQUITY SHARES
CHARITRA		MEHTA	00002693		1000	EQUITY SHARES
ASHOK	KUMAR	DAMANI	00002695		8100	EQUITY SHARES
RASIKLAL	BHAISHANKER	DAVE	00002697		100	EQUITY SHARES
JAYANT	C	VORA	00002698		200	EQUITY SHARES
JITENDRA	J	DOSHI	00002716		100	EQUITY SHARES
SHIVANI	KEKIN	VIRA	00002722		300	EQUITY SHARES
PARESH	M	PAREKH	00002724		500	EQUITY SHARES
HASMUKHBHAI	M	MODI	00002725		100	EQUITY SHARES
RAMAKRISHNA	G	GOWDA	00002728		1900	EQUITY SHARES
CHANDA	CHANDRASEN	VED	00002730		100	EQUITY SHARES
RAJEEV		SEHGAL	00002731		300	EQUITY SHARES
KAMAL		ASLI	00002734		500	EQUITY SHARES
BHAGWATI	DEVI	SINGHANIA	00002735		500	EQUITY SHARES
DINESH	KUMAR	GUPTA	00002737		500	EQUITY SHARES
BHARTI	S	BHANUSHALI	00002738		2000	EQUITY SHARES
DEEPAK	BABUBHAI	JHAVERI	00002740		2000	EQUITY SHARES
DEEPAK	B	JHAVERI	00002741		900	EQUITY SHARES
RASHMIKANT	M	SHAH	00002747		200	EQUITY SHARES
RADHIKA	ATUL	SARAF	00002757		1000	EQUITY SHARES
KAMLESH	TRIBHOVAN	PATEL	00002758		1000	EQUITY SHARES
TRIBHOVAN	PRAGJIBHAI	PATEL	00002761		1000	EQUITY SHARES
ATULKUMAR	TRIBHOVAN	PATEL	00002762		1000	EQUITY SHARES
RAKESH		GANDHI	00002769		200	EQUITY SHARES
BHARTI	S	BHANUSHALI	00002775		1000	EQUITY SHARES
HASMUKH	K	KANUNGO	00002782		1700	EQUITY SHARES
HASMUKH	K	KANUNGO	00002786		100	EQUITY SHARES
MANORAMA		DWIVEDI	00002787		100	EQUITY SHARES
VIBHA		BHATNAGAR	00002788		1300	EQUITY SHARES
ASHOK		CHHABRA	00002789		1000	EQUITY SHARES
VIRENDRA	P	SHAH	00002792		400	EQUITY SHARES
ALTAF	HAROON	GHANCHI	00002798		500	EQUITY SHARES
ANIL	KUMAR	DAS	00002799		100	EQUITY SHARES
ASHOK	KUMAR	TREFALLM	00002801		500	EQUITY SHARES
VIRENDRA	KUMAR	GODHA	00002804		200	EQUITY SHARES
MAHENDRA		TAORI	00002806		100	EQUITY SHARES
VILAS	V	KADAM	00002808		200	EQUITY SHARES
DEVILAL	K	SHARMA	00002809		100	EQUITY SHARES
HASMUKH	K	KANUNGO	00002812		400	EQUITY SHARES
KAMAL		NANGLIA	00002814		300	EQUITY SHARES
NANJ	M	DAMA	00002815		5000	EQUITY SHARES
RIKESH	V	PARIKH	00002816		100	EQUITY SHARES
VIBHA		BHATNAGAR	00002818		2100	EQUITY SHARES
SUREN	R	KARIA	00002823		500	EQUITY SHARES
SAFIA		BANU	00002824		100	EQUITY SHARES
NISHAR	AEHMAD	ABDUL GANI	00002825		100	EQUITY SHARES
PALLAVI		DOSHI	00002826		500	EQUITY SHARES
VIRENDRA	KUMAR	GODHA	00002828		100	EQUITY SHARES
N	C	DOSHI	00002830		500	EQUITY SHARES
LALIT	T	THAKKAR	00002836		100	EQUITY SHARES
SURYAPRAKASH		RAICHANDANI	00002838		300	EQUITY SHARES
KISHOR	M	SOMAIYA	00002840		100	EQUITY SHARES
NISHAR	AGHMAD	ABDUL GANI SHAIKH	00002841		100	EQUITY SHARES
BHAGHIRATH		VYAS	00002843		600	EQUITY SHARES
VILAS	V	KADAM	00002849		500	EQUITY SHARES
RAJESH	HIRALAL	KOTADIA	00002857		1800	EQUITY SHARES
K	U	KOTHARI	00002860		300	EQUITY SHARES

HEMO ORGANIC LIMITED
LIST OF SHAREHOLDERS AS ON 31-03-2021

First Name	Middle Name	Last Name	Folio Number	DP ID-Client ID Account Number	Number of Shares held	Class of Shares
ANIL		JAIN	00002870		300	EQUITY SHARES
VIMAL		GOHIL	00002888		300	EQUITY SHARES
CHANDRAKANT	C	MEHTA	00002890		200	EQUITY SHARES
CHANDRAKANT	C	MEHTA	00002892		100	EQUITY SHARES
NARESH		MOTWANI	00002897		100	EQUITY SHARES
VINOD	KUMAR	P GOYAL	00002901		800	EQUITY SHARES
NARESH	TEJBHAN	MOTWANI	00002904		100	EQUITY SHARES
RAJESH	HIRALAL	KOTADIA	00002909		500	EQUITY SHARES
LAXMI		GOPLANI	00002911		1000	EQUITY SHARES
SURESH	R	LAKHOTIYA	00002914		500	EQUITY SHARES
ANILKUMAR		DAS	00002918		300	EQUITY SHARES
JITENDRA	J	DOSHI	00002920		1200	EQUITY SHARES
NIRANJAN	VALLABHDAS	BHUPTANI	00002923		300	EQUITY SHARES
HASMUKHLAL	BALUBHAI	CHAUDHAN	00002925		500	EQUITY SHARES
GHANASHYAM	K	BHAVSAR	00002934		300	EQUITY SHARES
RAMCHANDRA	K	GHADGE	00002935		100	EQUITY SHARES
URWILA	S	MAROO	00002936		500	EQUITY SHARES
HARESH	V	SHAH	00002939		500	EQUITY SHARES
HARISH	R	BOHRA	00002942		100	EQUITY SHARES
JITENDRA	J	DOSHI	00002943		3500	EQUITY SHARES
PRABHAVATI		PORE	00002946		500	EQUITY SHARES
HEMANGINI	A	PAREKH	00002947		1000	EQUITY SHARES
RATAN	KISANGOPAL	RATHI	00002950		100	EQUITY SHARES
JITENDRA	J	DOSHI	00002951		1100	EQUITY SHARES
VASHRAM	MANJI	PATEL	00002956		200	EQUITY SHARES
SHILPA	RAJESH	GALA	00002961		4500	EQUITY SHARES
CHAND	RATAN	BALDEWA	00002965		100	EQUITY SHARES
RAJENDRA		KUMAR	00002969		700	EQUITY SHARES
KANTILAL	P	JAIN	00002970		500	EQUITY SHARES
RAMESH		MEHTA	00002971		500	EQUITY SHARES
ANILKUMAR		BHOOTRA	00002976		100	EQUITY SHARES
AMIT		SHAH	00002977		100	EQUITY SHARES
BHAVANA		SHAH	00002978		5900	EQUITY SHARES
VIDYA	KRISHNARAO	VINERKAR	00002980		500	EQUITY SHARES
BHAVESH	M	PATEL	00002983		1500	EQUITY SHARES
S	C	RAJPOPAT	00002985		200	EQUITY SHARES
NITIN		GANDHI	00002987		500	EQUITY SHARES
BHAVESH	M	PATEL	00002989		2700	EQUITY SHARES
JAYSHREEBEN	M	KANTRODIA	00002991		500	EQUITY SHARES
BHAVESH	M	PATEL	00002995		900	EQUITY SHARES
KAMINI	R	JAVERI	00002996		2000	EQUITY SHARES
R	K	PUNGALIA	00002997		1500	EQUITY SHARES
JASHUMATI	J	PADARIA	00003006		1900	EQUITY SHARES
DHIREN	M	SHAH	00003007		600	EQUITY SHARES
CHANDRAKANT	D	GANDHI HUF	00003008		1000	EQUITY SHARES
NAYNABEN	S	SHAH	00003011		100	EQUITY SHARES
MAHENDRAKUMAR		JAIN	00003020		200	EQUITY SHARES
KETAN	ANIL	DESAI	00003024		100	EQUITY SHARES
ANIL	MANILAL	DESAI	00003025		100	EQUITY SHARES
RAMILA	ANIL	DESAI	00003026		100	EQUITY SHARES
JAYSHREE	KETAN	DESAI	00003032		100	EQUITY SHARES
NARESH	A	SHAH	00003041		900	EQUITY SHARES
PALLAVI	P	SHAH	00003047		100	EQUITY SHARES
DINESH	KUMAR	MITTAL	00003048		500	EQUITY SHARES
MANJULA	S	PATEL	00003053		2000	EQUITY SHARES
SHYAM	SUNDER	MANDAL	00003069		300	EQUITY SHARES
JAYSHREE	R	MATHURIA	00003070		700	EQUITY SHARES
NIHAR	N	JAMBUSARIA	00003072		1000	EQUITY SHARES
KAILASH	CHANDRA	PARHI	00003079		500	EQUITY SHARES
V		KIRATHAN	00003089		200	EQUITY SHARES
RAMASWAMY		SUBRAMANIAN	00003094		500	EQUITY SHARES
NITINKUMAR	LALBHAI	MASRANI	00003165		100	EQUITY SHARES
PRATIBHABEN	DINESHBHAI	PATEL	00003182		500	EQUITY SHARES
ASHISH	GAJRAJ	CHOUDHARY	00003189		500	EQUITY SHARES
MANISH		SHAH	00003214		400	EQUITY SHARES
INDRA	KUMAR	BAGRI	00003222		400	EQUITY SHARES
TRANSIT			00055555		1500	EQUITY SHARES
DINENDRA		JAIN	00700001		200	EQUITY SHARES

DRAFT FORM MGT-8

Form No. MGT-8

[Pursuant to section 92(2) of the Companies Act, 2013 and rule 11(2) of Companies (Management and Administration) Rules, 2014]

To,
The Board of Directors,
Hemo Organic Limited
8-A, Gulnar, Chinar - Gulnar Appt,
V V Nagar Road,
Anand - 388 001

CERTIFICATE BY A COMPANY SECRETARY IN PRACTICE

I have examined the registers, records and books and papers of Hemo Organic Limited (“the Company”) as required to be maintained under the Companies Act, 2013 (the Act) and the rules made there under for the financial year ended on March 31, 2021. In my opinion and to the best of the information made available to me and according to the examinations carried out by me and explanations furnished to me by the company, its officers and agents, I certify that:

- A. The Annual Return states the facts as at the close of the aforesaid financial year correctly and adequately.
- B. During the aforesaid financial year the Company has complied with provisions of the Act & Rules made there under in respect of:
1. Its status under the Act - The Company is a Listed Public Company and its status remained same throughout financial year 2020-21.
 2. Maintenance of registers/records & making entries therein within the time prescribed therefore;
 3. Filing of forms and returns as stated in the annual return, with the Registrar of Companies within/beyond the prescribed time.

Further, the Company was not required to file any forms and returns with Regional Director, Central Government, the Tribunal, Court or other authorities.

4. Calling/ convening/ holding meetings of Board of Directors or its committees namely 1) Audit Committee, 2) Nomination and Remuneration Committee, 3) Stakeholders’ Grievances and Relationship Committee and 4) Meeting of Independent Director and the meetings of the members of the company on due dates as stated in the annual return in respect of which meetings, proper notices were given and the proceedings have been properly recorded in the Minute Book/registers maintained for the purpose and the same have been signed.

Further, the Company has not passed any resolution through circulation or postal ballot;

5. Closure of Register of Members;
6. Advances/loans to its directors and/or persons or firms or companies referred in section 185 of the Act;
Not Applicable as there was no such instance took placed during the financial year 2020-21.
7. Contracts/arrangements with related parties as specified in section 188 of the Act;
Not Applicable as there was no such instance took placed during the financial year 2020-21.
8. Issue or allotment or transfer or transmission or buy back of securities/ redemption of preference shares or debentures/ alteration or reduction of share capital/ conversion of shares/ securities and issue of security certificates in all instances;
Not Applicable as there was no such instance took placed during the financial year 2020-21.
9. Keeping in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares in compliance with the provisions of the Act.
Not Applicable as there was no such instance took placed during the financial year 2020-21.

DRAFT FORM MGT-8

10. Declaration / payment of dividend; transfer of unpaid/ unclaimed dividend/other amounts as applicable to the Investor Education and Protection Fund in accordance with section 125 of the Act;
Not Applicable as there was no such instance took placed during the financial year 2020-21.
11. Signing of audited financial statement as per the provisions of section 134 of the Act and report of directors is as per sub - sections (3), (4) and (5) thereof *except since the Company has not appointed Company Secretary in whole time employment and Chief Financial Officer up to October 18, 2020, they have not signed the Financial Statement.*
12. Constitution/ appointment/ re-appointments/ retirement/ filling up casual vacancies/ disclosures of the Directors, Key Managerial Personnel and the remuneration paid to them *except the Company had not appointed Company Secretary and Chief Financial Officer as required under Section 203 of the Companies Act, 2013 and as such is non-compliant of Section 203 of the Companies Act, 2013 up to October 18, 2020 and Independent Directors of the Company have not registered themselves in the Independent Directors' Data Bank as required under Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014;*
13. Appointment of statutory auditors as per the provisions of section 139(1) read with section 139(2) of the Act.
14. Approvals required to be taken from the Registrar under the various provisions of the Act.
Further, the Company was not required to take any approval from the Central Government, Tribunal, Regional Director, Court or such other authorities;
15. Acceptance/ renewal/ repayment of deposits;
Not Applicable as there was no such instance took placed during the financial year 2020-21.
16. Borrowings from its directors.
Further the Company has not borrowed any sums from its members, public financial institutions, banks and others.
17. Loans and investments or guarantees given or providing of securities to other bodies corporate or persons falling under the provisions of section 186 of the Act.
Not Applicable as there was no such instance took placed during the financial year 2020-21.
18. Alteration of the provisions of the Memorandum and/ or Articles of Association of the Company.
Not Applicable as there was no such instance took placed during the financial year 2020-21.

Place: Ahmedabad

Date:

Signature:

Name of Company Secretary in practice: Anand Lavingia

ACS No.: 26458

COP No.: 11410

UDIN:

HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Reg. Office: 8-A, Gulnar, Chinara - Gulnar Appt., V V Nagar Road, Anand, 388001

Contact No.: (91) (2692) 248535

E-mail.: drdineshpatel@rediffmail.com; Website: www.hemoorganicltd.com

No. of Committee Meetings held during F.Y. 2020-21

(refer Point no. IX(C) of the Form MGT-7)

Sr. No.	Type of Meeting	Date of Meeting	Total Number of Members as on the date of the meeting	Number of members Attended	% of attendance
1	Nomination and Remuneration Committee	04/09/2020	3	3	100.00
2	Nomination and Remuneration Committee	05/10/2020	2	2	100.00
3	Nomination and Remuneration Committee	19/10/2020	3	3	100.00
4	Nomination and Remuneration Committee	31/03/2021	3	3	100.00

For, Hemo Organic Limited

Dr. Dinesh Patel
Chairman and Managing Director
DIN: 00481641

PARTICULARS OF EMPLOYEES

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rules made there under

A. Information as per Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

- a) The ratio of remuneration of each director to the median remuneration of employees for the financial year and the Percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year:

Sr. No.	Name	Designation	Nature of Payment	Ratio against median employee's remuneration	Percentage Increase
1.	Dr. Dineshbhai Patel	Chairman and Managing Director	Remuneration	0.63 : 1.00	100.00%
2.	Mrs. Sonalben Patel	Executive Director	Remuneration	1.02 : 1.00	28.95%
3.	Mr. Dipak Joshi	Chief Financial Officer	Salary	Not Applicable	Not Applicable
4.	Ms. Payal Shah	Company Secretary	Salary	Not Applicable	Not Applicable

* Ratio against median employee's remuneration in respect of Non-Executive Directors are not provided since they are not being paid any remuneration for serving the Company in capacity of Non-Executive Directors.

- b) The percentage increase in the median remuneration of employees in the financial year:

There was no change in the median remuneration of the employees in current financial year over the previous financial year.

- c) The number of permanent employees on the rolls of the Company: 5 Employees as on March 31, 2021.

- d) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

No change was made in salary payable to employees.

The Board of Directors of the Company affirmed that remuneration of all the Key Managerial Personnel of the Company are as per the Remuneration Policy of the Company.

Registered office:

8-A, Gulnar, Chinar-Gulnar Appartment,
V V Nagar Road, Anand - 388 001, Gujarat

By order of the Board of Directors
For, HEMO ORGANIC LIMITED
CIN: L24231GJ1992PLC018224

Place: Anand

Date: August 11, 2021

Dr. Dinesh Patel
Chairman and Managing Director
DIN: 00481641

SECRETARIAL AUDIT REPORT

Form No. MR-3

For the financial year ended March 31, 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and

Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,

The Members,

HEMO ORGANIC LIMITED

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Hemo Organic Limited (hereinafter called 'the Company'). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, read with Annexure - I forming part of this report, the Company has, during the audit period covering the financial year ended on March 31, 2021, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2021 according to the provisions of:

- i. The Companies Act, 2013 ("the Act") and the rules made there under as applicable;
- ii. The Securities Contracts (Regulation) Act, 1956 ("SCRA") and the rules made there under;
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- iv. The Foreign Exchange Management Act, 1999 (FEMA) and the rules and regulations made there under to the extent of Foreign Direct Investment;
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Listing Agreement entered with BSE Limited (BSE);
- vi. The Revised Secretarial Standards issued by the Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules made there under, Regulations, guidelines etc. mentioned above except followings;

1. *Being Listed Company,*
 - (a) *had not appointed Company Secretary and Chief Financial Officer as required under Section 203 of the Companies Act, 2013 and as such is non-compliant of Section 203 of the Companies Act, 2013 up to October 18, 2020;*
 - (b) *has not appointed Internal Auditor for the financial year 2020-21 and as such is non-compliant of Section 138 of the Companies Act, 2013;*
2. *Independent Directors of the Company have not registered themselves in the Independent Directors' Data Bank as required under Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014;*
3. *The Company had not appointed qualified Company Secretary as Compliance Officer as required under Regulation 6 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 up to October 18, 2020;*
4. *The Company has not maintained functional website as required under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;*
5. *The Company has not complied with BSE Circular No. LIST/COMP/15/2018-19 dated July 05, 2018 read with Gazette notification dated June 8, 2018. Pursuant to amendment in Regulation 40 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding transfer of securities would be carried out in dematerialized form only. The Company has not taken special efforts through their RTAs to send the letter under Registered/Speed post to the holders of physical certificates appraising them about the amendment and sensitize them about the impact of the regulation on the transfer of shares held by them in physical form w.e.f. December 5, 2018.*

HEMO ORGANIC LIMITED

Additionally, I have relied on the representations made by the Company for systems and mechanisms formed by the Company for compliances under sector specific laws and regulations applicable to the Company other than those specifically provided above.

During the Period under review, provisions of the following Acts, Rules, Regulations, and Standards are not applicable to the Company,

- i. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; - the Company is not registered as Registrar to an Issue & Share Transfer Agent. However, the Company has appointed MCS Share Transfer Agent Limited as Registrar & Share Transfer Agent as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- ii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;
- iii. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
- iv. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
- v. The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018; and
- vi. The Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Overseas Direct Investment and External Commercial Borrowings.

I further report that -

The Board of Directors of the Company is duly constituted with Executive Directors, Non-Executive Director, Independent Directors and Woman Director in accordance with the act *except non-registration of Independent Directors of the Company in the Independent Directors' Data Bank due to which the status of Independent Directors may not be considered as such*. The changes in the composition that took place during the period under review were carried out in compliance with the provisions of the Act *except non-registration of Independent Director who was appointed, in the Independent Directors' Data Bank, due to which the status of Independent Director may not be considered as such*.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I further report that -

There are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that -

Suspension of in the trading of the Equity Shares of the Company has been revoked w.e.f. October 21, 2020.

For, **M/s. Payal Dhamecha & Associates**
Practicing Company Secretary

Payal Dhamecha
Proprietor
ACS No.: 47303 COP No. 20411
Unique Code: S2020GJ735800
UDIN: A047303C000769453

Place: Ahmedabad
Date: August 11, 2021

Note: This Report is to be read with my letter of even date which is annexed as Annexure - I and forms an integral part of this report.

To,

The Members,

HEMO ORGANIC LIMITED

My report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of secretarial records. The verification was done on test basis, on the records and documents provided by the Management of the Company, to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices followed by me provide a reasonable basis for my opinion.
3. In respect of laws, rules and regulations other than those specifically mentioned in my report above, I have limited my review, analysis and reporting up to process and system adopted by the Company for compliance with the same and have not verified detailed compliance, submissions, reporting under such laws etc. nor verified correctness and appropriateness thereof including financial records and books of accounts of the Company.
4. Wherever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, Rules, Regulations, standards and its proper and adequate presentation and submission in prescribed formats is the responsibility of management. My examination was limited to the verification of procedures on test basis and not its one to one contents.
6. The Secretarial Audit report is neither an assurance as to compliance in totality or the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.
7. Considering the limitations prevailing on account of global pandemic COVID - 19 and its severe repetition, particularly since March, 2021 and Lockdown and semi-lockdown situation, I am not able to verify all the information physically as well as in detail, and, therefore, in respect of some of the matters, I have relied up on the information and explanations as provided by the Company, its officers, agents and authorized representatives.

For, **M/s. Payal Dhamecha & Associates**
Practicing Company Secretary

Payal Dhamecha
Proprietor
ACS No.: 47303 COP No. 20411
Unique Code: S2020GJ735800
UDIN: A047303C000769453

Place: Ahmedabad
Date: August 11, 2021

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

SPECIAL NOTE ON CORONAVIRUS PANADEMIC

By mid of March 2020, the outbreak of Corona virus (COVID-19) pandemic has been rapidly spreading throughout the world, including India causing significant disturbance and slowdown of economic activity. The Company has made committed efforts to support its business stakeholders, employees and service providers. The effect of Covid-19 on the Company is insignificant. Looking at current situation the company does not predict any significant effect of Covid-19 on the Company as the Company is presently not carrying out any business activities. The Company is continuously monitoring the situation and taking necessary actions in response to the developments, to minimize the impact on the business of the Company's Future prospects.

FINANCIAL PERFORMANCE

(₹ in Thousands)

Particulars	F.Y. 2020-21	F.Y. 2019-20
Revenue from Operations	80.70	2,771.80
Other Income	-	-
Total Income	80.70	2,771.80
Operating Expenditure before Finance Cost, Depreciation and Amortization	559.43	2,990.06
Earnings before Finance Cost, Depreciation and Amortization	(478.73)	(218.26)
Less: Finance Cost	-	-
Depreciation and Amortization Expenses	-	-
Profit/(Loss) before Tax	(478.73)	(218.26)
Less: Tax Expense	-	-
Profit/(Loss) after Tax (PAT)	(478.73)	(218.26)

REVIEW OF PERFORMANCE

In the financial year 2020-21, the Company has earned ₹ 8,07,000 from revenue from operations compared to ₹ 27,71,800 for the financial year 2019-20. Due to high employee expenses, the Company has incurred Loss after tax of ₹ 4,78,730 during the financial year 2020-21 as compared to loss after tax of ₹ 2,18,260 in the financial year 2019-20.

OPPORTUNITIES

With the change in the segment of Company's Activities, following are the Opportunities for the Company:

- The Company is being managed by well experienced promoter with positive attribute to strive for challenges for future.
- Trading activities has turned out to be fruitful and there is good scope of future growth and profitability.

THREATS

- Future uncertain Factors
- Competition

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has an efficient system of internal controls for achieving the following business objectives of the Company: Efficiency of operations

- Protection of resources
- Accuracy and promptness of financial reporting
- Compliance with various laws and regulations
- Compliance with the laid down policies and procedures

HUMAN RERSOURCE

Equipping the Company with an engaged and productive workforce is essential to our success. We look for commitment, skills and innovative approach in people. In assessing capability, we consider technical skills and knowledge that have been acquired through experience and practice, along with mental processing ability, social process skills and their application. We continue to invest in developing a pipeline of future talent and nurture them. As part of this process, we provide development and training opportunities to our workforce, which motivates and encourages them to grow in their work. Total 5 employees were employed in the Company. The Company has been maintaining cordial and healthy Industrial Relations, which has helped to a great extent in achieving the upper growth.

CAUTIONARY STATEMENT

Statements in this Report, describing the Company's objectives, projections, estimates and expectations may constitute 'forward looking statements' within the meaning of applicable laws and regulations. Forward looking statements are based on certain assumptions and expectations of future events. These statements are subject to certain risks and uncertainties. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results may be different from those expressed or implied since the Company's operations are affected by many external and internal factors, which are beyond the control of the management. Hence the Company assumes no responsibility in respect of forward-looking statements that may be amended or modified in future on the basis of subsequent developments, information or events.

INDEPENDENT AUDITORS' REPORT

To

The Members

Hemo Organic Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone Ind AS financial statements of Hemo Organic Limited ("the Company"), which comprise the Balance Sheet as at 31st March 2021, the Statement of Profit and Loss, the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and summary of the significant accounting policies and other explanatory information (herein after referred to as "standalone Ind AS financial statements").

Except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, in our opinion and to the best of our information and according to the explanations given to us, standalone Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting standards prescribed under section 133 of the Act, read with companies Rules 2015, as amended (IND AS) and other accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2021, its loss (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Qualified Opinion

We have conducted our audit of the standalone Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Our responsibility under those Standards are further described in Auditor's Responsibility for the Audit of the standalone financial statements section of our report. We are independent of the company in accordance of with code of ethics issued by ICAI together with the independence requirement that are relevant to our audit of standalone financial statement under the provisions of the Act and the rules made there Code under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the stand alone financial statement except for the following matter:

- We have not been provided with the balance confirmation or any other details for the trade receivable and trade payable shown in the books of accounts.*
- We have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to us for verification. According to the management, the other accounts are dormant and therefore the same have not been collected from bank.*

Emphasis of Matter

- The Company has not charged depreciation on the fixed assets during the year and accordingly provision of Indian Accounting Standards relating to depreciation and Deferred Tax Asset / Liabilities have not been followed. The management represented that the amount of depreciation being negligible the same has been not been incorporated.*
- The closing stock has been calculated and certified by management only and we have not been provided with the basis of calculation.*

Key Audit Matters

Sr. No.	Key Audit Matters	How Our Audit addressed the Key Audit Matter
1	Revenue recognition: Company is engaged in the trading activities and there is no major transaction during the current financial year.	<ul style="list-style-type: none"> We have reviewed the transaction of purchase and sale and policy of recognition and accounting of the same.

Other Information

The company's management and board of directors are responsible for the other information. The other information comprises Board's Report on corporate governance and Business Responsibility report but does not include the consolidated financial statements, standalone financial statement and our auditor's report thereon.

Our opinion on the financial statement does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit procedures or otherwise appear to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report on that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Ind AS Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134 (5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone Ind AS financial statements that give a true and fair view of the state of affairs, Profit and Loss (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safe guarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of directors is also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these standalone financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risk of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedure responsive to those risk, and obtain evidence that are sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than the one resulting from error, as fraud may involve collusion, forgery, intentional, omission, misrepresentation, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial control system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations, except for the explanations and information described in the qualified opinion paragraph, which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss, Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d. In our opinion, the aforesaid standalone Ind AS financial statements comply with the Indian Accounting Standards prescribed under section 133 of the Act.
 - e. On the basis of the written representation received from the directors as on as on 31st March and taken on record by the board of directors, none of the directors is disqualified as on 31st March 2021 from being appointed as director in terms of Section 164(2) of the Act.
 - f. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. There is no pending litigation on the company therefore the same is not required to be disclosed.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For, M A A K & Associates
(Chartered Accountants)
FRN: 135024W

Date: 30/06/2021
Place: Ahmedabad
UDIN: 21137390AAAAFB6918

Archit A Shah
Partner
M. No.: 137390

(Referred to in our report of even date)

With reference to the Annexure A referred to in the Independent Auditors' report to the members of the Company on the standalone Ind AS financial statements for the year ended 31st March 2021, we report the following:

I. In Respect of Fixed Assets

- (a) As per the information provided by the management, the Company has maintained proper records showing full particulars including quantitative details and situation of Fixed Assets on the basis of available information.
- (b) As per the information and explanations given to us, the management at reasonable intervals during the year in accordance with a programme of physical verification, has physically verified the fixed assets and no material discrepancies were noticed on such verification as compared to the available records.
- (c) The Company does not hold the immovable property. Therefore, the provisions of Clause 3(i) (c) of the said order are not applicable to the Company.

II. In Respect of Inventories

As explained to us, inventory has been physically verified by the management during the year, no material discrepancies were noticed on such physical verification.

III. Compliance under section 189 of The Companies Act, 2013

As per information and explanation given to us, and subject to the observations given in the main audit report, the company has not granted loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.

IV. Compliance under section 185 and 186 of The Companies Act, 2013

In our opinion and according to information and explanations given to us, the Company has complied with provisions of Section 185 and 186 of the Companies Act, 2013 in respect of grant of loans, making investments, and providing guarantees and securities, as applicable.

V. Compliance under section 73 to 76 of The Companies Act, 2013 and Rules framed thereunder while accepting Deposits

As per information and explanation given to us, the Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.

VI. Maintenance of cost records

The Company is not required to maintain cost records pursuant to the Rules made by the Central Government for the maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013.

VII. Deposit of Statutory Dues

- (a) The company is regular in depositing the undisputed statutory dues including provident fund, employees' state insurance, income tax, sales tax, wealth tax, service tax, custom duty, excise duty, GST, Cess and other statutory dues applicable to the Company with the appropriate authorities. No undisputed amounts payable in respect of the aforesaid statutory dues were outstanding as at the last day of the financial year for a period of more than six months from the date they became payable.
- (b) As informed to us by the management, there is no dispute with the revenue authorities regarding any duty or tax payable.

VIII. Repayment of Loans and Borrowings

According to the information and explanation given to us, the company has not defaulted in any loan from financial institution, bank or debenture holders.

IX. Utilization of Money Raised by Public Offers and Term Loan For which they Raised

According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) and has not obtained any term loans during the year. Accordingly, paragraph 3(ix) of the Order is not applicable to the Company.

X. Reporting of Fraud During the Year

Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the Company or no fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.

XI. Managerial Remuneration

Managerial remuneration has not been paid or provided in the financial year, so the provisions of section 197 read with Schedule V to the Companies Act are not applicable.

XII. Compliance by Nidhi Company Regarding Net Owned Fund to Deposits Ratio

As per information and records available, the Company is not a Nidhi Company. Therefore, the provisions of clause 3(xii) of the order are not applicable to the Company and hence not commented upon.

XIII. Related party compliance with Section 177 and 188 of companies Act - 2013

According to the information and explanations given by the management, transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.

XIV. Compliance under section 42 of Companies Act - 2013 regarding Private placement of Shares or Debenture

According to the information and explanations given to us, and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.

XV. Compliance under section 192 of Companies Act - 2013

According to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in section 192 of Companies Act, 2013.

XVI. Requirement of Registration under 45-IA of Reserve Bank of India Act, 1934

According to the information and explanations given to us, the provisions of section 45-IA of are not applicable to the company.

**For, M A A K & Associates
(Chartered Accountants)
FRN: 135024W**

Date: 30/06/2021
Place: Ahmedabad
UDIN: 21137390AAAFB6918

**Archit A Shah
Partner
M. No.: 137390**

Annexure B to the Auditor's Report**Report on the Internal Financial Controls under****Clause (i) of Sub-Section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Hemo Organic Limited** ("the Company") as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For, M A A K & Associates
(Chartered Accountants)
FRN: 135024W

Date: 30/06/2021
Place: Ahmedabad
UDIN: 21137390AAAFB6918

Archit A Shah
Partner
M. No.: 137390

HEMO ORGANIC LIMITED

HEMO ORGANIC LIMITED Balance Sheet as at March 31, 2021

(₹ in Thousands)

Particulars	Note No.	As at March 31, 2021	As at March 31, 2020
ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	1	20.36	20.36
(b) Other Intangible assets		-	-
(c) Intangible assets under development		-	-
(d) Financial Assets		-	-
(i) Investments		-	-
(ii) Trade receivables		-	-
(iii) Loans & Advance		-	-
(iv) Other financial assets		-	-
(e) Deferred tax assets (net)		1,405.15	1,405.15
(f) Other non-current assets		-	-
Total Non - Current Assets		1,425.51	1,425.51
(2) Current Assets			
(a) Inventories	2	23.33	13.56
(b) Financial Assets		-	-
(i) Investments		-	-
(ii) Trade receivables	3 (i)	669.73	686.73
(iii) Cash and cash equivalents	3 (ii)	44.02	186.08
(iv) Bank balances other than (iii) above	3 (iii)	92.58	88.17
(v) Loans		-	-
(vi) Other financial assets		-	-
(c) Other current assets	4	78.49	71.53
Total Current Assets		908.15	1,046.08
(3) Non-Current Assets classified as held for sale			
		-	-
Total Assets		2,333.66	2,471.59
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity Share Capital	5	34,659.00	34,659.00
(b) Other Equity	6	(34,000.98)	(33,522.25)
Total Equity		658.02	1,136.75
LIABILITIES			
(1) Non-Current Liabilities			
(a) Financial Liabilities		-	-
(i) Borrowings	7	350.45	20.00
(ii) Trade Payables		-	-
(b) Provisions		-	-
(c) Deferred tax liabilities (Net)		-	-
Total Non - Current Liabilities		350.45	20.00
(2) Current Liabilities			
(a) Financial Liabilities		-	-
(i) Borrowings		-	-
(ii) Trade Payables	8(i)	802.62	993.90
(iii) Other Financial Liabilities	8(ii)	312.87	295.94
(b) Other current liabilities		180.00	-
(c) Provisions	9	29.70	25.00
Total Current Liabilities		1,325.19	1,314.84
Total Equity and Liabilities		2,333.66	2,471.59

See accompanying notes to the financial statements

As per our report of even date

For M A A K & Associates

Chartered Accountants

FRN No. 135024W

For and on behalf of Board of Directors of HEMO ORGANIC LIMITED
(Formerly Named as Dinesh Allorga LTD.)

Dr Dinesh Patel
Chairman and Managing Director
DIN 00481641

Sonal D. Patel
Executive Director
DIN 02848171

CA Archit A. Shah
Partner
M. No. 137390
UDIN: 21137390AAAAFB6918

Deepak Joshi
Chief Financial Officer

Payal Shah
Company Secretary

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

HEMO ORGANIC LIMITED

HEMO ORGANIC LIMITED

Statement of Profit and Loss for the year ended on March 31, 2021

(₹ in Thousands)

Particulars	Note No.	For the year ended on March 31, 2021	For the year ended on March 31, 2020
I. INCOME			
(a) Revenue from operations	10	80.70	2,771.80
(b) Other Income		-	-
Total Income		80.70	2,771.80
II. EXPENSES			
(a) Cost of materials consumed		-	-
(b) Excise duty on sale of goods		-	-
(c) Purchases of Stock-in-trade	11	54.76	1,902.70
(d) Changes in stock of finished goods, work-in-progress and stock-in-trade	12	(9.77)	7.23
(e) Employee benefit expense	13	381.00	258.00
(f) Finance costs		-	-
(g) Depreciation and amortisation expense		-	-
(h) Other expenses	14	133.44	822.13
Total Expenses		559.43	2,990.06
III. (Loss) before exceptional items and tax (I) - (II)		(478.73)	(218.26)
IV. Exceptional Items			
V. (Loss) before tax (III) - (IV)		(478.73)	(218.26)
VI. Tax Expense			
Deferred tax		-	-
Total tax expense		-	-
VII. (Loss) after tax for the period (V) - (VI)		(478.73)	(218.26)
VIII. Other comprehensive income			
A (i) Items that will not be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B (i) Items that will be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
IX. Total comprehensive income for the period		(478.73)	(218.26)
X. Earnings per equity share (Face value of Rs. 10 each)			
(1) Basic		(0.14)	(0.06)
(2) Diluted		(0.14)	(0.06)
See accompanying notes to the financial statements	15-17		

As per our report of even date
For M A A K & Associates
Chartered Accountants
FRN No. 135024W

For and on behalf of Board of Directors of HEMO ORGANIC LIMITED
(Formerly Named as Dinesh Allorga LTD.)

Dr Dinesh Patel
Chairman and Managing Director
DIN 00481641

Sonal D. Patel
Executive Director
DIN 02848171

CA Archit A. Shah
Partner
M. No. 137390
UDIN: 21137390AAAAFB6918

Deepak Joshi
Chief Financial Officer

Payal Shah
Company Secretary

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

HEMO ORGANIC LIMITED

Statement of Changes in Equity for the year ended on March 31, 2021

Equity Share Capital

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Balance at the beginning of the year	34,659.00	34,659.00
Changes during the year	-	-
Balance at the end of the year	34,659.00	34,659.00

Other Equity

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Reserves and Surplus		
(i) Securities Premium Reserve		
Balance at the beginning of the year	-	-
Balance at the end of the year	-	-
(ii) Retained Earnings		
Balance at the beginning of the year	(33,522.25)	(33,303.99)
(Loss) for the year	(478.73)	(218.26)
Other Comprehensive Income	-	-
Balance at the end of the year	(34,000.98)	(33,522.25)

See accompanying notes to the financial statements
As per our report of even date
For M A A K & Associates
Chartered Accountants
FRN No. 135024W

For and on behalf of Board of Directors of HEMO ORGANIC LIMITED
(Formerly Named as Dinesh Allorga LTD.)

Dr Dinesh Patel
Chairman and Managing Director
DIN 00481641

Sonal D. Patel
Executive Director
DIN 02848171

CA Archit A. Shah
Partner
M. No. 137390
UDIN: 21137390AAAAFB6918

Deepak Joshi
Chief Financial Officer

Payal Shah
Company Secretary

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

HEMO ORGANIC LIMITED

HEMO ORGANIC LIMITED Cash Flow Statement for the year ended on March 31, 2021

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
A. Cash Flow from Operating Activities		
(Loss) before tax	(478.73)	(218.26)
Adjustments for:		
- Depreciation and Amortization	-	-
- Interest income	-	-
Operating Profit Before Working Capital Changes	(478.73)	(218.26)
Changes in operating assets and liabilities:		
(Increase) / Decrease in Operating Assets:		
- Inventories	(9.77)	7.23
- Trade Receivables	17.00	6,682.36
- Current Loans	-	316.00
- Other current assets	(6.96)	102.71
Increase / (Decrease) in Operating Liabilities:		
- Long-term Provisions	-	-
- Trade Payables	(191.28)	(6,316.34)
- Other Financial Liabilities	16.93	295.94
- Liability of Borrowings	330.45	(810.00)
- Other Current Liability	180.00	-
- Short-term Provisions	4.70	-
Cash (used in) / generated from Operations	(137.66)	59.64
- Direct Taxes paid		
Net cash (used in) Operating Activities (A)	(137.66)	59.64
B. Cash Flow from Investing Activities		
- Loan given	-	-
- Interest Received	-	-
- Fixed Deposits Placed	-	-
Net cash flow (used in) investing activities (B)	-	-
C. Cash Flow from Financing Activities		
- Proceeds from Long-term Borrowings	-	-
- Repayment of Long-term Borrowings	-	-
- Proceeds from Short-term Borrowings (Net)	-	-
- Interest and Finance Charges paid	-	-
Net cash flow from financing activities (C)	-	-
Net increase / (decrease) in cash and cash equivalents (A + B + C)	(137.66)	59.64
Cash and Cash Equivalents at the beginning of year	274.26	214.62
Cash and Cash Equivalents at the end of year (Refer Note - 16)	136.60	274.26

See accompanying notes forming part of the financial statements

Notes:

- The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013.
- Previous year's figures have been regrouped wherever necessary to conform to current year's classification.

As per our report of even date
For M A A K & Associates
Chartered Accountants
FRN No. 135024W

For and on behalf of Board of Directors of HEMO ORGANIC LIMITED
(Formerly Named as Dinesh Allorga LTD.)

Dr Dinesh Patel
Chairman and Managing Director
DIN 00481641

Sonal D. Patel
Executive Director
DIN 02848171

CA Archit A. Shah
Partner
M. No. 137390
UDIN: 21137390AAAAB6918

Deepak Joshi
Chief Financial Officer

Payal Shah
Company Secretary

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

Note 1 A: Corporate Information

The standalone financial statements comprise of financial statements of Hemo Organic Limited for the year ended March 31, 2021. The Company is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. The Company's shares are listed on BSE, a recognised stock exchange, in India. The registered office of the company is located at 8-A, Gulnar, Chinar - Gulnar Appt., V V Nagar Road, Anand - 388001. The company is currently engaged in manufacture of "Ayurvedik" or "Unani" pharmaceutical preparation.

Note 1 B: Basis of preparation

The standalone financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.

For all periods up to and including the year ended March 31, 2017, the Company prepared its financial statements in accordance with the accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements are the Company's first standalone financial statements prepared in accordance with Ind AS based on the permissible options and exemptions available to the Company in terms of Ind AS 101 'First time adoption of Indian Accounting standards'.

The standalone financial statements have been prepared on a historical cost basis, on the accrual basis of accounting except for certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments).

The standalone financial statements are presented in Indian ₹ and all values are rounded to the nearest Rupees, except where otherwise indicated. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding off.

Note 1 C: Significant accounting policies and key accounting estimates**(A) Significant accounting policies****1. Current / non-current classification**

The Company presents assets and liabilities in the balance sheet based on current and non-current classification. An asset is treated as current when it is:

- a) expected to be realised or intended to be sold or consumed in normal operating cycle;
- b) held primarily for the purpose of trading;
- c) expected to be realised within twelve months after the reporting period; or
- d) cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current. A liability is treated as current when it is:

- a) expected to be settled in normal operating cycle;
- b) held primarily for the purpose of trading;
- c) due to be settled within twelve months after the reporting period; or
- d) there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets/materials for processing and their realisation in cash and cash equivalents. As the Company's normal operating cycle is not clearly identifiable, it is assumed to be twelve months.

2. Foreign currencies

Company has not made any transaction in foreign exchange during the year.

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

3. Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a) In the principal market for the asset or liability, or
- b) In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- a) Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- b) Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- c) Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

4. Property, plant and equipment

Property, plant and equipment are carried at cost less accumulated depreciation and impairment losses, if any. Depreciation in current year is not charged due to very minor amount. The cost of Property, plant and equipment comprises its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than those subsequently recoverable from the tax authorities).

5. Inventories

Inventories are valued at lower of cost and net realisable value. Cost is determined on a First in First out (FIFO) . Cost includes cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Obsolete, slow moving and defective inventories are identified and provided for.

Net Realizable value is the estimated selling price in the ordinary course of business, less estimated cost of completion and estimated costs necessary to make sale.

6. Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is any indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal or its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators. The Company bases its impairment calculation on detailed budgets and forecast calculations.

The Company has not impaired any asset, so there is no losses due to impairment.

7. Revenue recognition

Revenue is recognised to the extent it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks.

Sale of products

Revenue from the sale of products is recognised when the significant risks and rewards of ownership of the products have passed to the buyer, usually on delivery of the products. Revenue from the sale of products is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates.

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

8. Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

9. Taxes on Income

Tax on Income comprises current tax. It is recognised in statement of profit and loss except to the extent that it relates to a business combination, or items recognised directly in equity or in other comprehensive income.

Current tax

Tax on income for the current period is determined on the basis on estimated taxable income and tax credits computed in accordance with the provisions of the relevant tax laws and based on the expected outcome of assessments / appeals. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is recognized for the future tax consequences of deductible temporary differences between the carrying values of assets and liabilities and their respective tax bases at the reporting date, using the tax rates and laws that are enacted or substantively enacted as on reporting date. Deferred tax liability are generally recorded for all temporary timing differences. There is No deferred tax in current year.

The Company recognizes tax credits in the nature of MAT credit as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which tax credit is allowed to be carried forward. In the year in which the Company recognizes tax credits as an asset, the said asset is created by way of tax credit to the Statement of profit and loss. The Company reviews such tax credit asset at each reporting date and writes down the asset to the extent the Company does not have convincing evidence that it will pay normal tax during the specified period. Deferred tax includes MAT tax credit.

10. Employee benefits**Short Term Employee Benefits**

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by employees are recognised as an expense during the period when the employees render the services.

Post- Employment Benefits**Defined Contribution Plans**

The Company recognizes contribution payable to the provident fund scheme as an expense, when an employee renders the related services.

The gratuity liability is paid in terms of insurance premium and the company does not have any liability once the contribution in terms of premium is paid.

11. Earnings Per Share

The basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the period by the weighted average number of equity shares outstanding during the period. The number of shares used in computing diluted earnings per share comprises the weighted average shares considered for deriving basic earnings per share, and also the weighted average number of equity shares which could be issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless they have been issued at a later date. In computing dilutive earnings per share, only potential equity shares that are dilutive and that would, if issued, either reduce future earnings per share or increase loss per share, are included.

12. Dividend distribution

The Company recognises a liability to make cash distributions to equity holders of the parent when the distribution is authorised and the distribution is no longer at the discretion of the Company. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders. A corresponding amount is recognised directly in equity.

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

13. Provisions & contingent liabilities

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liability arises when the Company has:

- a) a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or
- b) a present obligation that arises from past events but is not recognised because:
 - (i) it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
 - (ii) the amount of the obligation cannot be measured with sufficient reliability.

Contingent liabilities are not recorded in the financial statement but, rather, are disclosed in the Balance sheet but are disclosed in the note to the financial statement.

(B) Key accounting estimates**1. Fair value measurement of financial instruments**

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value are measured using valuation techniques. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgment is required in establishing fair values. Judgments include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions relating to these factors could affect the reported fair value of financial instruments. See Note 16 for further disclosures.

2. Impairment of non-financial assets

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm's length, for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a discounted cash flow (DCF) model. The cash flows are derived from the budget and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the asset's performance of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. There is no losses due to impairment of asset.

3. Taxes

Deferred tax assets are recognised for unused tax credits to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgment is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

The Company has ₹ NIL as at March 31, 2021 (₹ NIL as at March 31, 2020) of tax credits carried forward. These credits can be utilised over the period of 15 years. The Company has taxable temporary difference and tax planning opportunities available that could support the recognition of these credits as deferred tax assets. On this basis, the Company has determined that it can recognise deferred tax assets on the tax credits carried forward. Refer to Note 19 for further details.

4. Property, Plant and Equipment

The carrying values of Property, plant and equipment have been disclosed in Note 1.

5. Intangible assets

There is no intangible asset in the company.

6. Allowance for doubtful trade receivables

Trade receivables do not carry any interest and are stated at their nominal value as reduced by appropriate allowances for estimated irrecoverable amounts.

Estimated irrecoverable amounts are derived based on a provision matrix which takes into account various factors such as customer specific risks, geographical region, product type, currency fluctuation risk, repatriation policy of the country, country specific economic risks, customer rating, and type of customer, etc. The allowances for doubtful trade receivables were NIL as at March 31, 2021 (as at March 31, 2020: ₹ NIL).

Individual trade receivables are written off when the management deems them not to be collectable.

HEMO ORGANIC LIMITED

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

NOTE - 1 : Property, Plant and Equipment

(₹ in Thousands)

Tangible Assets	Computer	Total
Opening gross carrying amount as at April 01,2019	33.70	33.70
Additions during the year	-	-
Disposals	-	-
Closing gross carrying amount as at March 31,2020	33.70	33.70
Accumulated depreciation and impairment as on April 01,2019		
Opening accumulated depreciation	13.34	13.34
Depreciation charge during the year	-	-
Closing accumulated depreciation as at March 31, 2020	13.34	13.34
NET CARRYING AMOUNT AS AT MARCH 31, 2020	20.36	20.36
Opening gross carrying amount as at April 01,2020	33.70	33.70
Additions during the year	-	-
Disposals	-	-
Closing gross carrying amount as at March 31,2021	33.70	33.70
Accumulated depreciation and impairment as on April 01,2020		
Opening accumulated depreciation	13.34	13.34
Depreciation charge during the year	-	-
Closing accumulated depreciation as at March 31, 2021	13.34	13.34
NET CARRYING AMOUNT AS AT MARCH 31, 2021	20.36	20.36

NOTE - 2 : Inventories

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Raw Materials	-	-
Packing Materials	-	-
Finished Goods #	23.33	13.56
TOTAL INVENTORIES	23.33	13.56

the inventories of finished goods are valued at lower of cost and net realisable value.

NOTE - 3 : Financial Assets (Current)

(i) Trade Receivables

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Trade Receivables	669.73	686.73
Less: Allowance for doubtful debts	-	-
TOTAL TRADE RECEIVABLES	669.73	686.73

HEMO ORGANIC LIMITED**HEMO ORGANIC LIMITED**

Notes forming part of the Financial Statements for the year ended on March 31, 2021

ii) Cash and Cash Equivalents

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Cash on Hand	44.02	186.08
TOTAL	44.02	186.08

iii) Other Bank Balances

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Balance with Banks		
- in Current Accounts	92.58	88.17
TOTAL	92.58	88.17

NOTE - 4 : Other Current Assets

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Unsecured and considered good		
Balance with government authorities	-	-
Minimum Alternative Tax	71.53	71.53
Other Current Assets	6.96	-
TOTAL	78.49	71.53

NOTE - 5 : Equity Share Capital

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Authorised Equity Share Capital		
3500000 Equity Shares of ₹ 10 each	35,000	35,000
	35,000	35,000
Issued, Subscribed and Paid up :		
3465900 Equity Shares (Previous Year: 3465900) Equity Shares of ₹ 10 each fully paid - up	34,659	34,659
TOTAL	34,659	34,659

(i) Reconciliation of number of equity shares outstanding at the beginning and at the end of the reporting year

Particulars	As at March 31, 2021	As at March 31, 2020
Balance at the beginning of the year (Nos.)	3465900	3465900
Issued during the year (Nos.)	-	-
Balance at the end of the year (Nos.)	3465900	3465900

(ii) Rights, Preferences and Restrictions attached to equity shares

The Company has one class of equity shares having a par value of Rs. 10 per share. Each shareholder is eligible for one vote per share held. The dividend, if any proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding.

HEMO ORGANIC LIMITED

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

(iii) Shareholders holding more than 5% of total equity shares

Particulars	As at March 31, 2021		As at March 31, 2020	
	Numbers	% Holding	Numbers	% Holding
Equity shares of ₹ 10 each fully paid				
Dr. Dinesh Patel	536940	15.94%	536940	15.94%
Indian Cleaning Corp Limited	279950	8.08%	279950	8.08%
Patel Bhailal Dahyabhai	204578	5.90%	204578	5.90%

(iv) The Company has not reserved any share for issue under options and contracts or commitments for the sale of shares or disinvestment.

NOTE - 6 : Other Equity

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
(i) Retained Earnings		
Balance at the beginning of the year	(33,522.25)	(33,303.99)
(Loss) for the year	(478.73)	(218.26)
Items of other comprehensive income recognised directly in retained earnings		
- Re-measurement of the defined benefit liabilities / (asset), net of tax	-	-
BALANCE AT THE END OF THE YEAR	(34,000.98)	(33,522.25)

NOTE - 7 : Financial Liabilities (Non-Current)

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Borrowings		
From banks	-	-
From others #	350.45	20.00
TOTAL LONG TERM BORROWINGS	350.45	20.00

Note: It is unsecured interest free loan taken from Director of Company.

NOTE - 8 : Financial Liabilities (Non-Current)

(i) Trade Payables

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Trade Payable		
- Due to Micro and small enterprises #	-	-
- Due to Others	802.62	993.89
TOTAL	802.62	993.89

Note: The Company has not received the information and Certificate of Registration under MSMED from its Supplier and hence, the details are not available for disclosure.

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

(ii) Other Financial Liabilities

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
TDS payable	2.93	15.60
Interest on TDS payable	0.16	2.01
Other payable	309.78	278.34
TOTAL	312.87	295.94

NOTE - 9 : Current Provisions

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Provision for Audit Fees	29.70	25.00
TOTAL	29.70	25.00

NOTE - 10 : Revenue from Operations

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
Sales	80.70	2,771.80
TOTAL	80.70	2,771.80

NOTE - 11 : Purchase of stock in trade

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
Purchase of trading material	80.70	2,771.80
TOTAL	80.70	2,771.80

NOTE - 12 : Changes in stock of finished goods

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
Opening Stock of trading material	13.56	20.79
Less: Closing stock of trading material	23.33	13.56
CHANGES IN STOCK OF FINISHED GOODS	(9.77)	7.23

NOTE - 13 : Employee benefit Expense

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
Salaries, Wages and Bonus	144.00	144.00
Director Remuneration	237.00	114.00
TOTAL	381.00	258.00

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

NOTE - 14 : Other Expenses

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
Advertisement Expense	6.80	-
Accounting Charge	6.00	-
Legal and Professional Charges	91.28	215.39
Statutory Audit Fees	25.00	25.00
Listing Fees	-	300.00
DSC Charge	-	1.00
Bank Charges	1.25	0.86
GST Expenses	-	115.70
VAT Expense	-	0.46
Interest Expense	-	14.40
Interest on TDS	0.16	12.96
Late Fees on TDS	-	3.40
Interest on Professional Fees	-	0.33
Miscellaneous Expense	0.05	-
Municipal Tax	2.90	-
Kasar	-	0.15
Miscellaneous Balance written off	-	132.48
TOTAL	133.44	822.13

(a) Details of payment to auditors (excluding applicable taxes)

(₹ in Thousands)

Particulars	For the year ended on March 31, 2021	For the year ended on March 31, 2020
Auditors' remuneration		
Statutory Audit Fee	25.00	25.00
Tax Audit Fee	-	-
TOTAL PAYMENT TO AUDITORS	25.00	25.00

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

15. Related party disclosures

The related party disclosures in accordance with the requirements of Ind AS - 24 "Related Party Disclosures" has been given below: -

(a) Name and nature of related party relationships:

(i) Key Managerial Personnel (KMP)	Relationship
Dr. Dinesh S. Patel	Chairman and Managing Director (MD)
Mrs. Sonal D. Patel	Executive Director (ED)
Mr. Krushnakant R. Patel	Independent Director (ID)
Mr. Pankaj R. Patel	Independent Director (ID)
Mrs. Kinnariben Patel	Non-Executive Director (NED)

(₹ in Thousands)

(b) Description of the nature of transactions with the related parties

(i) Particulars	Financial Year 2020-21	Financial Year 2020-21
Salary and Remuneration Paid		
Dr. Dinesh S. Patel	90.00	-
Mrs. Sonal D. Patel	147.00	114.00

(₹ in Thousands)

(ii) Names of Related Parties	Description of Relationship	Opening Balance	Loan Taken	Repayment	Closing Balance
Year Ended 31 March, 2021					
Dr. Dinesh S. Patel (Loan Taken)	Director	20.00	357.00	26.55	350.45
Year Ended 31 March, 2020					
Dr. Dinesh S. Patel (Loan Taken)	Director	830.15	33.50	843.65	20.00

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

16. A) Fair value measurement

(₹ in Thousands)

(a) Financial assets				
Particulars	As at March 31, 2021		As at March 31, 2020	
	Carrying value	Fair value	Carrying value	Fair value
(i) Measured at amortised cost				
Trade receivables	669.73	669.73	686.73	686.73
Cash and cash equivalents	44.02	44.02	186.08	186.08
Bank balances other than cash and cash equivalents	92.58	92.58	88.17	88.17
Loans	-	-	-	-
Total financial assets at amortised costs (A)	806.33	806.33	960.99	960.99
(ii) Measured at fair value through other comprehensive income				
Non-current Investments	-	-	-	-
Total financial assets at fair value through other comprehensive income (B)	-	-	-	-
TOTAL FINANCIAL ASSETS	806.33	806.33	960.99	960.99

(₹ in Thousands)

(a) Financial liabilities				
Particulars	As at March 31, 2021		As at March 31, 2020	
	Carrying value	Fair value	Carrying value	Fair value
(i) Measured at amortised cost				
Long term borrowings #	350.45	350.45	20.00	20.00
Short term Borrowings	-	-	-	-
Trade payables	802.62	802.62	993.90	993.90
Other financial liabilities	312.87	312.87	295.94	295.94
Total financial liabilities	1,465.94	1,465.94	1,309.84	1,309.84
TOTAL FINANCIAL LIABILITIES	806.33	806.33	960.99	960.99

includes current maturities of long term debt

The fair value of financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties in an orderly market transaction, other than in a forced or liquidation sale.

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

17. Capital management

a) Risk Management

The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximising the return to stakeholders through efficient allocation of capital towards expansion of business, optimisation of working capital requirements and deployment of surplus funds into various investment options.

b) Financial risk management

The company has a risk management committee which has the responsibility to identify the risk and suggest the management the mitigation plan for the identified risks in accordance with the risk management policy of the Company. The risk management policies are established to ensure timely identification and evaluation of risks, setting acceptable risk thresholds, identifying and mapping controls against these risks, monitor the risks and their limits, improve risk awareness and transparency. These risks include market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk. The Company seeks to minimise the effects of these risks by using derivative financial instruments, credit limit to exposures, etc., to hedge risk exposures.

(i) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: foreign currency risk, interest rate risk, investment risk.

(ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk because no funds are borrowed at both fixed and floating interest rates. The Company has no exposure to interest rate risk, arising principally on changes in base lending rate and LIBOR rates.

The following table provides a break-up of the Company's fixed and floating rate borrowings: -

(₹ in Thousands)

Particulars	As at March 31, 2021	As at March 31, 2020
Fixed rate borrowings	-	-
Floating rate borrowings	-	-
Total borrowings	-	-

(iii) Liquidity risk management

Liquidity risk is the risk that the company will not be able to meet its financial obligation as they become due. The company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due.

Maturity profile of financial liabilities:

The table below provides details regarding the remaining contractual maturities of financial liabilities at the reporting date.

(₹ in Thousands)

As at March 31, 2021	Up to 1 year	1-2 years	> 2 years	Total
Financial liabilities				
Long term borrowings	350.45	-	-	350.45
Current maturities of long term debt	-	-	-	-
Trade payables	802.62	-	-	802.62
Other financial liabilities	312.87	-	-	312.87
TOTAL FINANCIAL LIABILITIES	1,465.94	-	-	1,465.94

(₹ in Thousands)

As at March 31, 2020	Up to 1 year	1-2 years	> 2 years	Total
Financial liabilities				
Long term borrowings	20.00	-	-	20.00
Current maturities of long term debt	-	-	-	-
Trade payables	238.83	755.06	-	993.89
Other financial liabilities	295.94	-	-	295.94
TOTAL FINANCIAL LIABILITIES	554.78	755.06	-	1,309.84

HEMO ORGANIC LIMITED

Notes forming part of the Financial Statements for the year ended on March 31, 2021

(iv) Credit risk management

Credit risk refers to the risk that a customer will default on its contractual obligations resulting in financial loss to the Company. Customer credit risk is managed centrally by the Company and subject to established policy, procedures and control relating to customer credit risk management. The company also assesses the creditworthiness of the customers internally to whom goods are sold on credit terms in the normal course of business. The credit limit of each customer is defined in accordance with this assessment.

The impairment analysis is performed on client to client basis for the debtors that are past due at the end of each reporting date. The company has not considered an allowance for doubtful debts in case of trade receivables.

(₹ in Thousands)

Particulars	Neither impaired nor due	Up to 1 years	1-5 Years	Above 5 Years	Total
As at March 31, 2021					
Trade receivables	-	3.00	666.73	-	669.73
As at March 31, 2020					
Trade receivables	-	190.60	496.13	-	686.73

Note: Trade receivables are net of provision for doubtful debt and bills discounted.

As per our report of even date
For M A A K & Associates
Chartered Accountants
FRN No. 135024W

For and on behalf of Board of Directors of HEMO ORGANIC LIMITED
(Formerly Named as Dinesh Allorga LTD.)

Dr Dinesh Patel
Chairman and Managing Director
DIN 00481641

Sonal D. Patel
Executive Director
DIN 02848171

CA Archit A. Shah
Partner
M. No. 137390
UDIN: 21137390AAAAFB6918

Deepak Joshi
Chief Financial Officer

Payal Shah
Company Secretary

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021

Place : Ahmedabad
Date : 30/06/2021